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SUMMARY
Acute lung injury was studied in community-acquired 
pneumonia (CAP), smoke inhalation injury in fire victims 
and radiation injury following radiotherapy for bronchial 
carcinoma. In vitro methods for processing broncho- 
alveolar lavage (BAL) specimens and for studying alveolar 
macrophage (AM) function were developed, assessed and 
used in comparing these patient groups with control 
subjects (CS).
The AM was the predominant cell in BAL samples from 
radiogically clear areas (RCA) in CAP patients and in CS. 
The proportion of AM subgroups in BAL fluid from RCA as 
determined by macrophage markers was similar to CS apart 
from NA1/34 (T6) positive (Langerhans) cells which was 
lower in specimens from RCA. Furthermore BAL fluid from 
CS and RCA in CAP were similar in their levels of 
albumin, complement components and products of complement 
activation.
Both unstimulated and stimulated migration of AM 
from RCA in CAP towards zymosan activated (ZAS), casein 
and f-met-leu-phe was impaired. The impaired migration 
was associated with reduced generation of the respiratory 
burst by AM from RCA. This impairment of AM function 
could not be attributed to an inhibiting factor in the 
BAL fluid from these areas. Examination of peripheral 
blood cells did not reveal similar functional impairment 
thus making it unlikely to be due to a systemic effect of
- v -
pneumonia.
Neutrophils were the predominant cells in BAL fluid 
obtained from areas of consolidation (AOC) in CAP 
patients. AOC also contained significantly higher 
proportions of UCHM^ positive cells (monocytes) and RFD7 
positive cells. In addition BAL fluid from these lung 
areas showed significantly high chemotatic activity to 
neutrophils, along with very high levels of albumin, 
components of complement and products of complement 
activation. Due to technical difficulties limited 
information was obtained on function of AM from AOC. This 
suggested depression of generation of the respiratory 
burst.
The cell composition in BAL fluid from patients with 
smoke inhalation injury alone or with burns showed 
significantly higher proportions of neutrophils than CS. 
This increase in neutrophils was not seen in patients 
with burns only. There was a significant increase in the 
proportion of RFD9 positive cells in patients with smoke 
inhalation only and UCHM^ positive cells in those with 
smoke and burns injury.
AM from patients with smoke inhalation injury showed 
increased migration compared to those from CS. This was 
most marked in AM obtained from patients with combined 
smoke inhalation and burns injury. They showed 
significantly higher AM unstimulated and stimulated 
migration towards casein, ZAS and f-met-leu- phe. Again 
patients with burns only did not show such increase in AM
- vi -
migration. Furthermore, BAL fluid from patients with 
combined injury showed significantly higher functional 
chemotatic activity than those from CS; associated with 
significantly higher levels of albumin, complement 
components and products of complement activation. BAL 
fluid from patients with burns only did not show any 
chemotatic activity.
BAL samples from patients with bronchial carcinoma 
before radiotherapy showed similar proportions of cells 
to CS. However, BAL from tumour areas following 
radiotherapy contained significantly lower proportions of 
macrophages and significantly higher proportion of 
neutrophils than CS. There were no significant 
differences in the proportions of macrophage subgroups 
between CS and patients with bronchial carcinoma before 
or after radiotherapy. There was functional impairment 
of AM from patients with bronchial carcinoma and this was 
more marked in samples obtained from tumour areas. Some 
improvement in AM function appeared to occur following 
radiotherapy.
- vii -
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1CHAPTER 1 
LITERATURE REVIEW
1.1 Introduction:
Acute lung injury is a pathological process of the lung 
usually associated with inflammatory changes and occurring in 
various disease states. It can result from inhalation of many 
toxic substances such as ammonia (Sobonya, 1977), nitrogen 
dioxide (Lowry, 1956), fumes of a smoke bomb (Milliken, 1963) 
or smoke inhalation in fire victims (DiVincenti, 1971). 
Pneumonias caused by various microbiological agents such as 
viruses (Martin, 1959), bacteria (Tilghman, 1937; Austrian, 
1964), fungi (Young, 1974) or protozoa (Burke, 1973), are 
another form of acute lung injury. It may also result from 
radiation (Smith, 1963a&b), drug therapy (Rosenow, 1972) or 
oxygen therapy (Clark, 1971).
These are but a few examples of lung injury and different 
though they may be aetiologically, they often manifest 
themselves with similar clinical features. The
pathophysiological mechanisms of lung injury are poorly 
understood and most of the data available are based on animal 
studies. The use of animal models undoubtedly contributes a 
great deal to our understanding of various mechanisms in 
disease states but technical limitations in imitating natural 
disease states in animal models, and species differences make 
interpretation of data difficult.
The use of well circumscribed acute pathological
2conditions such as pneumonia, smoke inhalation in fire 
victims, and radiotherapy as models of acute lung injury 
avoids such problems. It was proposed therefore to apply 
bronchoalveolar lavage, a well established diagnostic and 
research tool, to the study of acute lung injury represented 
by these conditions.
1.2 Lung defences
Lung defences can be broadly divided into four main 
groups:
I Mechanical barriers and airway reflexes.
II Mucociliary transport.
III Humoral mucosal factors.
IV Cellular defences.
However this review will focus on humoral mucosal factors 
and cellular defences only.
1.2.1 Humoral mucosal factors:
The humoral factors supplement the physical clearance of 
foreign particulates by the mechanical barriers. The humoral 
factors consist of local non-specific soluble products and 
immunological factors.
31.2.1.1 Non-specific soluble products:
Most of these products are secreted by alveolar
macrophages and their protective role principally lies in
their antimicrobial activity. However some products serve to
neutralize enzymes while others serve to cleave complement 
precursors.
1.2.1.1.1 Lysozyme:
Although a product of macrophages and polymorphonuclear 
cells, its main function is in extracellular rather than 
intracellular digestion. It has a molecular weight of 14,000 
daltons and is also found in other body fluids like tears and
serum. It is known that it acts on the peptidoglycan of
bacterial cell walls specifically hydrolysing the 1-4
glycosidic linkages between n-acetylmuramic acid and n-acetyl
glucosamine (Unanue, 1976). Its production is increased in 
activated macrophages (Heise, 1966), but it is not modulated 
by a phagocytic stimulus like other enzymes.
1.2.1.1.2 Lactoferrin:
This is thought to be produced by
glandular mucosal cells (Tourville, 1969) and
polymorphonuclear leucocytes. It has a potent bacteriostatic 
activity.
41.2.1.1.3 Alpha-1-Anti-trypsin:
This is found in alveolar macrophages and in bronchial 
secretions (Cohen, 1973). It is capable of inhibiting 
bacterial enzymes but its better known role is in protection 
against proteases and lysosomal enzymes released by leucocyte 
granules. Deficiency of this enzyme is associated with 
emphysema and this appears to be accelerated by smoking.
1.2.1.1.4 Complement:
The role of complement in opsonisation and chemotaxis 
is well established. Further discussion of this aspect of 
host defence will be made under appropriate sections.
1.2.1.2 Immunological factors:
Early work on lung secretions concentrated on surfactant 
but it became clear that many other substances unrelated to 
surfactant are also found. It is now widely accepted that a 
local immune secretory system exists in the respiratory tract.
Bull & McKee (1929) demonstrated that rabbits could be
immunised against pneumococci by intranasal inoculation of 
these organisms without demonstrable serum antibodies. It has
also been shown that intravenous inoculation with killed
pneumococci results in production of large amounts of 
antibodies in the lungs (Askonas, 1958).
51.2.1.2.1 IgA:
Studies of bronchial secretions have shown that IgA is 
the major immunoglobulin component. Unlike serum IgA, which 
is a 7-S monomer, the secretory IgA is an 11-S dimer linked by 
a joining (J) chain to the secretory component (SC) (South, 
1968). The dimeric IgA with the J-chain is produced by local 
plasma cells and is exported into the interstitial spaces 
where it comes in contact with the epithelial cells. There is 
also evidence that some dimeric IgA, is selectively 
transported to the lung. The secretory component is a product 
of the epithelial cells and appears to be important in 
transportation of the IgA-J component before it is exported to 
the mucosal surface. Secretory IgA (slgA) is resistant to 
most forms of enzymatic degeneration. slgA may play a role in 
lung defence by neutralizing toxins and viruses, agglutinating 
bacteria and impairing bacterial adherence to the epithelial 
cells and therefore possibly preventing colonisation. IgA-
deficient patients are known to have an increased incidence of 
respiratory tract infections or associated allergic disorders 
such as eczema, allergic rhinitis or asthma (Schwartz, 1971). 
It should be mentioned that these atopic individuals do not
necessarily have an increased incidence of IgA deficiency
(Platt-Mills, 1976). Allergen-specific slgA has been
demonstrated in nasal secretions from atopic individuals
(Platt-Mills, 1976). There is therefore evidence that slgA 
plays a role in defence against microbial agents and possibly 
also in allergic disorders.
61.2.1.2.2 IgG:
IgG in pulmonary secretions was thought to 
originate solely from the serum by transudation, but several 
workers including Platt-Mills (1979) have reported that local 
synthesis also takes place. However the contribution of 
locally produced IgG in the normal lung appears to be smaller 
than that transuding from the serum. IgG in the respiratory 
tra.ct agglutinates bacteria, and promotes phagocytosis by 
alveolar macrophages. IgG immune complexes are not found in 
the healthy lung but have been identified in respiratory 
disorders.
The quantity of IgG in relation to IgA in the respiratory
tract appears to vary according to the area of the respiratory
tract examined. Kaltreider (1976) estimated levels of
immunoglobulins in stimulated saliva, tracheal washings and 
bronchopulmonary lavage supernatants in dogs and found higher 
levels of IgA in the upper respiratory tract compared to the 
lower respiratory tract and the converse with regard to IgG. 
Underlining the predominance of IgA even in the lower
respiratory tract, is the finding that there were more IgA 
than IgG secreting lymphocytes per million lymphocytes in the 
lavage fluid of normal volunteers (Laurence, 1978) . It is 
interesting that in the same study, both IgA and IgG secreting 
lymphocytes per million lymphocytes in the lavage fluid were 
more numerous than in the blood although the IgG secreting 
cells predominated in the blood.
71.2.1.2.3 IgM:
This large immunoglobulin is found in very small amounts 
in the normal lung and because of its size it is thought that 
it is entirely locally produced. Lawrence (1978) found IgM 
secreting cells in four out of seven lavage specimens
although all corresponding blood samples demonstrated these
cells. Recent work which has taken into account its rate of 
secretion into alveolar space relative to albumin, and also 
relative to the other body spaces such as the gut suggests 
that local synthesis of IgM is small (Delacroix, 1985). In
disease states IgM in the lung has been found to be high
and some workers have reported that this immunoglobulin 
allows differentiation between hypersensitivity pneumonitis 
and other interstitial lung diseases (Weinberger, 1978) 
although this has not been confirmed by Delacroix 1985.
1.2.1.2.4 IgE:
In the lower respiratory tract, IgE transudes from the 
serum since the levels in the two compartments are similar. 
However, high levels of IgE in the upper respiratory tract 
indicate that local synthesis is important. The role of IgE 
in the lung is not clearly understood but the finding of IgE 
receptors on a subpopulation of lymphocytes (Yodoi, 1979) and 
alveolar macrophages (Joseph, 1980) may indicate an important 
function. IgE secreting cells have been identified in lavage
8fluid from healthy individuals (Lawrence, 1978) .
1.2.1.2.5 IgD:
This immunoglobulin has not been detected in the lavage 
fluid (Huninghake, 1979) and has generally received little 
attention.
1.2.1.2.6 Alphag macroglobulin:
Very low levels of this protein have been found in the 
normal lung but up to a 120- fold rise has been found in 
disease states (Delacroix, 1985). It appears to offer 
protection to lung tissue against metabolites secreted by 
various cells including neutrophils and macrophages.
1.2.2 Cellular defences:
Particles which escape entrapment by mechanical barriers 
or clearance by the mucociliary transport system and airway 
secretions, reach the alveoli and are dealt with by the 
cellular defences in conjunction with the humoral factors. In 
health, the backbone of the cellular defence is the alveolar 
macrophage (AM) which plays a pivotal role in its interaction 
with the lymphocytes. Furthermore the alveolar macrophage's 
ability to recruit other cells such as neutrophils in immune 
or inflammatory reactions is crucial to host defence. Each 
of the cell types (macrophages, lymphocytes, neutrophils and
9eosinophils) will be briefly reviewed.
1.2.2.1 The alveolar macrophage
The AM is found mainly at the alveolus but is also found 
in the alveolar interstitial spaces.
1.2.2.1.1 Ontogeny:
The AM is part of the mononuclear macrophage system and 
originates from the bone marrow. Convincing evidence regarding 
its origin has come from bone marrow transplantation studies. 
Macrophages obtained from recipients of marrow from donors of 
the opposite sex have the sex chromosomes of the donor. 
Identification of the Y-limb in macrophages from female 
recipients of male donor marrow has been particularly 
convincing (Thomas, 1976; Winston, 1982) . Alveolar macrophages 
have been shown to be capable of vitro proliferation.
Bowden et al_ (1972) and others showed that the alveolar 
interstitial cell has the propensity to multiply and support 
the macrophage population locally. Macrophages from a male 
recipient of a female marrow donor have been shown to be of 
male origin up to four and a half years after successful 
transplantation underlining the ability of the alveolar 
macrophage to replicate locally within the lung. Following 
tracheal instillation of carbon particles in monocyte-depleted 
mice, AM increased four-fold in two weeks (Bowden, 1982). 
Thus although the ultimate origin of the AM is the bone
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marrow, local replication also plays a part in maintaining 
their population.
1.2.2.1.2 Life span and fate of AM:
Meuret (1973) estimated that the peripheral blood 
monocyte in man has a half life of about eight and a half 
hours in the circulation before it disappears into the 
tissues. Kinetic studies in mice have shown that about 70% of 
monocytes leaving the circulation end up as Kuppfer cells, 15% 
as alveolar macrophages and 8% as peritoneal macrophages (Van 
Furth, 1983). In mice the turnover of AM was estimated to be 
about six days. In human bone marrow transplants, Thomas et 
al (1976) estimated that the life span of the AM is about 
eighty-one days. It is thought that once macrophages reach 
their destination organ they do not re-enter the circulation 
although firm evidence for this is lacking. AM disappear from 
the lung via the airspaces or the lymphatics. Their exit via 
the lymphatics is considered to be important in disease states 
(Corry, 1984).
1.2.2.1.3 Maintenance of macrophage populations:
Using a mathematical approach, it has been estimated that 
in a normal steady state in mice about 75% of the alveolar 
macrophages are from the mono’cyte influx and 25% from 
replication of the local immature mononuclear cells 
originating from the bone marrow. Investigating the mechanism
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of increased production of monocytes in inflammatory 
reactions, Van Waardle and colleagues (1977a) injected 
particulate substances into the mouse peritoneum to induce 
monocytosis. They described a Factor Increasing
Monocytopoiesis (FIM) produced by macrophages at the site of 
inflammation, transported via the circulation to the bone 
marrow where it exerts its stimulatory action on the bone 
marrow. It is cell-line specific, not related to complement 
products, and has no chemotactic or colony-stimulating 
activity (van Waardle, 1977(b)). It has a short half life of 
about 20 minutes. Decreased monocyte production has been 
attributed to a Monocyte Production Inhibitor (Van Waardle, 
1978). The regulation of the macrophage population in a 
steady state is not clear. AM obtained from patients with 
chronic lung disorders in vitro have been shown to have an 
increased propensity for jLn vitro multiplication indicating a 
possible mechanism for the expansion of macrophage populations 
in these conditions (Bitterman, 1984) . Increased proportions 
of broncho-alveolar cells bearing monocyte markers have been 
documented in disease states (Hance, 1985).
1.2.2.1.4 Morphology of the AM:
Alveolar macrophages are heterogeneous in size ranging 
from 15-50 urn in diameter. They have a large cyto­
plasmic :nuclear ratio of about 3:1, single eccentric nucleus 
but are occasionally multinucleated. They have prominent 
nucleoli. Fusion of alveolar macrophages gives rise to larger
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multinucleated cells and this is thought to be influenced by 
cytokines such as interferon gamma (Nagasawa, 1987). Higher 
proportions of the larger multinucleated macrophages are found 
in smokers (Martin, 1973). The surface of AM is usually 
ruffled due to the presence of lamellipodia and filopodia. The 
cytoplasm of the AM is intensely granular because of the large 
numbers of the membrane-bound primary lysosomal enzymes and 
also heterogeneous secondary lysosomes and inclusion bodies. 
These inclusions consist of fused primary lysosomes and 
digestive vacuoles, such as the unique "smokers' inclusions" 
seen in macrophages obtained from cigarette smokers. The AM 
stains strongly with nonspecific alpha naphthyl esterase, 
periodic-acid Schiff reagents and it is peroxidase-negative. 
In wet preparations these cells show intense autofluorescence 
which can also be detected by a fluorescence-activated flow 
cytometer; (Hance, 1985).
1.2.2.1.5 Surface receptors:
AM can express more than thirty different receptors (Du 
Bois, 1985) but comprehensive discussion of these is beyond 
the scope of this thesis and only a few will be mentioned 
here. Receptors for the Fc fragment of IgG are amongst the 
most important and a single macrophage may have up to 1 x 10  ^
of these and this may double with cell activation. The AM was 
thought to lack receptors for IgA (Huninghake, 197 9; 
McDermott, 1982), but a recent study reported the presence of 
Fc receptors for IgA on AM (Gauldie, 1983). AM will sometimes
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interact indirectly with an immunoglobulin through some of its 
receptors. For example C3b receptors which are abundant on 
the ■ AM will allow interaction with an IgM-antigen immune 
complex. Other receptors expressed on AM include complement 
components C5a and C3d, glucocorticoids, beta-adrenergic 
agonists, lysosomal glycosidases, and lactoferrin. The 
mechanisms by which the regulation of different receptors are 
expressed on the surface of the cell to facilitate a 
particular function are not understood. It is clear that 
during maturation from monocyte to macrophage, a cell can lose 
receptors for some antigens or biochemical fragments while it 
acquires the ability to express other types of receptors 
(Zwaldo, 1985; Hance, 1985) .
1.2.2.1.6 Metabolism of AM:
Most of the data on metabolism of macrophages have come 
from animal work. Macrophages differ in their metabolism from 
other phagocytes like polymorphonuclear leucocytes. These 
latter cells for example depend on glycogen as an endogenous 
supply of energy for their metabolism, can handle only one 
phagocytic load and are unable to synthesize new granules or 
lysosomal enzymes. Macrophages may process repetitively and 
are capable of synthesizing new lysosomal enzymes (Mason, 
1977). Macrophages are larger than peripheral blood 
monocytes, contain more lysosomes and mitochondria, but have 
very little peroxidase so that they cannot iodinate bacteria. 
The resident AM shows a high level of glucose consumption but
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this does not appear to be affected by phagocytosis. AM 
metabolise glucose by glycolysis, the pentose phosphate 
pathway and Krebs cycle. The rate of phagocytosis is 
diminished by inhibitors of glycolysis and of the Krebs
cycle. AM can produce lactate in the presence of glucose under 
anaerobic conditions. AM are able to digest various ingested 
sugars because they contain enzymes such as hexosidases and 
hexosaminidases, components of complement, immunoglobulins, 
interferon, endogenous pyrogen and colony stimulating factor. 
They can also digest proteins which have been ingested by 
exposing them to enzymes intracellularly. The complexity of 
the intracellular organelles in the AM enables it to digest 
ingested proteins selectively so that it can leave highly 
antigenic molecules undigested before transporting them to the 
cell surface for delivery to other cells such as T- 
lymphocytes.
1.2.2.1.7 Functions of AM
AM are capable of movement towards and phagocytosis and 
killing of microorganisms, secretion of various factors and 
interaction with other cells to modulate the immune and 
inflammatory reactions of the lung.
(i) Chemotaxis:
Locomotion is an important cellular characteristic and it 
is now considered as an integral component of cell function. 
This is because a number of studies with polymorphonuclear
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leucocytes have established the co-existence of defective 
leucocyte locomotion with either a demonstrable impairment of 
intracellular killing, or with recurrent infections. Ward 
(1969) described a patient with recurrent infections
associated with impaired leucocyte locomotion. The
neutrophils from this patient were also defective in their 
bactericidal activity. The "lazy leucocyte syndrome" 
attributed to recurrent infections in two children with 
neutropenia and depressed neutrophil locomotion but with 
normal myeloid precursors and mature neutrophils in the bone 
marrow was described by Miller in 1971. Since then the 
literature covering various aspects of neutrophil chemotaxis 
has proliferated. AM locomotion is less well studied but 
there is evidence that AM can migrate from the bronchoalveolar 
space to the hilar lymph nodes. Corry (1984) reported that a 
proportion of live chromium or indium labelled AM 
intratracheally instilled into syngeneic guinea pigs migrated 
to the hilar lymph nodes. The importance of the capacity of 
macrophages to migrate to hilar nodes in antigen presentation 
and possible dissemination of infection to distant sites of 
the body is evident. Ln vivo migration of alveolar 
macrophages to sites of particle deposition has also been 
demonstrated in other studies. Warheit and colleagues (1984) 
have shown that following deposition of aerosolised asbestos 
fibres, there is accumulation of AM at the alveolar duct 
bifurcations where these cells are normally rarely found. In 
these experiments complement- deficient rats failed to 
achieve the same degree of macrophage accumulation compared to
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normal rats. Analysis of lavage fluid showed that the 
chemotactic factor responsible for attracting alveolar 
macrophages to these sites was C5a. _In vitro studies have 
also shown that C5a is chemotactic for alveolar macrophages 
(Fine, 1981; Richards, 1984). Winston (1982) reported 
depressed AM chemotaxis in a group of bone marrow transplant 
patients. Furthermore macrophages from these patients showed 
defective phagocytosis and killing of Candida albicans. Bone 
marrow transplant recipients often succumb to opportunistic 
infections (Deeg, 1985). Impaired migration of alveolar 
macrophages obtained from patients with malignant lung 
tumours has been reported by Le Marie, 1984. Demarest (1979) 
reported impaired chemotaxis of alveolar macrophages from a 
small group of smoke inhalation patients and concluded that 
this might be a predisposing factor to the increased incidence 
of pulmonary infections in fire victims. This study is of 
particular interest and will be discussed later.
There is little doubt therefore that AM chemotaxis is 
important in vivo, but this aspect of macrophage function is 
less well studied and the mechanisms regulating it are less 
well defined.
(ii) Phagocytosis:
The AM is responsible for clearing airborne particulates 
from the lower respiratory tract as well as locally produced 
debris or sequestrae. Asbestos-laden macrophages obtained 
from patients exposed to asbestos, and macrophages containing
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proteinaceous material obtained from patients with alveolar 
proteinosis (Golde, 1977) are two examples of this interaction 
in vivo.
Ingestion of microorganisms by AM depends upon 
recognition of IgG- or C3b-opsonised microorganism by 
respective surface receptors on the macrophages, followed by 
attachment to the cell membrane (Reynolds, 1975). There is 
evidence that surfactant can also act as an opsonin for 
microorganisms (O'Neill, 1984). Until recently it was 
thought that IgA was not capable of mediating phagocytosis, 
but Richards et al (1985) reported IgA-mediated phagocytosis 
by AM but not by peritoneal macrophages. Attachment to the 
macrophage of unopsonised particles is also possible and may 
be due to charge interactions (Huninghake, 197 9). Human 
plasma fibronectin has also been shown to augment opsonin- 
independent phagocytosis (Czop, 1982). Whatever the mechanism 
of attachment to the macrophage, a series of events appears to 
follow. It is believed that the attachment of the particle 
traps and immobilizes proteins in the vicinity, allows them to 
form a cluster and increases permeability of the membrane to 
sodium ions. This is followed by depolarization which allows 
influx of calcium ions into the macrophage. This triggers 
contraction of microfilaments situated beneath the cell 
membrane in the peripheral cytoplasm and allows the plasma 
membrane to move forward over the attached particle, 
completing phagocytosis (Alison, 1977).
Phagocytosis by AM depends on energy from the Krebs 
cycle, the pentose phosphate pathway and glycolysis. This is
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the only phagocytic cell which uses the Krebs cycle for a 
major part of its energy production (Mason, 1977). Cellular 
events associated with phagocytosis including increased oxygen 
consumption and activity of the pentose phosphate pathway can 
be triggered by soluble factors alone (without phagocytosis 
taking place) like endotoxin, digitonin and detergents.
Once phagocytosis is achieved, the particle encased by 
the cytoplasmic membrane fuses with the lysosome to produce 
the phagolysosome. This primary phagolysosome finally 
detaches to become a secondary phagolysosome. Phagocytic 
vacuoles in AM have been found to lack enzymes such as 
myeloperoxidase, but have been found to be rich in lysosomal 
hydrolases, catalase and lipid hydroperoxidase (Gee, 1977). 
It is in these phagocytic vacuoles that intracellular killing 
or degradation of particles takes place.
(iii) Killing:
Killing of microorganisms can be intracellular or 
extracellular. Intracellular killing follows phagocytosis. 
Phagocytic activity or stimulation of the membrane by soluble 
substrates is accompanied by intracellular biochemical changes 
including increased oxygen consumption and activation of the 
hexose monophosphate shunt pathway. This ’’respiratory burst" 
is associated with generation of reactive oxygen species such 
as superoxide, hydrogen peroxide, singlet oxygen and hydroxyl 
radicals (Adams, 1984). The generation of superoxide is 
thought to be due to oxidation of NADP to NADPH by an oxidase
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enzyme called NADPH oxidase. The metabolic process leads to a 
change in the cell pH which is bactericidal. In addition 
there is release of extracellular enzymes which are also 
bactericidal. The mechanisms by which the release of these 
enzymes is regulated in other phagocytes such as 
polymorphonuclear leucocytes depend on the levels of cyclic 
AMP and cyclic GMP, but in the AM this is less clear. 
Lysozyme does not depend on phagocytic stimuli for its 
release. In addition to the above changes, the fusion of the 
phagolysosomes to form the phagocytic vacuole exposes 
particulate matter to lysosomal enzymes in the microbicidal 
environment of the phagocytic vacuoles. The release of 
lysosomal enzymes to the extracellular compartment may lead to 
tissue damage and this will be dealt with later in greater 
detail.
1.2.2.1.8 Secretory functions of the AM
The macrophage can secrete more than fifty products (Du 
Bois, 1985) and a few of these have been referred to earlier. 
These include products with potent antimicrobial activity, 
products which are capable of protecting the host from 
proteases released by other cells or even by the macrophage 
itself, and others which mediate macrophage interaction with 
other cells in modulating immune and inflammatory reactions. 
Equally important is the destructive effect of many of the 
products secreted by the macrophages and the role of these in 
the pathogenesis of interstitial lung diseases has become the
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subject of extensive research.
(i) Lysozyme
This is a low molecular weight protein produced by the 
macrophage continuously, independent of the phagocytic 
stimulus. BCG-activated macrophages (Heise, 1967) secrete 
large amounts of this protein and this is not influenced by a 
high concentration of serum as occurs with lysosomal enzymes. 
The macrophage has the capacity to secrete lysozyme and 
increase the extracellular concentration four-fold while 
keeping the intracellular concentration unchanged (Gordon, 
1974). Its bactericidal activity depends on its ability to 
hydrolyse the peptidoglycan of the bacterial cell wall.
(ii) Lysosomal enzymes:
These enzymes unlike lysozyme are released by the 
activated macrophage following a phagocytic stimulus during 
the stage of interiorization of the particle as the lysosome 
fuses with endocytic vacuole (reviewed by Unanue, 1976). 
Macrophage interaction with antigen-antibody complexes leading 
to perturbation of the cell membrane can cause release of 
lysosomal enzymes. The lymphokine interferon gamma can also 
activate the macrophage to release these enzymes. Release of 
lysosomal enzymes is energy dependent and can be modulated by 
cyclic GMP. It is a selective process so that following a 
phagocytic stimulus there is a release of acid hydrolases
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without any lactic dehydrogenase which appears in the 
extracellular compartment following cell death.
(iii) Neutral proteases:
These enzymes including collagenase, elastase, 
plasminogen activator and cytolytic proteinase are poorly 
secreted by the resident alveolar macrophage; but are readily 
produced by the exudate macrophage. Their production is a 
two-stage process heralded by a priming signal which can be 
from a lymphokine or endotoxin followed by a second signal 
triggering the secretion. Secretion of these enzymes can be 
triggered in a variety of ways depending on the protease, and 
the secretion can be shut off by binding with alpha2
macroglobulin-trypsin complex (Adams and Hamilton, 1984).
(iv) Alveolar macrophage-derived neutrophil chemotactic 
factor:
Huninghake and colleagues (1978) reported that pig 
alveolar macrophages secreted a chemotactic factor for
neutrophils following ingestion of heat-killed aureus. This
factor was less than 5000 daltons in molecular weight and was 
not a peptide or a complement fragment. Further work revealed 
that this factor did not only stimulate neutrophil migration 
but also stimulated the cells to release lysozyme and 
lactoferrin (Huninghake, 1980). This underlines the potential 
of the AM in both lung defence and also in lung injury. In
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humans this factor was found to be released by the AM from 
smokers but not from non-smokers (Huninghake, 1983).
(v) Arachidonic acid metabolites:
Macrophages are a major source of these products which 
have important functional roles iri vivo. The production of 
these metabolites depends on the presence of arachidonic acid, 
calcium, and phospholipase A2. The levels of cyclooxygenase 
and lipoxygenase control the metabolism of arachidonic acid. 
Prostaglandin E2 (PGE2) has an important role in tumour 
cytolysis. EGF2' FGE2' leukotrine C4 (LTC4), LTB^ and
thromboxane B2 (TXB2) are potent chemotactic agents. LTD4 is 
an extremely potent bronchoconstrictor having 1000-fold 
greater potency than histamine. Alveolar macrophages do not 
normally release prostaglandins or leukotrienes spontaneously 
and often in vitro experiments require a phagocytic stimulus 
or calcium ionophore A23187. LTB4 is more chemotactic to 
neutrophils than monocytes or alveolar macrophages. This 
underlies the potential mechanism for recruitment by AM of 
neutrophils to the lungs. There appears to be some
controversy regarding the synthesis of LTD4 by the AM. Martin
(1984) failed to find any LTD4 release by AM whereas this was
reported by Damon and colleagues (1983). In animal models 
immunologically activated macrophages produce less
arachidonic acid metabolites than human alveolar macrophages 
from patients with sarcoidosis, cryptogenic fibrosing 
alveolitis, and AM from smokers produce significantly less
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arachidonic acid metabolites than non-smokers' macrophages 
(Bachwich, 1986).
(vi) Interferon:
Interferon (IFN) was discovered in 1957 by Isaacs and 
Lindenmann following the observation that viral replication in 
a cell previously infected with another virus was inhibited 
(virus interference). Three major types of interferons are now 
recognised. These are INF, alpha, beta and gamma respectively 
produced by leucocytes, fibroblasts and lymphocytes, though 
not exclusively. These various cells need induction by an 
RNA-virus, double stranded RNA or a variety of immune 
stimuli. IFNs are proteins with a molecular weight between 
10,000 to 50,000 daltons consisting of 166 aminoacids for INF 
alpha and beta and 142 aminoacids for INF gamma (reviewed by 
Burke, 1985) . Their anti-viral activity is not due to direct 
neutralization but they protect the cell by producing a series 
of changes in cellular metabolism which interfere with nucleic 
acid and protein synthesis and also with the assembly of the 
virus particles. IFN gamma has been found to be identical 
to Macrophage Activating Factor and has a myriad of effects on 
macrophages and lymphocytes. Apart from its antiviral 
activity it can induce expression of DR- determinants, enhance 
presentation of antigens, activate mononuclear phagocytes for 
tumour cell lysis and intracellular parasite killing, 
stimulate T-lymphocytes in expression of interleukin-2 
receptors, enhance natural killer cell activity and induce
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expression of DR-determinants on B-cells.
The human alveolar macrophage, like other mononuclear 
phagocytes has been shown to be capable of producing 
interferon. Nugent (1985) reported that human alveolar 
macrophages from healthy volunteers released IFN alpha and 
IFN gamma following induction by influenza-A virus and the 
mitogen (concavalin A) respectively. Alveolar macrophages and 
lung T-lymphocytes from patients with active sarcoidosis were 
shown to release IFN gamma spontaneously (Robinson, 1985),
but peripheral blood cells from these patients failed to do 
likewise. Alveolar macrophages from these patients showed an 
increased propensity to kill tumour cells compared to control 
macrophages, and this was further augmented by purified IFN 
gamma. Murray (1985) showed increased generation of H2O2 in 
vitro by alveolar macrophages from patients with acquired- 
immunodeficiency syndrome (AIDS) following stimulation with 
IFN gamma. These macrophages also showed increased inhibition 
of replication of Toxoplasma gondii and Chlamydia psitaci. 
This report underlined the normal antimicrobial activities of 
macrophages from patients with AIDS and their normal 
responsiveness to T-cell products.
Interferons have been used widely in a variety of 
clinical conditions often with an ameliorating rather than 
a curative effect.
1.2.2.1.9 Interaction of AM with lymphocytes:
This arm of lung defence is one of the most important and
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forms the basis of delayed immunity. Macrophages are capable
of ingesting foreign material (antigen), digesting
(processing) it, and delivering (presenting) it to lymphocytes 
which in turn release a variety of lymphokines which can
affect the macrophage. After the initial controversy on the 
role of alveolar macrophages in antigen presentation and 
interaction with lymphocytes, Huninghake in a recent editorial 
(1987), pointed out that this controversy was due to 
differences in techniques in various studies, and that the AM 
is capable of all these functions. There are three 
requirements for a cell to be capable of antigen presentation: 
i) express Class II (la antigens) glycoproteins on its 
surface, ii) process antigens and iii) synthesize and release 
interleukin-1 (IL-1) (Unanue, 1984a). Hocking (1981) reported 
that human alveolar macrophages can express Ia-like antigens 
and since then various workers have confirmed this (Clerici, 
1984; Campbell, 1986). The extent of expression of Class II 
MHC antigens on cells is a dynamic process, so that expression 
of la antigens on young macrophages in culture and i_n vivo 
rapidly decays (Unanue, 1984b). The macrophages have a 
reciprocating interaction with the lymphocyte in the chain of 
events in immunoregulation. For example, following the 
activation of T-helper cells by la positive macrophages a
lymphokine is produced by T cells which in turn induces
expression of la antigens on the surface of the macrophage.
Using a sophisticated technique of scanning and integrating 
microdensitometry in conjunction with antihuman HLA-DR 
antibody, Campbell and colleagues (1986) found increased
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expression of antigen on macrophages obtained from patients 
with sarcoidosis, a condition with a preponderance of helper 
T-cells in the lungs.
1.2.2.1.10 Alveolar macrophages from smokers and non-
smokers :
Cigarette smoking contributes to many diseases especially 
in the lung. The AM of smokers and non-smokers show some 
differences and a few of these will be described. Macrophage 
yields of lavages from smokers are three to five times 
higher than from non-smokers. There is an increase in the 
large-sized and multinucleated macrophages (Martin, 1973). 
Their surface morphology is often plate-like in appearance and 
has a ridge-like membrane compared to the ruffled surface of 
the AM from non-smokers (Ando, 1984). They often contain 
smokers' inclusions and they autofluoresce more commonly. 
Although macrophages obtained from smokers are usually in a 
more active state, they show functional impairment in many 
respects. Harris (1984) reported abnormal phagolysosome 
fusion in the AM from rats exposed to cigarette smoke although 
the phagocytic rates between these and control macrophages 
were similar. _In vitro migration of alveolar macrophages from 
smokers is increased (Richards, 1984) . These macrophages also 
contain more hydrolase enzymes (Martin, 1973). Both 
neutrophil elastase (serine enzyme) and macrophage elastase 
(metalloenzyme) are increased in the lavage fluid of cigarette 
smokers (Janoff, 1983) . The macrophage elastase cannot be
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inhibited by alpha-1 antitrypsin unlike neutrophil elastase. 
Alpha2 macroglobulin is thought to be the main inhibitor of 
macrophage elastase (Du Bois, 1985) but a recent study 
reported the secretion of a separate tissue inhibitor of 
metalloproteinase (Albin, 1987). AM from smokers were found 
to contain a two-fold increase in cathepsin-B (like) activity 
compared to non-smokers and the lavage content of this enzyme 
from smokers was ten times that of non-smokers (Chang, 1986). 
Lavages from smokers contain not only increased numbers of 
macrophages but also of neutrophils. The presence of
excessive neutrophils in the lungs in smokers and the 
resultant imbalance between neutrophil elastase and alpha-^
proteinease inhibitor form the basis of the widely published 
hypothesis of the pathogenesis of emphysema. This theory 
appears to be more convincing in alpha-1 anti-trypsin
deficiency. In this condition (Pi ZZ phenotype) the enzyme is 
reduced in the alveolar macrophage.
1.2.2.2 The lymphocyte:
1.2.2.2.1 The lymphatic system of the lung
Interaction of lymphocytes with macrophages forms the
backbone of long term immune surveillance. The lymphoid 
system of the lung consists of the lymphatic system and 
bronchus associated lymphoid tissue (BALT). The lymphatic
system comprises of a complex drainage system and the
bronchial lymph nodes. Detailed description of this system is
beyond the scope of this work and only a brief mention will be 
made (reviewed in detail by Leak, 1 977). It is an 
unidirectional drainage system whose major vessels are the 
thoracic duct and the right lymphatic duct which empty at the 
junction of the jugular and subclavian veins. The lymphatic 
drainage serves to return to the circulation the connective 
tissue fluids which have escaped from the pulmonary 
capillaries.
1.2.2.2.2 Bronchus-associated lymphoid tissue (BALT) :
Most of the information arises from work on the rabbit 
and after some initial controversy, it is now accepted that 
BALT exists in man, at least in children (reviewed by
McDermott, 1982). It is absent immediately after birth but
appears at the age of one week and development continues
throughout infancy and early childhood. BALT resembles 
lymphoid tissue of the gut (GALT), and occurs along the entire 
length of the bronchial mucosa. Structurally two main features 
can be recognised namely the lymphoepithelium and the lymphoid 
follicles. The lymphoepithelium consists of lymphocytes and
flattened non-ciliated epithelial cells with microvilli. 
Goblet cells are notably absent but macrophages are present 
and this may be important functionally. Beneath the 
lymphoepithelium lie the lymphoid follicles, which exhibit 
discretely organised areas, domed, follicular and 
parafollicular. BALT cells consist of 50% B cells and 18% T 
cells, but discrete B or T cell areas have not been
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identified. The lymphoid tissue is concentrated at the 
bronchial bifurcations where antigens are maximally deposited. 
BALT is poorly developed in germ-free animals and in antigen- 
free transplanted foetal lungs.
Histological observations suggest that blood-borne 
lymphocytes enter these structures. Discontinuities in the 
basal lamina of the lymphoepithelium are occupied by 
lymphocytes. Cytokinetic studies have shown that labelled 
follicular cells migrate into the lymphoepithelium. Thus 
cells may enter from the blood, proliferate locally following 
antigenic stimulation and migrate either into the bronchial 
lumen via the lymphoepithelium or to the other sites in the 
body via the lymphatics.
Functionally BALT is less well understood. However it is 
known that in the rabbit, lymphoepithelium is capable of 
absorbing antigens by pinocytosis. Carbon particles instilled 
into the respiratory tract were not found in the 
lymphoepithelium or in follicles but accumulated in the 
alveolar macrophages. Although lymphoepithelium can absorb 
antigens and can transfer these to the follicular areas which 
are abundant in lymphocytes, their ability to process antigen 
is unknown. It is speculated that M cells (which have derived 
their name because of numerous microfolds) in the 
lymphoepithelium are functionally similar to macrophages in 
that respect.
Migration of lymphocytes to and from the lungs is less 
well studied. Small lymphocytes can reach the lungs via the 
high epithelial venules found in the lymphoid tissue but their
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return to the circulation is only presumed to be through the 
bronchial lymph nodes to the lymphatics and thence to the 
blood stream. The mechanisms regulating the preponderance of 
one subgroup of lymphocytes in a disease state are not clear. 
There is a tendency for cells taken from one anatomical site 
(e.g. the intestine) to return to the same area although a 
significant proportion may accumulate at distant sites 
(McDermott, 1979) . This propensity is in keeping with the 
predominance of pathology in one organ in some diseases e.g. 
lung more than gut in sarcoid and overt disease in gut in 
Crohn's colitis with subclinical alveolitis in the lung
(Wallert, 1985) . In the steady state, lymphocytes in lavage
fluid correlate well with blood lymphocytes but this
correlation is not maintained in some disease states. The 
mechanisms for this are not well understood. In active 
sarcoidosis there is a disparity between blood and lung
lymphocytes (Reynolds, 1987). The observation that alveolar 
macrophages from patients with this condition release IL-1
(Huninghake, 1984) and that interleukin-1 is chemotactic to 
helper T-cells) (Huninghake, 1987) provides a possible 
explanation for this difference between lung and blood
lymphocytes.
In brief the lymphocyte plays an essential role in lung 
defence; can enter the lung from the circulation; can 
replicate locally with antigenic stimulation and its
concentration in the lung is disturbed in disease. But our 
understanding of the various facets of its regulation both in 
health and disease is far from complete.
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1.2.2.3 Neutrophils:
1.2.2.3.1 Origin and Function
Under normal circumstances the main phagocyte of the lung 
is the alveolar macrophage but in inflammation neutrophils 
gain access to the lung and may even outnumber the
macrophages. Research into the effector mechanisms of
neutrophils and potential injurious effects has been extensive
and the literature on the subject is formidable. No attempt 
is made here to cover even the tip of this iceberg and only a 
short summary is given.
Neutrophils originate from the bone marrow and at the 
promyelocyte stage clearly recognizable granules are seen. 
During the early stage of development these primary granules 
stain only with azure dyes (azurophilic) and later become 
neutrophilic and stain with either acidic or basic dyes. At 
this stage new and more profuse secondary granules appear and 
outnumber the initial (primary) granules by more than two to 
one. The primary granules are peroxidase positive and the 
secondary granules are peroxidase negative. Primary granules 
contain acid hydrolases, neutral proteases (including 
collagenase and elastase) cationic proteins, myeloperoxidase, 
lysozyme and acid mucopolysaccharide. Secondary granules 
contain lysozyme, lactoferrin, cobalophilin (vitamin B-12 
binding protein), collagenase and acid proteins reviewed by 
Wright (1982). Because lactoferrin and cobalophilin (regarded
as specific cytochemical markers for neutrophils) are 
contained in secondary granules, these are also known as
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specific granules.
It is now well established that both phagocytic and 
various humoral stimuli can cause degranulation of 
neutrophils, which can be intracellular as well as 
extracellular. Secondary granules are released
extracellularly more readily than primary granules. Granule 
extrusion is energy dependent, requires extracellular calcium 
and can be influenced by the guanyl and adenylcyclase systems.
Phagocytic and humoral stimuli also induce an oxidative 
metabolic burst with consequent production of metabolites; 
hydrogen peroxide, superoxide anion, hydroxyl radical and 
singlet oxygen. This oxidative apparatus is located at the 
plasma membrane and the respiratory burst is not necessary 
for the process of degranulation. Neutrophils from Chronic 
Granulomatous Disease patients are not capable of this 
metabolic burst but are still able to undergo degranulation 
albeit at a reduced rate. Neutrophil activation leads to 
production of other metabolites such as arachidonates, 
prostaglandins, thromboxanes, hydroxyeicosotetranoic acid 
(HETE) and platelet-activating factor. HETE stimulates 
granule exocytosis and it has been suggested that it is an 
endogenous neutrophil ionophore.
Secretory products of neutrophils provide antimicrobial 
activity; amplify, facilitate and regulate the inflammatory 
process and influence the functions of other exudate cells. 
Lysozyme participates in the control of bacterial 
colonization. Lactoferrin when not fully saturated with iron 
is bacteriostatic but this activity is lost when fully
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saturated. Cobalophilin has also been shown to have 
antibacterial activity as have products of oxygen metabolites. 
Chemotactic factors stimulate granule extrusion, promote 
directed migration and initiation of the oxidative burst. 
Exocytosis of granules also increases neutrophil adhesiveness 
to the endothelium. HETE promotes neutrophil adhesion. 
Neutrophils are capable of loosening intercellular and surface 
attachments of endothelial cells and fibroblasts in culture. 
All these events lead to accumulation of neutrophils and other 
cells at the site of inflammation and through the effects of 
primary and secondary granules, digestion of collagen and 
fibronectin can take place.
1.2.2.3.2 Neutrophils and the lung:
In an infection, migration of neutrophils into the lungs 
can be stimulated by activation of complement by bacterial 
products or as a result of cytokines released by macrophages 
and lymphocytes. The alveolar macrophage-derived chemotactic 
factor for neutrophils has been referred to previously. 
The arrival of large numbers of neutrophils into the 
lung during an infective episode serves to provide potent 
scavengers against microbes and is free of long term effects 
except in rare conditions. However perpetuation of increased 
neutrophils within the lung, even when not in such large 
numbers, appears to be related to the development of chronic 
lung disorders.
Broncho-alveolar lavage fluid from patients with
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cryptogenic fibrosing alveolitis contains increased numbers of 
neutrophils and eosinophils with or without increased 
lymphocytes. Frequently patients with increased lymphocytes 
show improvement with treatment, but in those who fail to 
improve, neutrophil and eosinophil counts tend to remain 
elevated. (Turner Warwick, 1987). Neutrophils have been 
implicated in the pathogenesis of emphysema. Elastase 
purified from pig neutrophil granules was shown to be capable 
of producing emphysema in the same species (Sloan, 1981). The 
relationship of neutrophils in smokers and the subsequent 
development of emphysema has been referred to earlier. This 
is most severe in the rare alpha-^-antitrypsin deficiency 
especially the Pi-ZZ phenotype. The mechanism involved here 
is the lack of alpha-^  protease inhibitor which normally serves 
to inhibit the neutrophil protease. Cigarette smoke not only 
activates the macrophages to attract the neutrophils into the 
lungs but •also stimulates the release of proteases by 
neutrophils. In a recent study, Anderson (1987) reported that 
neutrophils from cigarette smokers released more extracellular 
and intracellular oxidants when activated with the chemotactic 
agent f-met-leu-phe, a synthetic tripeptide. There were more 
receptors for this agent on neutrophils from smokers than from 
non-smokers. Ayars in 1984 reported direct toxic effects on 
pneumocytes of metabolites released by neutrophils. In an 
attempt to try to identify the exact injurious agent, Kuroda 
(1987) and colleagues found that the hydroxyl radical was more 
damaging than either hydrogen peroxide or the superoxide 
radical. Neutrophils as a potential source of lung injury
35
have been implicated not only in chronic lung diseases but 
also in acute situations. For example neutrophils from the 
pulmonary artery in patients with adult respiratory distress 
syndrome (ARDS) showed higher chemiluminescence and 
chemotactic index compared to normal controls (Zimmerman,
1983).
Thus the neutrophil is extremely important in lung 
defence in acute infection, but it has also been associated 
with chronic lung damage and shows a similar potential in 
acute lung injury in ARDS.
1.2.2.4 Eosinophils:
1.2.2.4.1 Structure
The eosinophil contains prominent cytoplasmic granules 
and has an unilobular(especially in tissues) or multilobular 
nucleus. The granules are characteristically eosinophilic 
(hence the name) and under the electron microscope they show a 
dense core with electron-lucent matrix. Eosinophils are rich 
in arginine, histamine and peroxidase, but lack lysozyme and 
phagocytin. The granules when disrupted show a major 
electrophoretic protein band with a molecular weight of 11000 
daltons and which behaves like a basic molecule. This protein 
has been called major basic protein (MBP). It has antigenic 
and a weak antibacterial activity but a potent antiparasitic 
action. Eosinophils but not neutrophils can bind irreversibly 
to parasites such as the schistozomule in the presence of
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antibody and calcium ionophore A23187. In experiments on 
guinea pig trachea MBP caused extensive damage including 
exfoliation of epithelial cells, and impairment of ciliary 
beating with loss of the tubular structure of axonemes. There 
was also bronchial mucosal oedema and separation of collagen 
fibrils. These features especially excessive shedding and 
desquamation of epithelium are similar to those in bronchial 
asthma (reviewed by Ackerman, 1982). Patients with bronchial 
asthma have high serum and sputum levels of MBP, which , fall 
after therapy. It is believed that this finding in asthma and 
other diseases is due to degranulation of eosinophils with 
consequent release of granule constituents. The eosinophil 
peroxidase (EPO) differs from the neutrophil myeloperoxidase 
(MPO) both biochemically and functionally. EPO is less 
efficient in bacterial killing than MPO. Ijg vitro studies 
have shown that in the presence of H2O2 and an halide, EPO 
induces mast cell degranulation, and is toxic to the 
schistosomule of mansoni. Another eosinophil constituent 
are the eosinophil cationic proteins (ECP), thought to 
originate from the granule matrix. ECP have no bactericidal 
activity but have both coagulant and fibrinolytic activities. 
Their blood levels correlate poorly with disease activity. 
Charcot-Leyden crystal (CLC) proteins are lysophospholipases 
biochemically and originate from the eosinophil plasma 
membrane. Their serum levels are raised in patients with 
eosinophilia. Eosinophil derived neurotoxin (EDN) originates 
from the granule matrix and is a potent toxin to myelinated 
neurones. When injected intrathecally, it causes predictable
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neurological manifestations (Gordon phenomenon) characterised 
by stiffness in the limbs and ataxia associated with
histological abnormalities in the cerebellum, pons and the 
spinal cord.
1.2.2.4.2 Functions of eosinophils:
Many iri vitro studies have shown that the eosinophil can 
phagocytose a variety of substances, but iri vivo phagocytosis 
is rarely observed (reviewed by Bass, 1982). Eosinophil 
phagocytic and bactericidal capacities are significantly less 
efficient than those of neutrophils. The antiparasitic 
activities of eosinophils have been referred to earlier.
Evidence from iri vitro studies point to the effects of
eosinophils in detoxification of mediators of anaphylaxis. For 
example, the eosinophil can deactivate histamine, slow-
reacting-substance of anaphylaxis (leukotriene C) and platelet 
activating factor by histaminase, arylsulfatase-B and 
phospholipase-D respectively. The potential for the harmful 
effects of the eosinophil is underlined by the pathogenetic 
actions of its various constituents as mentioned above.
1.2.2.4.3 Eosinophils and the lung:
Analysis of effector cells using bronchoalveolar lavage 
and mechanical lung disruption has shown that eosinophils are 
only rarely found in the normal human lung. Accumulation of 
the eosinophils in the upper airways can occur following mast
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cell degranulation with release of eosinophil chemotactic 
factor of anaphylaxis or IgE induced release of LTB^ which is 
also chemotactic to eosinophils. Mechanisms for accumulation 
of eosinophils in the lower respiratory tract in pulmonary 
fibrosis are not clear. In the normal lung, eosinophils 
constitute less than 1% of bronchoalveolar cells but in 
patients with interstitial lung diseases up to 20% of lavages 
have been found to have more than 5% eosinophils (Davis, 
1984). Increased proportions of eosinophils amongst 
bronchoalveolar cells from patients with pulmonary fibrosis 
has been found to indicate a bad prognosis (Haslam, 1980; 
Peterson, 1987). These data suggest deleterious effects of 
eosinophils in these patients but there have been only a few 
studies investigating this possibility. Haslam (1981) reported 
increased histamine levels in lung lavage fluid from patients 
with cryptogenic fibrosing alveolitis. In a more direct 
approach, Davis and colleagues evaluated the effects of guinea 
pig and human eosinophils on lung connective tissue. They 
found that eosinophil granules contained a collagenase which 
specifically cleaved human collagen types I and III (Davis,
1984). More importantly eosinophils purified from
bronchoalveolar cells from patients with lung disease 
demonstrated spontaneous cytotoxicity to lung cells. It 
should be mentioned however that chronic eosinophilic 
pneumonia and histiocytosis-X are two exceptions in which lung 
eosinophilia does not carry a bad prognosis. In another 
adverse report on eosinophils, Godard (1982) found that 
viability of alveolar macrophages from asthmatic subjects
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inversely correlated with the percentage of eosinophils. 
Furthermore phagocytosis by AM was significantly less in 
asthmatics.
The eosinophil then appears to be less useful in the lung 
than the neutrophil in that its phagocytic and bactericidal 
capacities are less efficient. Apart from the ability of the 
eosinophil to deactivate mediators of allergy, there is ample 
evidence both from its biological effects and from 
circumstantial clinical observation to indicate that the 
eosinophil is potentially more harmful than useful in the 
lower respiratory tract.
The role of the alveolar macrophage in acute lung injury 
forms the theme of this thesis and before describing the 
investigations carried out I shall review the clinical 
conditions studied - community acquired pneumonia (CAP), 
smoke inhalation injury and radiation injury following 
radiotherapy.
1.3 Community-Acquired Pneumonia (CAP)
1.3.1 Historical Background:
"Peripneumony", "Peripneumonia" and finally pneumonia are 
the terms of this common inflammation of the "substance" of 
the lung. As far back as the 1800's an extensive description 
of this disease was written by Laennec in his book - "A 
Treatise on the Diseases of the Chest and on Mediate 
Auscultation" translated by Forbes in 1827. The description
40
of macroscopic pathology and the various stages of lobar 
pneumonia given in this treatise have largely remained 
unchanged.
1.3.2 Incidence:
It is extremely difficult to obtain reliable data on the 
incidence of pneumonia in the community, since patients are 
often treated at home and the disease is not notifiable unless 
it is fatal. Furthermore in death certificates pneumonia is 
often a convenient label especially in the elderly. In this 
population it is regarded as the most common infectious cause 
of death and the fourth most common causes of death (reviewed 
by Varghese and Berk, 1983). The incidence of pneumonia 
increases during influenza epidemics. A survey conducted in 
West Germany in 1983, revealed an incidence of 1970/100,000 
respiratory disease, 50% of which was infective, with 
pneumonia specifically 9/100,000. In 1984 bronchitis and
pneumonia was the primary cause of death in 16,308 cases
(population 61 million) (Ringlemann, 1986). In the majority
of cases pneumonia is fortunately a single lifetime episode
but recurrent episodes occur in patients with underlying 
pulmonary and extrapulmonary disease.
1.3.3 Classification of Pneumonia:
Pneumonia is commonly classified anatomically, 
aetiologically or whether it is acquired at home (community-
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acquired) or in hospital (nosocomial). Anatomically it can be 
lobar when it is confined to one lobe, or bronchopneumonia 
when incomplete and usually non-adjacent areas of more than 
one lobe are involved.- Aetiological classification 
(pneumococcal, staphylococcal etc.), though more logical is 
limited by the frequent inability to identify the causative 
agent.
1.3.4 Aetiology:
Pneumonia in the community can be caused by viruses, gram 
-positive or gram-negative bacteria, fungi or protozoa. Some 
of the more common types of CAP will be briefly outlined 
below.
1.3.4.1 Pneumococcal Pneumonia:
The causative agent is Streptococcus pneumoniae, a gram- 
positive diplococcus which has 83 serological types. This 
organism accounts for 50-80% of hospitalised cases of 
pneumonia, with serotype 3 being the most virulent. It is 
most common between the ages of 30-50 with males more commonly 
affected than females. It affects previously healthy 
individuals, but those with cirrhosis of the liver, diabetes 
mellitus, renal failure, leukemia, multiple myeloma or sickle 
cell disease have an increased risk. Previous viral infection 
appears to predispose to it, and it tends to be fulminating in 
alcoholics and the elderly (Fraser & Peter Pare, 1978).
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1.3.4.2 Staphylococcal pneumonia:
During influenza epidemics, Staphyloccal aureus is one of 
the principal secondary bacterial agents. Sporadic cases 
commonly occur among drug abusers and occasionally as a 
complication of post-operative staphylococcal septicemia.
1.3.4.3 H. Influenzae pneumonia:
H . influenzae and S_^  pneumoniae are the most common 
organisms isolated from patients with chronic bronchitis. H . 
influenzae exists in capsulated or non-capsulated forms and 
the pathogenicity of the latter in the respiratory tract is 
not clear and has been largely regarded as a colonizing 
microorganism. Serotype b of the capsulated form accounts for 
the vast majority of pneumonia due to this species. In one 
study influenzae accounted for 12% of all cases of CAP
(Carbon, 1986). Special conditions and growth factors in the 
media are needed for the isolation of influenzae.
1.3.4.4 Mycoplasma pneumonia:
Mycoplasma pneumoniae is the second commonest cause of 
CAP. It is responsible for up to 20% of cases of CAP in the 
population at large and up to 50% in closed communities such 
as military bases, although radiological changes develop in 3- 
10% of infected cases (reviewed by Moskal, 1987).
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1.3.4.5 Klebsiella pneumonia:
Types 1, 3, 4 and 5 of this non-motile, encapsulated
gram-negative rod, account' for < 1 % of all pneumonias, y
Victims are often vagrants and alcoholics. It commonly affects 
the upper lobes or apical segments of lower lobes and often 
cavitates.
1.3.4.6 Legionellosis:
The causative agent Legionella pneumophila has been
identified as a gram-negative bacterium belonging to several 
serological types (I to IV). This disease has tended to
occur in outbreaks in institutions such as hospitals, but
sporadic cases also occur especially among those who have 
recently returned from abroad. The agent relishes in warm and 
humid conditions and has been isolated in air-conditioning 
systems during outbreaks. Mortality can be as high as 20%. 
Pontiac fever is a milder form of legionellosis which 
manifests with constitutional symptoms without associated 
pneumonia or mortality. Other members of this species
(Legionella-like organisms (LLO)) such as L^ micdadei_____
(Pittsburg pneumonia agent - PPA) and its genetically related 
organisms Tatlock and Heba have been implicated in nosocomial 
pneumonia (Muder, 1983).
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1.3.5 Lung defences in pneumonia:
Lung defence mechanisms are normally capable of 
protecting the host from serious lower respiratory infections 
but when these are compromised such as in tracheostomy, 
development of pneumonia is likely. In 1956 Leper reported the 
development of pneumonia in 100% of patients with anterior 
poliomyelitis, who had undergone tracheostomy and received 
intermittent positive pressure ventilation.
The spread of bacterial agents such as the pneumococcus 
into the lungs sufficient to cause significant infection 
depends on the interplay between the initial dose of 
organisms, excessive mucus in the air passages, the presence 
of interlobar septa which provide a mechanical barrier against 
spread, virulence of the organisms and the response of the 
host to infection, including hypersensitivity and other 
abnormal immunological responses (reviewed by Spencer,
1985).
Onoforio and colleagues (1983) investigated infecting 
doses and demonstrated that precise inocula of S^ aureus may 
be delivered to the lung without causing lung injury and a 
progressive increase in the size of the inoculum was inversely 
related to clearance capability by the host defences.
Epidemiological data suggest that cellular defences in 
the host are compromised in viral infections which accounts 
for the high mortality during viral epidemics. Jakab (1974) 
has shown that in mice previously exposed to aerosolized 
Sendai virus, clearance of S. aureus from non-consolidated
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lungs was impaired. Further work revealed that this might be 
due to a phagolysosome fusion defect in the alveolar 
macrophage exposed to the virus infection (Jakab, 1980). Later
antilymphocyte serum was found to be capable of reducing the
virus-induced AM phagocytic defect (Jakab, 1982). More 
recently virus-induced immune complexes were thought to be at 
least partly responsible for this suppressed AM activity
(Astry, 1984). Using a purely in vitro approach, Nugent (1979) 
failed to demonstrate impairment of ingestion of S_^_ aureus by 
alveolar macrophage monolayers previously exposed to a virus 
infection.
The AM rids the lower respiratory tract of particulates 
and microorganisms through the opsonic and non-opsonic 
dependent mechanisms referred to earlier. Rehm and
colleagues have demonstrated that the early phase of
pneumococcal killing in decomplemented rats was normal (1982).
There is now evidence which suggests that even non- 
phagocytic cells such as lung lymphocytes exert an IgA- 
dependent natural antibacterial activity in the lung (Sestini, 
1988). However a large enough dose of a pathogen in the lung 
eventually attracts polymorphonuclear leucocytes into the 
lung, either by the secretion of the AM-derived neutrophil 
chemotactic factor or activation of complement products by 
bacterial factors (Heidbrink, 1982)". Vial et al (1984) 
found that following pulmonary inoculation of pneumoniae
there is rapid production of chemotaxins with consequent 
recruitment of neutrophils within four hours. Furthermore,
this study has demonstrated that the numbers of neutrophils
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were proportional to the size of the dose of pneumococci
instilled. The requirements for the clearance of
microorganisms from the lower respiratory tract are not the 
same for all pathogens. Heidbrink (1982) has shown that 
complement acted chiefly as a chemotaxin in clearance of 
pneumococci but as an opsonin in clearance of pseudomonas.
The increased incidence of pneumonia in some groups may
be related to relatively compromised host factors. In 
alcoholics not only the mechanical barriers may be compromised 
because of altered level of consciousness and increased risk 
of aspiration, but nutritional deficiency often prevalent in 
these individuals may impair the cellular defences. Animal 
data suggest that alveolar macrophage phagocytic activity can 
be adversely affected by nutritional deficiencies (Moriguchi, 
1983; 1984; Shennib, 1984). Children with protein-calorie
malnutrition have been shown to have reduced immune reactivity 
(Edelman, 1973). CAP is responsible for high morbidity and 
mortality in the elderly population and there is ample 
evidence that aging affects both cellular and humoral 
immunity. In experimental pneumonia, Eposito and Pennington 
(1983) showed that the host response to pulmonary bacterial 
challenge was different in scenescent and young mice (1983) . 
Howells (1975) compared the antibody response to influenza 
vaccine in elderly nursing home patients with a group of young 
adult controls and found lower antibody levels in the elderly. 
T-cell function is also impaired in the elderly (Roberts- 
Thompson, 1974; Canguly, 1987) .
The AM and other lung defences in the normal state
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are capable of protecting the host from development of 
pneumonia but when these are compromised, recruitment of 
additional phagocytes mainly neutrophils is needed and the 
final outcome depends on the interplay between host and 
pathogen factors.
1.3.6 Pathology of Pneumonia:
The classical pathological changes of pneumonia are seen 
in pneumococcal pneumonia. Four stages are recognised in 
pneumococcal pneumonia i) Spreading of inflammatory oedema 
this is usually a clinically imperceptible stage which results 
from the tissue reaction to the causative agent and the fluid 
is usually rich in the organism. This stage is seen only in 
those patients who die rapidly within a few hours of the 
illness and is followed rapidly by exudation into the alveolar 
space of red blood cells and neutrophils associated with more 
oedema fluid and fibrin. The alveoli are congested leading to 
compression of the alveolar capillaries. Macroscopically the 
lungs look red and this is called red hepatization. Increase 
in fibrin and polymorphonuclear leucocytes with a slight 
reduction in red blood cells leads to further engorgement of 
the alveoli and compression of the bronchial capillaries with 
almost complete shunting of the blood supply to the unaffected 
areas of the lung. The lung looks bloodless and grey - grey 
hepatization. The pulmonary arteriole may become thrombosed 
possibly due to a direct microbial toxic effect on the 
endothelium. There then follows the stage of resolution which
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is heralded by the arrival of macrophages which progressively 
increase as they replace the neutrophils, which they 
phagocytose together with their contents. The neutrophils 
engulf the pneumococci but do not destroy them and the 
presence of the macrophage reaction is necessary for the 
resolution of the exudate (Spencer, 1985).
In bronchopneumonia the focus of the inflammatory process 
is around the respiratory bronchioles and the surrounding 
alveoli, unlike lobar pneumonia where it is in the alveolar 
spaces. Staphylococcal and Klebsiella pneumonia are prone to 
cavitation whereas this rarely occurs in pneumococcal 
pneumonia.
1.3.7 Bronchoalveolar Lavage in CAP:
Bronchoalveolar lavage has been used widely as a research 
tool in experimental pneumonia and is employed increasingly as 
a diagnostic tool in immunocompromised patients. However 
there is a notable deficiency of human data in the literature 
from bronchoalveolar lavage in CAP, especially in terms of the 
cellular aspects. Lafitte (1983), performed serial lavages 
on patients with pneumonia and found that during the initial 
period there was polymorphonuclear leucocytosis followed about 
ten days later by increased lymphocytes of up 
to 70%. The lymphocytosis was delayed in alcoholics. This 
study also found positive pneumococcal antigen in the 
concentrated lavage fluid both in bacteraemic and non- 
bacteraemic patients. Alveolar macrophage function was not
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investigated in this study.
1.4 Smoke Inhalation:
1.4.1 Historical Background:
The lethal effects of inhalation injury were recognised 
as early as the first Century A.D. when it was 
reported by Pliny that the Romans executed their prisoners by 
placing them over smoke of green wood fires (Dressier, 1976). 
In 1840 Long published postmortem findings of burns and
described hepatization of the lungs and associated pleural 
effusion (Long, 1840). In the more recent past the
contribution to mortality from smoke inhalation was 
highlighted by the Coconut Grove Night Club fire. Aub (1943), 
in his clinical description of the victims of that disaster, 
described how some survived by covering their mouths with wet 
cloths underlining the importance of smoke inhalation in those 
who died. Phillips (1962) pinpointed respiratory damage as 
the principal killer in the Massachussetts experience of fatal 
burns over a period of eighteen years. The effects of
experimentally induced thermal injuries to the lung were
documented by Moritz and colleagues (1945).
1.4.2 Incidence:
The precise incidence of inhalation injury and its 
contribution to mortality is difficult to measure because of
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the difficulty in separating the contribution from inhalation 
and cutaneous thermal injuries towards lung complications and 
mortality amongst fire victims. In Massachussetts General 
Hospital between 1939 to 1958, there were 106 deaths among 
1140 cases of burns and 42% died of respiratory complications 
with or without respiratory sepsis (Phillips, 1962).
Divincenti (1971), reported the incidence of 2.9% in 
inhalation injury among a total of 2,297 patients treated for 
burns but those with respiratory tract injury sustained a 
mortality of 76.3% compared to the overall mortality of 9.5%. 
In 1985 there were 978 deaths from fires in the United
Kingdom, 155 in Scotland and 81 in the Strathclyde Region.
While the overall mortality from fires has remained largely
unchanged between 1979 to 1985, it is striking that
among those who die from smoke or gas, mortaility has slowly 
increased (U.K. Fire Statistics, 1978-1985) . Since the 
majority of fires occur in habitated dwellings, there is no
sexual preponderance but the effect of age is important. In 
1985, children below the age of five years had twice the risk 
of dying from fire compared to those aged between 15-59 years. 
In the same year 48% who died were aged over 60 years and 29% 
were aged above 75 years. In the latter group the risk of 
dying from fire was seven fold that of those aged between 15- 
59 years.
1.4.3 Physiopathology:
Death from inhalation injury can be early, delayed or
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late. This chronological sequence is roughly in keeping with 
different operative mechanisms. Early death from a few 
minutes to several hours can be attributed to various noxious 
products of combustion. Carbon monoxide poisoning with 
resultant hypoxemia plays a major role during the early phase. 
Carbon monoxide (CO) forms a stable compound 
carboxyhaemoglobin (COHb) due to its high affinity for 
haemoglobin. Because it does not dissociate easily, COHb 
levels can rapidly build up and critically impair oxygen 
delivery to the tissues. Blood gas analysis can be misleading 
as typically PaC^ is normal and it may be assumed that Sa02 is 
also normal, but the measured SaC^ is low. A fatal hypoxemic 
episode with levels of COHb greater than 60% is frequent 
(Cahalane, 1984) . The carotid body is less sensitive to oxygen 
concentration and therefore there is often no compensatory 
tachypnea. Pyrolysis reduces the oxygen content of air leading 
not only to reduced inhaled oxygen but also reducing the 
dissociation of COHb which depends on oxygen concentration. 
Hyperbaric oxygen rapidly dissociates CO from haemoglobin.
In this acute phase, another problem is cyanide 
poisoning. Partial combustion of many household items such as 
furniture, nylon, asphalt, wool, silk and polyurethane- 
containing materials, produce cyanide. This cell poison 
inhibits cellular oxidation. Pyrolysis products of these 
synthetic materials are also toxic to the central nervous 
system and coupled with hypoxemia and the frequently 
associated alcoholism often leads to collapse in the enclosed 
environment increasing the incidence of a fatal outcome.
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Underlining this sequence of events in early deaths for 
example is the finding that among the U.K. fatalities in 1985, 
63% of fatal casualties from fires in dwellings were found in 
the room of origin of the fire compared to 20% found elsewhere 
on the same floor.
Those patients who survive the "biochemical effects" of 
fire in the form of hypoxemia, carbon monoxide poisoning and
cyanide poisoning still face the threat of structural damage 
to the respiratory tract. Structural damage can be due to
thermal or chemical injury. Direct thermal injury of the
lower respiratory tract is rare unless one inhales steam. This
is because of excellent cooling capacity of the upper 
respiratory tract (URT) and very low specific heat (heat 
carrying capacity) of dry air which is 1/4000 that of steam. 
Moritz (1945) demonstrated that pumping hot dry air at 500°C 
transorally, its temperature dropped to around 270°C when it 
reached the larynx and 50°C when it reached the trachea. 
This explains why the upper respiratory tract bears the brunt 
of thermal injury. The larynx undergoes reflex closure when 
it is exposed to high heat or chemical irritants.
Presence of facio-oral burns or singeing of nasal hairs 
may indicate upper respiratory thermal damage. Hoarseness of 
voice needs to be taken seriously and may indicate the 
presence of laryngeal edema. In a recent study the severity 
of oedema of laryngeal structures characterised by
nasopharyngoscopy correlated with increased surface burns,
burns of face and neck and with rapidity of fluid therapy
(Haponik, 1987). Damage to the URT beyond the larynx is also
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caused by hot smoke debris which has a higher specific heat 
than dry air. Tracheitis and denudation of the respiratory 
mucosa with loss of cilia occurs within the first 24 hours. 
This is accompanied by excessive mucus production and 
increases the hazards of infection in the lower respiratory 
tract. Clark (1985) found that severe changes (Grade 3) of 
endobronchial architecture diagnosed bronchoscopically were
associated with 100% mortality.
Chemical injury to the lower respiratory tract (LRT) or
the URT may result from inhalation of toxic gases, depending
on the solubility of these gases. The more soluble gases
dissolve in the URT while the less soluble ones dissolve in 
the LRT (Carpo, 1981).
Damage to the LRT accounts for the fatalities during the 
delayed phase of 1-5 days post injury and the late phase at 
about fourteen days. In severe cases, within 24 hours 
exudation of fluid into lungs with radiological changes may
take place and this occasionally may progress within the next
few days to the full picture of the Adult Respiratory Distress 
Syndrome (ARDS). Patients with pure smoke inhalation injury 
usually do not develop severe pulmonary complications but
those with both burns and inhalation injuries often succumb to 
these. These are brought about by a number of factors
including shallow breathing from pain due to burns or skeletal 
injuries, narcotics, treatment factors such as fluid overload, 
hyperoxia, sepsis from ventilation, wounds or aspiration. 
Other extrapulmonary factors include coagulation problems and 
cardiac causes.
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Late deaths are usually a result of sepsis of the LRT 
and/or pulmonary embolism (Aucher, 1973). For those who 
survive, various long-term sequelae have been reported. These 
include bronchiectasis, tracheal stenosis (Donnellen, 1965), 
endobronchial polyposis (Adams, 1979). Chronic airways 
obstruction has been reported following inhalation of 
overheated cooking oil fumes (Simpson, 1985) and amongst fire 
fighters (Loke, 1980) .
1.4.4 Cellular and humoral changes in fire victims:
From the above discussion it is clear that pulmonary 
complications among fire victims are a result of an interplay 
of complex patho-physiological processes. Most of the data 
that are currently available have addressed the changes that 
occur in burns. Among the most important of these, is 
complement activation, and consumption. Dhenin (1978) found a 
transient fall in complement due to leakage at the sites of 
burn wounds followed by increased complement levels. 
Heidenman (1979) reported aggregation of platelets with 
entrapment in the lungs associated with initial leucopenia 
followed by leucocytosis and activation of the complement 
system in dogs exposed to thermal injury. Neutropenia which 
follows intravascular complement activation was thought to be 
due to increased neutrophil adherence with consequent 
margination (O'Flaherty, 1977). The neutrophils become 
entrapped within the pulmonary vasculature (Ward, 1981) . 
Furthermore neutrophils have been found to be activated
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following thermal injury although interestingly they show 
reduced chemotactic response towards C5a (Moore, 1986), but 
only a transient depression of this response towards f-met- 
leu-phe. This ' indicates incomplete paralysis of neutrophil 
migration apparatus. In a number of studies impaired 
chemotaxis of neutrophils associated with increased lysosomal 
enzyme release has been found in patients with ARDS (Fowler,
1984). In a study of potential ARDS patients an early reduced 
neutrophil migratory response towards C5a but not f-met-leu- 
phe was seen in all those patients who developed ARDS 
(Solomkin, 1985).
Reduced neutrophil accumulation at sites of burns wounds 
is explained by this impaired chemotaxis. The accumulation of 
neutrophils in the lungs can be explained by increased 
aggregation of neutrophils, but it is conceivable that other 
factors which might attract these neutrophils (largely 
unresponsive to C5a) may also take part. It is interesting 
that Fowler and colleagues (1984) failed to reproduce these 
changes in donor neutrophils exposed to serum from patients 
with ARDS, thus excluding a serum factor for depressed 
chemotaxis. Bronchoalveolar lavage fluid from patients with 
ARDS has been shown to have chemotactic activity to 
neutrophils, and preliminary data indicate that the 
chemotactic activity could not be attributed to C5a, C3, 
fibrinogen or C5a desarg (Parsons, 1985). Whichever 
mechanisms operate in the accumulation of neutrophils in the 
lungs in ARDS, their injurious effects are thought to be 
responsible for the ensuing lung damage. Till and colleagues
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(1982) reported damage to endothelial cell lining, destruction 
of endothelial cells and plugging of pulmonary capillaries by 
neutrophils following intravascular activation of complement. 
The injurious effects of neutrophils on pneumocytes has been 
referred to earlier (Ayars, 1984). In the study by Solomkin 
(1985) neutrophils of patients with ARDS were found to have a 
reduced cellular content of lysozyme and beta-glucuronidase 
indicating previous degranulation. Cochrane (1983) reported 
oxidative and proteolytic cleavage of alpha-l-proteinase 
inhibitor by BAL fluid from patients with ARDS. Elastolytic 
activity of BAL fluid from similar patients was shown by other 
workers (Lee, 1981). There is thus ample evidence implicating 
the neutrophil in the acute lung injury of ARDS.
ARDS has been overshadowed by the predominance of 
neutrophil-derived injury. This is clearly important but the 
macrophage which may be equally important has received little 
attention. In thermal injury and smoke inhalation for 
example the evidence in the literature appears largely to 
underline depression of the alveolar macrophage function. 
Dressier (1974) reported increased bacterial phagocytosis and 
killing which became depressed when the animals became 
septic. Fick and colleagues (1984) reported impairment of 
phagocytic activity of alveolar macrophages from rabbits 
exposed to woodsmoke. In his study the lavage was performed 
shortly after the exposure and there were no polymorphonuclear 
leucocytes (PMN) in the lavage fluid. Interestingly the 
viability of macrophages showed positive correlation with 
longer exposure and CoHb levels. In another recent report by
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Loose and colleagues (1984) alveolar macrophages from burned 
rats showed depressed phagocytic activity and chemotaxis but 
increased micr.obicidal activity. Demarest et ad (1979) 
reported impairment of AM chemotaxis in a group of patients 
with smoke inhalation. It is notable that the bronchoalveolar 
cell population in this study consisted of a high proportion 
of neutrophils which could have interfered with migration of 
macrophages in the membrane assay deployed. However in a 
study involving a larger group of fire victims, in which 
serial lavages were performed in the course of 24 hours after 
admission demonstrated that there was a depression of 
respiratory burst of the AM obtained early after injury. 
Macrophages obtained later from a different site of the lung 
demonstrated increased initiation of the respiratory burst and 
phagocytic activity compared to those from control subjects. 
(Gemmell 1987). The recent finding of synergistic effects of 
leucocytic proteases and macrophages in oxygen radical 
responses (reviewed by Ward, 1986) underlines the importance 
of examining different aspects of AM function in this complex 
issue of lung injury in smoke inhalation with or without 
associated burns injury.
Another aspect of lung injury which has been 
investigated following smoke inhalation is surfactant 
activity. Neimann (1980) using a surface area curve as an 
indicator of the surfactant activity in dogs exposed to 
kerosine-ignited wood smoke found that there is immediate 
reduction in surfactant activity with consequent dense non- 
segmental atelactasis. However direct estimation of
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surfactant in patients with inhalation injury was found to be 
normal (Head, 1980).
1.4.5 Diagnosis of Smoke Inhalation:
Diagnosis of smoke inhalation depends largely on clinical 
history and physical examination and arterial CoHb estimation. 
Until recently accurate quantification of severity of smoke 
inhalation was difficult but the work of Clark (1985) has 
demonstrated that the use of a clinical scoring system coupled 
with CoHb measurement allows fairly accurate estimation of the 
severity of inhalation injury. The following criteria each 
given a score of one were used. A score of more than two 
indicated significant smoke inhalation: i) A history of being
trapped in a house or industrial fire in an enclosed space, 
ii) Production of carbonaceous sputum. iii) Perioral facial 
burns - affecting the nose, lips, mouth or throat, iv) Altered 
level of consciousness at any time after the incident 
including confusion. v) Symptoms of respiratory distress, vi) 
Signs of respiratory distress including stertorous or 
laboured breathing or auscultatory abnormalities. vii) 
Hoarseness or loss of voice.
In this study a clinical score of seven was associated 
with 100% mortality. Measurement of COHb and use of a 
normogram enabled one to extrapolate COHb back to the time of 
injury.
The chest X-rays are not helpful in the diagnosis of 
smoke inhalation injury as they are commonly normal. However
59
they are helpful in the follow-up of patients. 
Nasopharyngoscopy and bronchoscopy have been used to 
characterise URT and LRT damage. These may give an early 
indication for intubation although initial normal airways do 
not preclude later need for this procedure. Early intubation 
is advised for high risk patients as intubation later may be 
difficult (Achauer, 1973). Detection of high risk patients can 
be made with the use of Clark's mortality probability equation 
(Clark, 1986). Ventilation perfusion scanning using xenon 
has been reported to detect early small airways abnormality 
(Cahalane, 1984). However this is not routinely used in 
clinical practice for management of smoke inhalation 
injuries. Spirometry and analysis of flow volume loops may 
yield the same results.
1.5 Radiotherapy
1.5.1 Historical background
Radiotherapy for malignant conditions started during the 
first and second decades of this century and in 1921 the first 
paper was presented on the effects of radiation on the lung. 
The effects of radiation on skin and lung were compared and 
since then several reports have appeared describing the 
pathological changes, respiratory function impairment, effect 
of dosage and rate of delivery and the use of steroids.
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1.5.2 Radiation Injury:
1.5.2.1 Incidence
Radiation injury is probably much commoner than the 
reported incidence of radiation pneumonitis, since it is 
likely that injury can occur without development of 
radiological changes. However radiation pneumonitis based on 
radiological changes is not infrequent but symptomatic 
pneumonitis is much less common. Using megavoltage for breast 
cancer, reports of radiation pneumonitis have varied between 
24.5% to 70%, with a mean occurrence of about 41%
(reviewed by Gross 1977a). In one series radiological changes 
following radiotherapy for lung cancer were observed in 13% of 
patients at three months, 33% at six months, and 66% at twelve 
months and 100% at thirty months. In this series 4.6% 
developed symptoms. In another series only 6% radiation 
pneumonitis was reported while in yet another, 15% of patients 
were reported to have developed radiation pneumonitis of whom 
a third had a fatal outcome. Radiation pneumonitis can also 
develop following mediastinal radiation with rates of between 
6.4% to 65% in different series. Fatalities attributed to 
pneumonitis have been reported between 0.25% to 5.8% in these 
series. It should be mentioned that the above rates pertain 
to the higher dosage schedules employed in the past and 
efforts still continue to define dosage and fractionation of 
radiation with improvement in shielding techniques in order to
61
reduce the incidence of radiation pneumonitis. In a recent 
prospective study acute radiation damage as detected by 
computerised tomography scans occurred in thirty six of fifty 
four patients (Mah, 1988).
1.5.2.2 Biologic aspects of radiation damage:
Absorption of X-rays by tissues leads to ionisation of 
chemicals with production of free radicals. In the presence 
of oxygen molecules these radicals produce organic peroxides 
which aggravate the damage, (Gross 1981). Tissue damage can be 
either on genetic (DNA) or on non-genetic material (proteins 
and carbohydrates). Mitosis is the crucial stage at which 
genetic material is affected by radiation, where chromosomal 
aberration may result in anaphase arrest. Genetic material 
damage is usually apparent much later than non-genetic 
material damage, and the speed with which this appears is a 
function of rate of mitosis. Damage to non-genetic material is 
usually more widespread and acute. Functional impairment can 
occur fairly acutely due to increased permeability of 
membranes with the consequent exudation of tissue fluids, 
followed later by less acute manifestations and repair of 
membranes. Data from cytokinetic studies in small mammals 
indicate that radiation-induced chromosomal damage is most 
marked on bronchial epithelial cells, capillary endothelial 
cells and type II pneumocytes. Type I pneumocytes are not 
affected genetically because they do not enter into mitosis 
but suffer non-genetic damage. The capillary endothelium has
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been viewed as the common target determining radiation 
tolerance in many organs. In the lung type II pneumocytes 
have also been considered important in this regard because of 
their secretory function. Chronologically radiation injury is 
usually considered under three somewhat overlapping phases 
which can be dissociated; the early phase occurring up to two 
months following radiation, the intermediate phase from two to 
nine months and the late phase after nine months.
1.5.2.3 Pathological Changes:
Typically early pathological changes are characterised by 
exudation of fluid into the alveoli and interstitial oedema. 
This may resolve leaving no radiological abnormality or may 
progress to a chronic phase. Warren and Spencer in 1940 
described hyaline membrane formation as a reliable diagnostic 
finding of radiation pneumonitis (reviewed by Rubin and 
Casarett, 1968). Jennings and Arden in 1962 attempted to 
correlate pathological changes with the radiation dose and 
time interval and found fibrin (hyaline) membranes in 41% of 
all irradiated lungs usually and most prominently at 6 months 
to 2 years after irradiation with a dosage greater than 2000R. 
Other features include vascular lesions with engorged and 
thrombosed capillaries and arterioles, oedema, intimal 
proliferation and medial changes together with subintimal 
accumulation of lipid-laden macrophages. Atypia, hyperplasia 
and epithilial desquamation are also common findings. 
Inflammatory cells are notably absent. Necrosis of bronchial
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mucosa and bronchiectasis also occur. Pulmonary function 
tests in patients with radiation pneumonitis show a 
restrictive defect with a drop in the transfer factor and lung 
volumes. Deterioration in lung function in patients who have 
undergone bone marrow transplantation is multifactorial, but 
radiation injury is one of the contributing factors. In a 
recent study (Sutedja, 1988) a large total body irradiation
dose was found to be one of the major factors associated with
early deterioration of lung function.
1.5.2.4 Factors that may influence development of radiation 
pneumonitis:
The incidence and severity of radiation injury depends on 
the volume of the lung irradiated, the total dose of 
radiation, the rate and quality of radiation and other 
modifying factors. The larger the lung volume irradiated the 
greater is the likeliehood of producing significant radiation 
injury even when using the same dosage delivered in the same 
manner.
Rubin and Casarret (1968) regard lung volume as the most 
important single factor determining radiation tolerance. 
Fractionation of dose allows repair of sublethal damage
between fractions and therefore the rate of delivery of
radiation is more important than the total dose. Errors in 
technique and dosimetry can influence the radiation absorbed 
and the incidence of radiation damage. Mah and colleagues 
(1988) found that a 5% increase in lung dosage higher than the
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uncorrected prescribed dosage produced a 12% increase in acute
radiation injury and the average lung dose can be up to 17%
higher depending on lung geometry, technique and densitometric
considerations. Other factors that may influence the
development of radiation injury include repeht radiotherapy,
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concomitant or previous chemotherapeutic agents and use of 
steroids. Radiation injury can occur following direct lung 
radiation, or radiation to contralateral lung only,' 
mediastinal irradiation, total body irradiation or irradiation 
of the upper half of the body. In one study Prato and 
colleagues (1977) found that mediastinal irradiation was most 
important in development of radiation pneumonitis.
1.5.2.5 Bronchoalveolar lavage in radiation injury:
Studies on this well recognised complication of 
radiotherapy have been largely histopathological and broncho­
alveolar lavage as an approach has been rarely used. Among 
the few studies is that by Cordier et ad. (1984) who have 
reported cellular data from six patients with early radiation 
pneumonitis. Lavage from these patients showed increased 
numbers of lymphocytes and in one patient these lymphocytes 
were activated. The lavage fluid also showed collagenolytic 
activity for type I human collagen. There were also 
increased serum proteins including high molecular weight 
species. These workers concluded that the radiation injury 
seen in their patients was a lymphocytic alveolitis possibly 
perpetuated by activated lymphocytes and collagenolytic
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activity in alveolar structures contributed to possible
fibrosis. In another study, Tsao and Ward (1985) reported 
increased numbers of macrophages in rats lavaged between two 
and six months following irradiation to the hemithorax. Fifty 
to sixty per cent of these macrophages were larger than 
control macrophages and were foamy in appearance and contained 
many lipid vacuoles. These macrophages also showed reduced 
plasminogen activator activity with some degree of recovery at 
six months. Alveolar macrophages have been shown to be
affected by radiation. Sabloniere and colleagues (1983)
reported an initial reduction in phagocytic activity of rat
alveolar macrophages at 14 days after whole-body irradiation, 
followed by an increase to 75% above control macrophages at 21 
days and returning to normal again at 35 days. The number of 
macrophages was also increased in the irradiated mice. 
Ultrastructural examination of the alveolar macrophage 
cytoskeleton following _in vitro irradiation showed that at a- 
dose of 120 Gy reproducible changes in the cytoskeleton take 
place but this change undergoes repair within hours (Ladyman, 
1984). Patients undergoing allogeneic bone marrow
transplantation are ndrmally conditioned with total body 
irradiation and often succumb to interstitial pneumonitis. 
Alveolar macrophage function in a group of bone marrow 
transplant patients was reported as defective. (Winston,
1982).
Thus radiation injury to the lung is a common 
complication of radiotherapy and can be fatal. Its diagnosis 
is crude as it depends on X-ray changes and probably
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underestimates the true incidence. Studies in its 
pathogenesis have been largely histopathological with few data 
from broncho-alveolar lavage. It is likely that in future 
with more sophisticated radiation techniques the incidence 
will be reduced.
1.6 Bronchoalveolar Lavage (BAL)
1.6.1 Historical Background:
Following the optimal development of the rigid 
bronchoscope at the beginning of this century, bronchial 
washing was used as a therapeutic procedure (Reynolds, 1987) . 
Later various catheters were designed to be used through the
rigid bronchoscope. In 1961 the technique of obtaining pure
macrophage populations from a rabbit by bronchoalveolar lavage 
was described (Myrvick, 1961). The concept of flexible fibre 
optic bronchoscopy was developed by Ikeda in Japan in the
early 60's but it was not until 1967 that the first fibre-
optic bronchoscope was produced by the Machida and Olympus
companies. In the West this equipment became available a few 
years later and its widespread use started in the early 70's.
1.6.2 Safety and Complications of BAL:
Compared to many invasive techniques BAL is very safe 
with an incidence of less than 5% minor complications with no 
major ones (Strumpf, 1981). Transient pyrexia can occur in a
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small proportion (2.5%) of patients (Strumpf, 1981) but in
a study where four separate lobes were lavaged pyrexia 
occurred in 50% of cases (Pingleton, 1983). This was
unusually high and could not be explained. Transient pyrexia 
is thought to be due to pyrogen release and not due to 
infection (Reynolds, 1987). Bronchospasm especially in 
asthmatics may occur but nebulized bronchodilators are usually 
adequate to deal with this complication. Special guidelines
for bronchoscopy and BAL have been laid for asthmatics
(Bernstein, 1985). Bleeding can occur but this is usually
bronchoscopy related and not lavage related. Finally it is
not unusual to have non-infective radiological infiltrates a
few hours after the procedure but these disappear 
spontaneously.
1.6.3 Distribution and yield of the lavage fluid:
Kelly et ad (1987) using digital subtraction radiography 
demonstrated that following instillation of the first aliquot 
of fluid, it remained near the tip of the bronchoscope and an 
even distribution is obtained with further aliquots. The 
retrieval from the first aliquot is usually small but this 
increases subsequently. In general 50-60% of the total
instillate is recovered from the normal lung, but this is 
affected by diseases such as emphysema where the yield can 
drop to as low as 10-40% (Reynolds, 1987). The right middle 
lobe and the lingula have been found to give greater fluid 
yields than the lower lobes, though the content of lavage
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fluid from these different sites was similar (Pingleton,
1983). The temperature of the instillate was not found to 
affect the yield in this study but in a recent state of art 
review by Reynolds (1987) it is stated that warming the fluid 
increases the recovery slightly. Local anaesthetic was not 
found to affect either the volume or the content of the fluid 
recovered (Davidson, 1986).
1.6.4 Content of the BAL Fluid:
The lavage fluid consists of cellular and acellular or 
soluble components. These may be affected by procedure 
variables, smoking and disease states.
Alveolar macrophages constitute by far the highest 
proportion of cells in BAL fluid from normal individuals with 
a range of 85-93% (Huninghake, 1979; Reynolds, 1987); 
lymphocytes 7-12% and polymorphonuclear leucocytes (PMN) 1-2%. 
Eosinophils and basophils constitute less than 1%. T-cells 
make up to 80% of all the lymphocytes with a ratio of T4:Tg of
1.5 - 1.6:1 similar to that in the peripheral blood. A good
BAL fluid lavage should contain less than 5% epithelial cells. 
A high epithilial cell count indicates bronchial rather than 
alveolar origin (Robinson, 1988). Red blood cells normally 
constitute less than 5%, but bronchoscopic or suction trauma 
can increase the red cell population.
BAL fluid contains proteins, carbohydrates, lipids, 
electrolytes and enzymes. The contents of soluble components 
in the BAL fluid is much more variable than the cellular
69
contents. These components are much more sensitive to the 
effect of dilution and variability of the volumes of the 
instillate. In an attempt to standardise these constituents, 
a ratio of the particular constituent to the albumin content 
is used. Another source of variability of the soluble 
components in BAL fluid is the small quantities of these 
constituents. This means they are more likely to be affected 
by methodological considerations. The concentration of many 
of the soluble contents in the BAL fluid is influenced by 
diffusion from the circulation. Small proteins of 150,000 
daltons are fairly diffusible but those of larger molecular 
weight are progressively less diffusible so that alpha-2
macroglobulins and betalipoproteins are not found in the 
normal lung (Huninghake, 197 9) . A few examples of these
constituents and their levels in smokers and non-smokers are 
given below.
1.6.5 Effects of aliquots:
The first aliquot retrieved differs from subsequent 
aliquots both in volume and content. Cell yields in 
sequential aliquots do not follow dilution models and often 
the second aliquot especially in smokers show maximal cell 
numbers which drop only a little in subsequent aliquots
(Davis, 1982) . Dohn (1982) found increased numbers of PMN and
lymphocytes in the first aliquots of control patients but an 
increasing proportion of these cells in the later two aliquots 
from patients with interstitial lung diseases (ILD). However
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Robinson et al_ (1988) did not confirm these findings. In 
their study, they found reducing proportions of PMN in 
subsequent aliquots from ILD patients. Similar findings of 
high content of PMN in the initial aliquot was reported by 
Martin (1985) from patients with or without airflow 
obstruction.
Merrill and colleagues (1982) assessed the effect of
sequential aliquots on proteins and found that there was a 
progressive reduction of total proteins, albumin, 
immunoglobulins and free secretory component in subsequent 
aliquots. However the ratios of different proteins remained 
constant in all the aliquots. The effect of volume of
instillate in this study revealed that when a smaller aliquot
was used the content of the fluid was more attributable to 
airways origin rather than alveolar origin. The first aliquot 
then contains larger numbers of PMN and a higher concentration 
of proteins.
1.6.6 The Effect of Smoking:
Cigarette smoking increases the proportion of neutrophils 
but reduces the lymphocytes. It also affects the soluble
components. Some examples of the changes in content of the
BAL fluid in smokers are given overleaf, (table 1.1).
1.6.7 BAL-Versus Histology:
Lung biopsy tissue provides the most direct assessment of
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Table 1.1: BAL in smokers and non-smokers
Constituent Non-Smokers Smokers References
Volume of fluid Reduced Finley* 1972 
Bell 1981 
Villager 1981 
Huninghake 1983
Cell Yields
/ml BAL 
fluid
2.6 (+ 0.6)x 
10/ml BAL fluid
6.3 (+ 1.1) x 
10 /ml BAL 
fluid
Yeager* 1974
Total cells 15.8 (+ 2.8)x 10 
(Total cells)
78 (+ 7.0) x 
10
Merrill 1981*
% Macrophages 88
92 (+ 4)
93.8
96 (+ 3)
Merrill 1981* 
Costabel 1986*
% Neutrophils 1 (+ 1) 
1.5 (+ 0.3) 
0.2 (+ 0.1)
1 (+)
3 (+ 0.5) 
4.4 (+ 1)
Costabel 
Merrill 1981 
Huninghake 1983*
% Lymphocytes 7.0 (+ 3.0) 
7.2 (+ 1.0) 
8.7 (+ 1.2)
3 (+ 2) 
2.9 (+ 1.0) 
3.1 (+ 0.3)
Costabel 1986* 
Bell 1981* 
Merrill 1981
i-3 00 1.9 (+ 0.8) 0.9 (+ 0.4) Costabel 1986*
Immunoglobulins
IgG /Albumin ( g/ 
IgG
g) 0.082 (+ 0.01) 
0.043 (+ 0.006)
0.196 (+ 0.032) 
0.045 (+ 0.015)
*
IgG 0.003 (+ 0.002) 0.084 (+ 0.003) Merrill
IgG
IgGA
IgGE
0.009 (+ 0.006) 
0.319 (+ 0.04) 
0.017 (+ 0.004)
0.0162 (+ 0.116) 1985 
0.222 (+ 0.04)
0.08 (+ 0.06)
Fibronectin ug/mg
albumin
Carcino-embryonic 
Antigen ng/mg
7.3 (+ 2.9) 11.3 (+3.9) Villager
1981*
protein 0.04 0.08 Merrill
1981*
* indicates significant difference between smokers and non- 
smokers .
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inflammation but is anatomically selective and invasive. The 
availability of a procedure less invasive which can be 
performed at multiple sites repeatedly, such as BAL is 
opportune provided it can reliably give comparable information 
to that which has hitherto been regarded as the gold standard. 
Like many tests in clinical use, BAL has limitations.
Biopsies from patients with cryptogenic fibrosing 
alveolitis (CFA), were found to have more airspace cells, 
mainly PMN and eosinophils, whereas the interstitium showed 
more lymphocytes (Davis, 1978) . Comparison of airspace cells 
in open lung biopsies showed a close linear relationship 
between the percentages of lymphocytes in the BAL (Davis, 
1976). Thus the lung lavage showed good correlation with free 
luminal cells but did not get over the discrepancy between 
lung interstitium cells and free alveolar cells. Haslam et ad 
(1984) using semi-quantitative analysis of cells in 
histological specimens, quantification of cells in lung 
extracts and analysis of BAL from patients with ILD, found 
that the eosinophils and PMN correlated well in the latter two 
techniques but lymphocytes did not. There was no correlation 
between BAL or lung extraction with histological semi- 
quantitative analysis. Huninghake comparing lung extract 
cells and lavage cells in individual patients showed excellent 
correlation of cell proportions between these two techniques. 
In a recent study by Watters et ad (198 6) lymphocyte content 
of lavage fluid was said to show significant correlation with 
histopathological evidence of potentially reversible alveolar 
septal inflammation. Lymphocyte content showed negative
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correlation with pathologic honeycombing. Thus the main 
message in CFA is the lack of correlation between 
predominantly lymphocytic cells in the interstitium with 
predominant neutrophils and eosinophils in the lavage.
In sarcoidosis light microscopy of biopsy specimens 
normally shows very few cells of any type in the alveolar 
airspaces while lavage fluid shows predominance of 
lymphocytes. Using immunocytochemical techniques on cryostat 
preparations from transbronchial biopsies (TBB) and on lavage 
cells from five patients with sarcoidosis, Campbell (1985) 
reported that subsets of lymphocytes in BAL accurately
reflected type and proportion of subsets present in TBB. The 
value of T^:Tg cells in BAL from each individual patient was 
in accord with the TBB specimen. Macrophage phenotypes
however only showed qualitative but not quantitative 
correlation. In another study Semenzato et al_ (1985) used 
similar histochemical technique and monoclonal markers on lung 
biopsies and BAL specimens from 33 patients with sarcoidosis 
and hypersensitivity pneumonitis and showed that the relative 
proportions of inflammatory and immunocompetent cells were 
well correlated. However BAL tended to overestimate 
percentages of lymphocytes especially in high intensity
alveolitis and particularly in hypersensitivity pneumonitis. 
Thus despite the light microscopy findings in sarcoidosis 
referred to earlier, BAL analysis appears to give some
correlation with cells in biopsy specimens.
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1.6.8 Uses of BAL:
1.6.8.1 Therapeutic:
BAL had been used as a therapeutic measure in the past in 
conditions such as bronchiectasis, asthma or cystic fibrosis. 
Therapeutic bronchoscopic suction of bronchial secretions 
especially in the intensive care setting is more common. 
However proper therapeutic lavage of the alveolar compartment 
is now rare and is indicated in the rare condition of alveolar 
proteinosis, and microlithiasis. In the former condition 
bilateral whole lung lavage using large volumes of fluid is 
repeated at intervals (du Bois, 1983).
1.6.8.2 Diagnostic:
Several reports have now shown that BAL can be used 
successfully in the diagnosis of pneumonia of the immuno­
compromised patients. It was recently recommended in making 
the diagnosis of pneumonia in a hospital outbreak of 
Legionaires disease (Winter et al., 1987). The role of BAL in 
the diagnosis and staging of ILD is controversial, especially 
in CFA. The BAL changes in CFA are variable and cannot be 
used to make a firm diagnosis in the individual patient. In 
sarcoidosis some authorities appear more confident with BAL. 
In a recent editorial Springmeyer (1987) , stated that in their 
experience a T-lymphocyte predominant lavage with a T4:T8 
ratio of 4:1 or greater was nearly 95% specific for the
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diagnosis of sarcoidosis. Hypersensitivity pneumonitis, 
however has a much larger lymphocyte predominance usually, 
with the T^:Tq ratio of less than 1:1. Use of monoclonal 
markers to detect B-lymphocytes has been reported to be 
diagnostic of lymphoma (Davis, 1987). Pulmonary alveolar 
proteinosis can be diagnosed by the characteristic lamellar 
bodies in the alveolar macrophage (du Bois, 1983). Langerhans 
cells which are OK T6 (or the equivalent NA1/34) positive 
cells with the Langerhans granules in a proportion of 5% or 
more of BAL cells may confirm the diagnosis of histiocytosis X 
(Chollet, 1984). Demonstration of siderin granules in alveolar 
macrophages indicates pulmonary haemorrhage.
Finally the impact of BAL cell analysis on clinicians' 
diagnostic evaluation of ILD patients was recently assessed by
Stoller et ad (1987). In this study clinicians were asked in
a questionnaire about the likeliest diagnosis for the patient 
and the confidence of each diagnosis and any proximate plans, 
when they submitted lavage specimens and when they obtained 
the results. The study revealed that BAL results influenced 
the clinicians' diagnostic thinking in 59% of cases; and in 
52% of cases this change was appropriate compared to 9% 
inappropriate. In addition clinically impressive change 
occurred in 9% of cases including an unexpected case of AIDS
among the total of 78 patients in the study.
1.6.8.3 Patient Follow-Up:
While controversy exists regarding the diagnostic
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capability of BAL in ILD some use regarding prediction of 
prognosis has been reported. Turner Warwick et aJL (1987) 
reported that CFA patients with predominantly lymphocytic 
lavage, were more likely to respond to corticosteroids while 
those with predominant neutrophil and eosinophil counts often 
responded to cyclophosphamide. With regards to sarcoidosis, 
another study by Turner Warwick (1984) in which BAL,
angiotensin converting enzyme (ACE) and gallium scan were 
performed but not used in decision making, revealed that there 
was a clear improvement of many parameters in many patients in 
the absence of high initial lymphocyte count of the lavage 
fluid. In addition in some individuals some of the parameters 
including chest x-rays, physiology, gallium scan and ACE 
returned to normal while lymphocyte counts remained high.
Huninghake (1986) has reported that in their experience
lymphocyte counts might remain high following treatment with 
corticosteroids and for this reason it is their policy to 
continue corticosteroids until BAL lymphocyte counts 
normalize. This policy ensured that only few patients
relapsed.
1.6.9 Processing of the Lavage Fluid:
BAL fluid is collected into the container in individual
aliquots by direct suction through the bronchoscope with a
syringe on the suction pump; or pooled together in one larger 
container. Some workers use siliconised containers to
minimise cell loss. Some recommend collecting samples on ice
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(Huninghake, 1979) while others are not so specific (Reynolds, 
1987). An attempt should be made to examine the fluid as soon 
as possible. Buffering of the lavage fluid is known to 
improve the viability of cells (Haslam - personal 
communication) and it is conceivable that delay in examination 
of cells can adversely affect the viability.
Once the BAL fluid is in the laboratory, excess mucus is 
removed by a pipette and an original total cell yield is made 
before further processing of the fluid. Some workers use 
Coulter counters for this purpose (Haslam, 1986) but most use 
one of the many counting chambers and a white cell dilution 
fluid. Sometimes it is necessary to sieve the BAL fluid on a 
layer of surgical gauze to remove mucus and debris. As this 
treatment can affect the cell counts (Kelly, 1987) 
substantially, it is important that the original count should 
have been made before this step as mentioned above. Cytospin 
preparations are made from the original fluid for differential 
counts. The use of cytospin preparations has been found to 
underestimate lymphocyte counts (Saltini, 1984), due to the 
less adherent property of these cells compared to macrophages. 
However most authorities regard cytospin preparations adequate 
(Huninghake, 1979; Haslam, 1986; Reynolds, 1987). The most 
commonly used stain for differential counts is May-Grunwald- 
Giemsa stain.
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CHAPTER 2 
METHODS
2.1 Bronchoalveolar Lavage (BAL)
2.1.1 The technique:
The procedure is performed under local anaesthetic 
coupled with some premedication. The patient who has been 
previously fasted for about eight hours receives intramuscular 
premedication in the ward about half an hour earlier or
intravenous (i.v.) premedication in the bronchoscopy suite. 
Our regimen consists of i.v. atropine immediately prior to 
bronchoscopy followed by i.v. diazepam with or without
fentanyl depending on the age and the general condition of the 
patient. Local anaesthesia is achieved by 10% lignocaine 
nasal (Plate 2.1(a)) and pharyngeal spray. The bronchoscope 
is introduced nasally and anaesthesia of the larynx and major 
airways is achieved by spraying aliquots of 4% lignocaine 
under vision through the bronchoscope channel. Supplemental 
oxygen is given through nasal prongs if needed. Usually a 
quick survey of the bronchial tree is done before the
bronchoscope is wedged into the subsegment chosen for lavage. 
At this point it is our practice to change the collecting trap 
to minimise the content of lignocaine. Buffered normal saline 
(pH 7.2) is then instilled into the chosen subsegment (Plate 
2 .1 (b)) and fluid is sucked back into the collecting pot.
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Plate 2.1(a): Local anaesthesia of the nose with 10% lignocaine 
spray.
Plate 2.1(h): Instillation of buffered normal saline.
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Aliquots of 50 mis are instilled to a total of 150-200 mis for 
unilateral lavages and 300-400 mis for bilateral lavages, 
depending on the volume of the fluid recovered. These volumes 
are recorded in each case. Most centres use 300 mis but up to 
400 mis have been used (Pingleton, 1983). Ear oximetry and 
cardiac rhythm monitoring is recommended in sick patients by 
some authorities (Reynolds, 1987) but this practice is not 
widespread in this country and we have not found it necessary. 
Facilities for resuscitation have always been at hand.
2.1.2 Processing of BAL fluid
2.1.2.1 Pooling and cleaning:
The fluid was pooled, excess mucus aspirated and an 
aliquot of 5 mis set aside for original (total) cell* yield 
and differential counts. Total cell yields were made by using 
a Fuchs-Rosenthal counting chamber with or without white cell 
dilution fluid. In some cases especially at the beginning of 
the project it was found necessary to clear BALF of mucus by 
passing through 2 layers of gauze. The effect of this was 
assessed (see Tables 2 (a) and (b)).
2.1.2.2 Preparation of cystospins:
Cystospins were made using a cytocentrifuge (Shandon).
*Throughout the test "original cells" indicate cell counts 
done on the unprocessed BAL fluid other than clearing of 
mucus by aspiration and excluding sieving.
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The concentration of cells was adjusted to 1 x 105 cells/ml
for Leishman's staining and 5 x 10^/ml for esterase staining.
0.2 mis was placed in the cytospin bucket which was 
centrifuged at 900 r.p.m. for 4 minutes. Labelled double 
frost microscope slides (25 mm x 76 mm) were used to collect 
the cells. These were fixed appropriately according to the 
stain used.
2.1.2.3 Wright-Giemsa stain:
Cytospins (2 x 10^ cells) were heat fixed, before being 
covered with 2.5 mis of Leishman's stain for 30 seconds. The 
stain was then diluted by an equal volume of tap water. After 
10 minutes excess stain was rinsed off and the slides air 
dried. Differential counts were made under oil immersion from
a total of 500 cells (Plate 2.2a & b).
2.1.2.4 Non-specific esterase:
Cells were fixed in citrate-acetone-methanol mixture for 
30 seconds. The esterase stain was prepared from a 
commercially obtained kit (see Appendix). In a Coplin jar 
protected from light, slides were incubated at 37°C for 10 
minutes, gently washed in running water for 3 minutes before 
counterstaining with Mayer's haematoxylin for 15 minutes. 
Differential counts were made from a total of 500 cells. 
Esterase positive cells were recognised by their dark brown to 
black granules (see Plate 2.3(a) & (b)). Data comparing
82
w %
Plate 2.2(a): Leishman's stain of BAL cells from a non-smoking 
control.
Plate 2.2(b): Leishman's stain of BAL cells from a smoking 
control.
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Plate 2.3(a): Showing varying degrees of esterase positive 
AM and an esterase negative cell (PMN) (arrow)
Plate 2.3(b): Strongly esterase positive AM and esterase 
negative cells (lymphocyte) (arrow).
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esterase and Leishman's stain is presented later in this 
chapter.
2.1.2.5 Assessment of the effect of sieving:
BAL fluid was obtained from patients undergoing routine 
diagnostic bronchoscopy mainly for bronchogenic carcinoma. 
Fluid was pooled, an aliquot removed for original counts, 
before being divided in two equal parts. One part was passed 
through 2 layers of surgical gauze and the other through 4 
layers. Total and differential cell counts were made and 
compared to the original counts.
There was no significant change in differential counts 
of BAL cells following sieving through either 2 or 4 layers 
of surgical gauze. These results are partially in agreement 
with those by Kelly et al (1986) who found that filtration of
o ,
BAL fluid with 200 urn steel mesh significantly reduced the 
total cells. However the differential cell counts were not 
affected in this study. This could be due to the physical 
differences between surgical gauze and stainless steel mesh.
2.1.2.6 Enrichment of macrophages using adherence technique:
The adherence technique described by Ackerman (1978) was 
assessed using samples with high neutrophil content. Following 
the initial processing of the BAL fluid outlined above, cells 
were centrifuged at 200 g for 5 minutes in 20 ml universal 
containers. The cells were washed twice and resuspended in
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Table 2.1(a): Effect of sieving on total cell yields.
n = 8
Unprocessed
Fluid 2 layers 4 layers
Cell yields x 10^ 
/ml BAL fluid
3.40 2.75* 2.56*
Cell loss NA 19.1% 24.7%
Viability (%) 79.4 78.5 79.5
NA = Not applicable.
* There was significant cell loss following passage of BAL 
fluid through surgical gauze 2 layers (P = 0.025) and 4 
layers (P = 0.036). Viability however was not affected by 
sieving.
Table 2.1(b): Effect of sieving on cell composition.
Mean (%) differential cell counts
n = 8
Macro­
phages
Neutro­
phils
Eosino­
phils
Lympho­
cytes
Epithel­
ial cell
Unprocessed
fluid 89.05 5.06 0.14 2.56 4.08
2 layers 90.2 4.63 0.20 2.97 2.35
4 layers 89.75 5.06 0.28 3.15 2.30
medium 199/20% foetal calf serum (FCS). An aliquot was taken 
for total and differential counts. 10 mis of a known number
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of cells were placed in previously used tissue culture flasks 
and incubated at 37°C in an atmosphere containing 5% C02 in 
air for 45 minutes to allow macrophages to attach. Non­
adherent cells including lymphocytes and neutrophils were 
decanted and rinsed with 3 changes of PBS (pH 7.4) prewarmed 
to 37°C. Macrophages were detached by addition of 3.5 mis 
each of 10 mM EDTA/PBS and medium 199/20% FCS and incubation 
at 37°C (5% C02) for 15 minutes. The flasks were removed and 
shaken vigorously and macrophages were decanted into the test 
tubes. Further vigorous rinsing of the flasks with 5 mis 
199/20% FCS was done to remove the remaining macrophages. 
Cells were centrifuged for 5 minutes at 200g, and resuspended 
in M199. Cell loss and purity and viability of macrophage was 
assessed.
Table 2.2: Total cell yield viability and differential
counts following macrophage enrichment using 
adherence technique.
n = 3
Macrophages %
via-
i n 6 j n • +-
% differential cell 
BAL fluid
counts of
-L U UillLy
Macro­
phages
Neutro­
phils
Eosino­
phils
Lympho­
cytes
Pre 22.1 84 74.7 23.4 0.6 1.3
Post 5.17 53 96.0 4 0 0
Excellent macrophage enrichment was obtained using 
adherence technique but this resulted in an unacceptable high 
cell loss (macrophages) both in numbers (> 7 6%) and viability.
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2.1.2.7 Enrichment of Macrophage using density gradient: 
Method:
7 mis of BAL fluid was placed in conical tubes and 3 mis 
of lymphocyte separation medium was injected beneath it 
through a size 20 gauge lumbar puncture needle. This was 
centrifuged for 25 minutes at 160 x g. The cell-free 
supernatant was aspirated to within 1 cm of the interface 
layer of cells (IFC) and placed in universal containers for 
further processing. The IFC were aspirated, pooled, 
centrifuged at 200xg, washed and resuspended once in medium
199 (M199). Total and differential cell counts were made, and 
viability was assessed by trypan-blue exclusion test. The 
concentration of cells was adjusted as needed.
2.1.2.8 Trypan-blue dye exclusion test:
8 ul of cells were mixed with an equal volume of 0.1% 
trypan blue and covered by a coverslip (24 mm x 24 mm) 
coverslip before examination under the microscope. A total of
200 cells were counted and dead cells were recognised by the 
blue staining of their nuclei.
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2.1.2.9 Assessment of macrophage-enrichment using density 
gradient:
The effect of cell loss, viability, and purity of the 
macrophage population was assessed using the procedure 
outlined above, (tables 2.3a&b).
Table 2.3(a): Macrophage enrichment in samples with low 
neutrophil content using Ficoll-hypaque 
density gradient centrifugation.
n = 8
X
Total macro­
phages
%
viability
% Differential cell count of 
BAL fluid
106 (Mean) Macro­
phages
Neutro­
phils
Eosino­
phils
Lympho
cytes
Pre 44.20 76.50 92.42 2.52 0.52 4.50
Post 20.04 71.62 96.25 1.31 0.17 2.57
P value 0.018 NS 0.028 0.018 NS 0.043
Ficoll hypaque density centrifugation also resulted in 
substantial and significant loss of about 54% macrophages but 
viability of the cells was not significantly affected. There 
was also significant macrophage enrichment and neutrophil 
reduction in these samples. It is interesting that the effect 
of Ficoll-hypaque (lymphocyte separation medium)
centrifugation resulted in a reduction rather than enrichment 
of lymphocytes in BAL fluid, unlike in blood samples.
Centrifugation of BAL fluid with a high neutrophil 
content on Ficoll-hypaque resulted in significant loss of
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Table 2.3(b): Macrophage enrichment in samples with a high
neutrophil content using Ficoll-hypaque density 
gradient centrifugation.
Total cells % % Differential cell counts of
Via- BAL fluid
n = 5 x 10 bility ---------------------------------
Macro- Neutro- Eosino- Lympho-
phages phils phils cytes
Pre 138.36 90.4 26.82 62.64 0.32 10 .24
Post 66.43 87.4 36.04 55.34 0.12 8.66
P value 0.043 0.195 0.068 0.225 0.593 0.345
cells. There was also a trend towards some macrophage 
enrichment but this was not significant. The reduction in 
neutrophil proportion was not significant although it was 
apparent on examining the pelleted cells that these contained 
even higher neutrophil proportions (data not shown).
Comparison of Leishman's staining and esterase staining 
on 20 random samples from controls, smoke inhalation and CAP 
patients was performed to demonstrate correlation between 
these procedures.
2.1.2.10 Comparison of esterase and Leishman's stain:
In the earlier part of this project both the original and 
the interface layer of cells were stained with both Leishman's 
and esterase stains, but in the later part of the study the 
interface layer of cells were stained with Leishman's stain
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only. Correlation of these two stains was assessed.
Table 2.4: Comparison of Leishman's stain with esterase 
stain.
% Differential cell counts
n = 20
Macrophages
(Esterase
positive)
Neutrophils & Eosin 
(Esterase negative 
polymorphonuclear 
cells)
Lymphocytes 
(Esterase 
negative moi 
nuclear cel!
Leishman's 
Stain 62.58 28.06 9.28
Esterase
Stain 64.47 25.89 9.64
rg value 0.9594 0.9759 0.9477
rg = Spearman rank correlation.
Excellent correlation was obtained between Leishman's
and esterase staining. Although this was clear from very
early on during the study, it was decided to continue using
both stains simultaneously to ensure that proportions of 
cells were adequately assessed especially in samples with a 
high neutrophil content some of which may be immature with 
atypical forms. These results are also presented in Figure 
2.1 (a-c).
2.1.2.11 Concentration of lavage fluid:
Various methods including pressure filtration, 
lyophilization, oncotic methods or membrane filtration of the 
soluble constituents of BAL fluid have been used by different
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Fig. 2.1(a-c): Correlation of Leishman's and esterase stain of BAL cells.
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workers (Huninghake, 1979) . Membrane filtration was chosen in 
this work because it is by far the cheapest and does not need 
elaborate apparatus.
Method:
The cell free supernatant was centrifuged in sterile 
universal containers at 2000 g for 10 minutes to remove any 
remaining debris or bacteria. This was then passed through
j*
0.22 u filters, placed in the membrane tubing and covered with 
polyethylene glycol overnight until completely dry. Sterile 
distilled water was injected. into the tubing to reconstitute 
the fluid to 1/10 of its original volume. Thorough mixing was 
achieved by gentle massaging of the tubing. The concentrated 
fluid was aliquoted into five equal portions and stored at 
20°C (1 portion) and -70°C (4 portions) until they were used
or analysed.
2.2 Isolation of peripheral blood cells:
2.2.1 Neutrophils and peripheral blood mononuclear cells
This was done by the method described by Boyum (1968). 7
mis of heparinised blood was mixed with 3 mis of 5% dextran- 
saline and allowed to sediment for 30 minutes. 7 mis of 
leucocyte-rich plasma was placed in conical tubes and 3 mis of 
Lymphocyte-Separation Medium was injected beneath it using a 
lumbar puncture needle. This was centrifuged for 30 minutes at
Chemotactic factors with molecular weight of less than 12000 
daltons could have been lost during the concentration procedure.
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289xg. The interface layer of cells was aspirated and 
centrifuged at 289xg for 5 minutes, washed once and 
resuspended in gel-Hanks. This was used as unpurified 
monocytes (peripheral blood mononuclear cells - PBMC) (Plate 
2.4). The pellet cells were resuspended in 0.875% cold 
ammonium chloride for 15 minutes to lyse any contaminating red 
blood cells. These were centrifuged at 289xg for 5 minutes, 
resuspended in gel-Hanks and washed again once. An aliquot of 
cells was diluted in white cell dilution fluid and counted in 
Rosenthal-Fuchs counting chamber. These cells were more than 
95% neutrophils (PMN) with more than 98% viability.
2.2.2 Isolation of monocytes using nycodenz monocytes (Boyum, 
1983)
10 mis EDTA venous blood was mixed with 1 ml 6% dextran- 
saline and allowed to sediment at room temperature for 45 
minutes. 7 ml of leucocyte-rich plasma was placed in conical 
tubes and 3 mis of monocyte nycodenz solution was injected 
beneath it with a lumbar puncture needle, before 
centrifugation at 600xg for 15 minutes. The leucocyte-free 
supernatant plasma was aspirated up to 3 mm above the 
interface layer of cells and was reconstituted (6 parts 
supernatant: 94 parts saline) for use as a "washing fluid".
Monocyte-rich supernatant including the monocyte-nycodenz 
solution was aspirated up to 3 mm above the cell pellet, and 
mixed with an equal volume of washing fluid before 
centrifugation at 600xg for 10 minutes. Cells were resuspended
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Plate 2.4: Ficoll-hypaque separation of PMN (pellet 
cells) and mononuclear cells (interface 
layer).
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in washing fluid and the procedure repeated once before 
resuspending the cells in gel Hanks and adjusting the 
concentration as needed. Cytospin preparations were made and 
purity was checked using non-specific esterase stain. In our 
hands this method yielded 80% purity.
2.3 Phagocytosis and killing:
2.3.1 Introduction:
Phagocytosis involves recognition of the particle by the 
phagocyte, followed by attachment and ingestion. For optimal 
ingestion particles need to be opsonised and this is achieved 
by a specific antibody of IgG subclass with or without 
complement. The IgG antibodies are bound to particles at 
their (Fab)2 sites leaving the Fc segment exposed thus 
allowing the phagocyte to recognise the particle through the 
Fc receptor on its surface. Weak IgA-mediated phagocytosis by 
alveolar macrophages has been shown (Richards, 1985). IgM has 
no opsonic activity but its ability to induce complement 
activation leads to deposition of 03b on the particle which is 
then recognised by the phagocytes 03b receptors. Receptor- 
ligand interaction and receptor-opsonin interaction leads to 
engulfment of the particle by the phagocyte membrane, fusion 
of the phagocyte pseudopodia, dislodging of the particle into 
the phagosome and fusion of the lysosome leading to formation 
of the phagolysosome. The phagocytic process evokes a number 
of oxygen and non oxygen-dependent mechanisms increased oxygen
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consumption and production of superoxide anion, hydrogen 
peroxide and hydroxyl radical, leading to intracellular 
killing of micro-organisms.
Many in vitro methods have been employed in the 
assessment of phagocytosis and killing, and though they may be 
different in detail their general principles are similar. 
These are summarised overleaf.
2.3.3 Assessment of phagocytosis and killing:
This was done using prelabelled bacteria, labelling 
bacteria after phagocytosis or killing and pour plate method.
2.3.3.1 Uptake method:
Bacterial ingestion using the method described by 
Peterson et al_ (1977) was used. Experiments were performed
# n
using PMN, PBMC (1 x 10 /ml) from healthy donors, and alveolar 
macrophages from patients with negative bronchoscopy, and 
normal chest x-rays. Bacteria were prepared as follows: A
clinical isolate of Staph aureus 502A was grown overnight in 
10 ml Mueller-Hinton (M-H) broth to which 100 mcl ^H-Adenine 
was added. Bacteria were washed thrice in sterile saline and
, n
their concentration was adjusted to 1 x 10 colony forming 
units (c.f.u.)/ml. Using a spectrophotometer an optical 
density of 0.025 was found to correspond to a concentration of
n
1 x 10 cfu/ml. For opsonisation the bacteria were incubated 
with an equal volume of 10% pooled serum in an orbital shaker
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2.3.2 In-vitro methods in phagocytosis and killing
Principle Example Comment
PHAGOCYTOSIS
Determination of 
increase in 
number of intra­
cellular 
particles
Determination of 
decrease in 
number of extra­
cellular organism
Light and/or electron 
microscopy
Labelling particles 
with fluorescent or 
radioactive probe
a) employ direct 
microbiological 
methods
b) use of radioactive 
probe
labour intensive 
Difficulty of 
distinguishing 
between extra­
cellular and intra­
cellular particles. 
Some methods do not 
distinguish between 
intracellular 
ingestion and 
extracellular 
attachment.
Allows kinetic 
studies.
Bactericidal factors 
to the extracellular 
organisms not 
accounted for. 
often lack distinction 
between ingestion 
and attachment.
KILLING
Direct measure- % Measurement of decrease
ment of: in total number of live
microbicidal microorganisms by radio­
activity active probe or micro­
biological methods.
Indirect measure- Measurement of metabolic
ment of micro- burst accompanying
bicidal activity phagocytes.
of phagocytes
Affected by rate of 
ingestion and extra­
cellular microbicidal 
mechanisms.
Non-specific 
activation accom­
panied by metabolic 
burst may not be 
accompanied by 
intracellular 
killing.
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(150 r.p.m.) at 37°C. After 15 minutes the bacteria were
centrifuged at 2020xg for 10 minutes and resuspended to their 
original volume in gel-Hanks. Phagocytosis mixtures were set 
up incubating 0.1 ml bacteria and 0.1 ml phagocytes for 15, 30 
or 45 minutes in triplicate according to the protocol shown 
overleaf.
2.3.3.2 Killing assay:
Unlabelled bacteria was used. Phagocytes and bacteria 
were incubated in 0.1 ml volumes for 15, 30, or 45 minutes at
37°C, before lysing the cells by adding 3 mis distilled water 
to the mixture. For total bacterial counts cells were lysed 
at 0 minutes. An aliquot of 0.1 ml was taken from each tube 
and serial dilution with saline was made before plating 20 ul 
volumes on blood agar and counting c.f.u. % Killing was 
calculated according to the formula shown.
2.3.3.3 Phagocytosis and killing - labelling of bacteria 
after phagocytosis and killing
2.3.3.3.1 Principle of the method
The method used is based on the principle described by 
Lam and Mathison (1979) that uridine is not significantly 
incorporated by PMN while bacteria in the logarithmic growth 
phase will do so. The killing part of the assay was adopted 
from the method described by White and Walker (1981) who 
employed freezing and thawing to disrupt the phagocytes.
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Assessment of Ingestion using —H-adenine Labelled Staph aureus 502A
Tube A
0.1 ml ^H-Adenine 
labelled Bact.
+ 0.1 ml phagocytes
Tube B
0.1 mis H-Adenine 
labelled Bact.
+ 0.1 ml phagocytes
Tube C
0.1 ml gel Hanks 
+ 0.1 ml phagocytes
Incubate at 37°C 
for phagocytosis
Incubate at 37°C 
for phagocytosis
Incubate at 37°C
No washing or 
spinning
Centrifuge at 162xg 
and wash x 3
Centrifuge at 162xg 
and wash x 3
3 mis Scintillation 
Fluid
3 mis Scintillation 
fluid
3 mis Scintillation 
fluid
Total (A) 
bacteria cpm
Cell Associated (B) 
bacteria cpm
Background cpm (C)
% Bacterial uptake = (C)
(A)
x 100.
Killing: Counting live c.f.u 
Tube A
0.1 ml cell + 0.1 ml Bact.
At 0 min 
Add 3 ml distilled water
Total Bacteria (A)
Tube B
0.1 ml cells + 0.1 ml Bact
Incubate for phagocytosis 
and killing at 37°C for 
desired period.
Add 3 mis distilled water
Live Bacteria (B)
Serial Dilution + Pour plating
n -r-* i i * Total Bact. - Live Bact.
% Killing =  Total Bact.------  x 100
I.e. = R ~ B x 100
A
100
2.3.3.3.2 Preparation of bacteria:
On the morning of the experiment, a fresh suspension of 
Staph aureus 502A was prepared in an M-H broth from a similar 
overnight culture. The bacteria was washed twice in saline and
, 7
the concentration adjusted to 1 x 10 c.f.u. before 
opsonisation in 10% serum.
2 . 3.3.3.3 Phagocytosis:
Mixtures were set up in triplicate as shown in the
protocol overleaf. Phagocytosis was terminated by placing the
tubes on ice before adding ^H-undine. For assessment of
killing, JH-undine was added following the disruption of
phagocytes by freezing and thawing, on methanol - CC>2 mixture,
and the mixtures were incubated for one hour at 37°C to allow
labelling of bacteria. 1 ml of gel Hanks was added to each
tube and an aliquot of 200 ul was passed through a filter
(0.22 urn pore size) and washed to remove excessive unbound
label. The filter was placed in scintillation tubes and 3 mis
of scintillation fluid was added before readings were made on
a scintillation counter.
Comparison of each of the three assays to assess the
ingestion or killing of Staph. aureus by donor neutrophils
showed some discrepancy in the results between the different
methods. More important was the fact that in some
3experiments, ingestion and killing (by H-undme labelling) 
failed to work completely. The reason for this failure could 
not be identified readily (Tables 2.5a-c).
Assessment of ingestion:____ post-phagocytosis labelling of
bacteria
Tube A
0.1 ml Bact. + 0.1 ml 
Gel Hanks
Incubate at 37°C 
for desired period
Place on ice
Add 20 ul 3H- 
Uridine
Incubate at 37°C 
for 1 hr to label 
all the bacteria
Add 1 ml cold 
Gel-Hanks
Filter 200 ul 
aliquot and wash 
unbound label
Place dry filter 
into scint. tube 
and add 3 ml scint. 
fluid
Tube B
0.1 ml Phagocytes + 
0.1 ml Bact.
Incubate at 37°C 
for desired period
Place on ice to 
terminate phagocytosi
Add 20 ul 3H-Uridine
Incubate at 37°C for 
1 hr to label extra­
cellular bact.
Add 1 ml cold 
Gel-Hanks
Filter 200 ul 
aliquot and wash 
unbound label
Place dry filter 
into scintillation 
tube and add 3 ml 
scint. fluid
Tube C
0.1 ml phagocytes 
+0.1 ml Gel Hanks
Incubate at 37°C 
for desired period
Place on ice
Add 20 ul3H- 
Uridine
Incubate at 37°C 
for 1 hr to 
obtain back­
ground cpm.
Add 1 ml cold 
Gel-Hanks
Filter 200 ul 
aliquot and 
wash unbound 
label
Place dry filter 
into scint. tube 
and add 3 ml 
scint. fluid
Total bact. cpm Extracellular Bact. "Phagocytes"
cpm only"
Background
cpm
A B C
A - B - C
% Ingestion = — A - C—  x ^00
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Killing assay using freezing and thawing of phagocytes and 
labelling of bacteria.
Tube A
0.1 ml bact. +
0.1 ml gel Hanks
Incubate at 37°C 
for desired period
Tube B
0.1 ml cells + 
0.1 ml bact.
Incubate at 37°C 
for desired period
Tube C
0.1 ml phagocytes + 
0.1 ml gel Hanks
Incubate at 37°C 
for desired period
Freeze in dry ice & 
thaw in warm water 
x 2
Add 20 ul 3-H 
uridine
Incubate for 1 hr 
at 37 C to label 
all bacteria
Filter on 0.22 u 
Sweenex filters or 
microtitre plates
Place filter in scint 
tube and add 3 ml 
scint. fluid
Total bact. cpm
Total cpm 
A
% Killing =
Freeze in dry ice & 
thaw in warm 
water x 2
Add 20 ul 3H- 
uridine
Incubate for 1 hr at 
37 C to label live 
bacteria
Filter and wash to 
remove unbound label
Place filter in 
scint. tube & add 
3 ml scintillation 
fluid
Live Bact.
Live Bact. 
B
Freeze in dry ice & 
thaw in warm water
Add 20 ul 3H- 
uridine
Incubate for 1 hr 
at 37 C to obtain 
background cpm
Filter and wash to 
remove unbound label
Place filter in 
scint. tube & add 
3 mis scint. fluid
Phagocytes only 
Background cpm
C
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Table 2.5(a): Ingestion and killing of staph. 502A by
healthy donor neutrophils.
(%)
Experiment Ingestion Ingestion Killing Killing
O O colony
No. H-Adenine °H-uridine H-uridine counting
1 ND 66 77 89.4
2 85.7 0 0 90
3 2.2 83 89 100
4 60 56.3 4.29 ND
5 ND 40.1 51.8 68
6 0 0 41 31
7 ND ND 9.6 28
ND = Not done.
Table 2.5(b): Ingestion and killing of Staph. 502A by 
peripheral blood mononuclear cells.
(%)
Experiment Ingestion Ingestion Killing Killing
3 3 . 3No. 1 H-Adenine H-Uridine H-Undine Colony
counting
1 0 0 0 ND
2 ND ND 16 33
3 ND ND 49.4 35
4 91.9 0 0 ND
5 61.9 17.2 0 20.9
6 ND 0 0 26.7
ND = Not done.
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Similar problems were encountered in these assays when 
mononuclear cells were used.
Table 2.5(c): Ingestion and killing of Staph. 502A aureus
by alveolar macrophages.
(%)
Experiment Ingestion Ingestion Killing Killing
No. ( H-Adenme) (^H-Uridine ) (^H-Uridine) (Colony
counting)
1 ND 0 0 ND
2 ND 27 93 ND
3 29.3 77.3 77.7 31.5
4 36 0 ND ND
5 57.8 79 14 ND
6 ND 9.24 0 26.9
7 ND 0 0 8.2
8 ND 12.7 23.7 ND
9 ND 7.6 0 38.6
10 ND 9.3 19.5 ND
11 0 21.4 25.5 0
12 28.40 58 11.2 16.5
ND = Not done.
These experiments represent a selection of the results 
of ingestion and killing assays using alveolar macrophages 
and it is clear that discrepancies are apparent. The lack of 
reproducibility especially in the freeze and thaw cycle
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method was a major problem. Various manoeuvres were tried 
including change of bacteria-cell ratio, ensuring that fresh 
bacteria were used, and variation of incubation period. It 
was often noted that tubes which contained bacteria and cells 
had higher bacterial counts than those with bacteria only. 
Thus these live phagocytic cells were "enhancing" bacterial 
multiplication rather than killing them.
Because of these problems which could not be overcome 
these methods had to be abandoned.
2.4 Chemotaxis
2.4.1 Historical background:
Studies on inflammation began during the early nineteenth 
century by many workers including Addison 1843, Waaler, 1846, 
Cohnheim, 1867, Hess, 1888. Observations of adhesion of 
leucocytes to blood vessels and their subsequent accumulation 
into the extravascular compartment had been made during that 
early period but it was not until 1888 when definite reports 
of chemotaxis were made by Theodor Leber. Metchnikoff, 
working on phagocytosis, recognised the importance of Leber's 
observations, and with his co-worker Gabrietchevsky confirmed 
that dead or live bacteria were able to attract leucocytes. 
Metchnikoff (reviewed by Wilkinson, 1982) recognised that 
macrophages and microphages moved differently and realized the 
presence of chemotaxins. Commandon demonstrated the first 
successful in vitro experiment in 1917 using time-lapse
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cinematography. His work provided the first insight into the 
sequence of morphological changes of white cell during 
locomotion and phagocytosis. A great deal of work was carried 
out by McCutcheon, using time lapse cinematography. His work 
defined the relative speed of cell locomotion including 
lymphocytes and the role of chemotaxins. In 1955 Rebuck and 
Crowley described the skin window technique. The introduction 
in 1962 of the membrane assay by Boyden marked a turning point 
in contemporary chemotaxis work. The under-agarose technique 
was reported by Nelson (1975).
2.4.2 Definitions:
Locomotion of a cell (or organism) is the process which
involves physical transfer of the cell from one point to
another. It is limited by the intrinsic capacity of the cell 
to do so, and can be influenced by many environmental factors. 
Locomotor responses are generally described as "tactic” or 
"kinetic". Tactic responses are directional toward a gradient 
source and essentially involve physical orientation towards 
the source. Kinetic reactions relate to speed of migration in 
which cells move faster or slower. These are positive or 
negative kinetic responses respectively.
Random locomotion: describes that tendency of the cell to 
migrate from one point to another without a special
orientation to a stimulus or gradient and any inherent
orientation exhibited in that process is determined solely by 
chance. Random locomotion is often spuriously used to mean
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unstimulated locomotion but these two terms are not 
synonymous. In systems where spatial orientation cannot be 
demonstrated such as membrane assays, the terms chemotaxis and 
random migration are best replaced by stimulated and 
unstimulated migration respectively. Another term conveniently 
defined here is "leading front". The foremost cells in a 
population of cells migrating towards a gradient form the
leading front and the methods where the distance from the
starting point to the front is measured bear this name.
2.4.3 Behaviour of cells in migration:
The physiology of locomotion of cells is a complex 
subject and is beyond the scope of this thesis. For a 
detailed description the reader is referred to the excellent 
reviews of Wilkinson (1981, 1982) and Zigmond (1981). A short
summary on cell behaviour will be given here.
Both neutrophils and monocytes undergo morphological 
changes during locomotion. Neutrophils exposed to a gradient 
polarize within a minute or two with their leading rounded end 
(lamellipodia) facing the gradient source. The accuracy of 
this orientation is governed by the potency of the gradient 
and occurs before translocation takes place. This orientation 
and the changes that take place when the gradient changes has 
led to the belief that neutrophils can sense different 
concentrations of the gradient along its body. It has been 
proposed that detection of a gradient by the cells is achieved 
by sensing differences in the number of receptors occupied on
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their surfaces over some distance along the gradient (Zigmond,
1981). At certain concentrations of some chemotoxins the rate 
of locomotion correlates with the number of receptors 
occupied. Receptors for several different chemotaxins have 
been described for PMN (Wilkinson, 1982) and macrophages 
(Wilkinson, 1985). An important property determining cell 
locomotion is adhesion. Too rigid adhesion to the substratum 
renders the cell immotile and reduction of adhesion can 
increase locomotion to an optimum beyond which, further 
reduction leads to impaired locomotion. Physiological 
adhesion such as on protein-coated surfaces shows temperature 
and divalent cation dependency unlike adhesion to uncoated 
glass or plastic. The magnitude and duration of adhesion in 
PMN appear to depend on receptor occupancy. A suitable 
substratum is essential for locomotion. For example PMN on an 
uncoated filter or glass surface in the presence of a gradient 
do not show locomotion but when exposed to the same gradient 
on albumin coated surfaces they show vigorous migration.
2.4.4 Methods Used in Chemotaxis:
An exhaustive review of these methods is deemed 
unnecessary and beyond the scope of this work. A brief 
discussion of the principles involved in the main methods in 
use will be made here: Assays for chemotaxis fall into two
main categories. The first include those which examine the 
behaviour of individual cells over a period of time. These 
employ visual assays. The second are those which examine the
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response of populations of cells and the majority of assays
fall under this category.
2.4.4.1 Visual Assays:
These assays were developed before membrane assays but 
nevertheless they are becoming more popular again (Wilkinson, 
1985). The principle involves filming of a cell as it moves 
towards a gradient and its course can be plotted. Both 
chemotaxis and chemokinesis are best studied by these assays 
but membrane assays are superior in obtaining dose response 
data of pharmacological agents (reviewed by Wilkinson, 1982).
2.4.4.2 Membrane Assays:
These consist of porous membranes separating two 
chambers, one containing the cells and the other usually below 
it, containing the chemoattractant. The pore sizes of these 
membranes are such that they prevent the cells dropping 
through by gravity but allow them to actively squeeze
themselves through the membrane matrix towards the attractant. 
For PMN 3 micron pore size membranes are used, monocytes 5 
microns, macrophages 5 or 8 microns and lymphocytes usually 8
microns. The membranes are either thick or thin.
2. 4. 4.2.1 Thick membranes:
The thickness of these membranes are of the order of 150
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microns and measurement of the distance travelled by the
leading front of cells is usually determined. This is done by
focusing through the mounted membrane and the distance is 
determined by a micrometer attached to the focusing apparatus 
of the microscope. Some workers use the leading front as well 
as determining the total number of cells that have migrated to 
a given distance through the membrane. The thick membranes 
allow development of a gradient across their thickness but do 
not allow morphological appreciation of the cells and it is 
imperative that only pure populations of cells be studied.
2.4.4.2.2 Thin membranes:
These are of the order of 10-12 microns thick and
measurement of the numbers of cells that have migrated to the
undersurface of the membrane is made. This system allows
appreciation of morphology and in a mixed population a
reliable differential count can be made. However some 
authorities believe that the thickness of these membranes is 
not sufficient to allow the development of a gradient
(Wilkinson, 1985). Another criticism against thin membranes 
is the possibility that the faster cells may drop off once 
they reach the undersurface making cell counts unreliable. To 
get over this problem some workers have deployed membranes
without a wetting agent (polyvinyl-pyrrolidone-free membranes) 
and have found that cells do not drop off (Harvath, 1980) . 
Others have employed a double membrane system where a cell- 
impermeable membrane (pore size 0.20 - 0.45 microns) is
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placed below these membranes and have counted cells on both 
membranes. Apart from direct microscopic counting of cells 
various ingenious methods including image analysis (Falk, 
1978), enzyme estimation (Mroweitz, 1986) or radiolabelling of 
cells (Gallin, 1978) have been used.
2.4.4.2.3 Chambers used in membrane assays:
Since the introduction of Boyden chambers in 1962, 
several chambers have been described and a brief description 
of the one we have used will be given here. This 48-well 
microchemotaxis chamber was produced by Neuroprobe and 
described by Falk et ad (1978) . It consists of two acrylic 
plates (see Plate 2.5 ). The lower plate consists of 25 mcl 
wells for chemotaxins, on which the membrane (25 mm x 80 mm) 
is laid followed by the gasket before screwing the top plate 
in position. Once this is in place it forms the upper wells 
which are 50 mcl in volume. This chamber has a number of 
advantages including economy in cells and chemotaxins, ability 
to test many chemotaxins or different samples of cells 
simultaneously and reducing the variability in filters which 
is often a problem in Boyden chambers. Because many samples 
can be examined simultaneously, this enables better 
standardization of the microenvironment.
2.4.4.3 Checkerboard assays:
This is not a separate method but rather a protocol often
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Plate 2.5: 48-well microchemotaxis chamber.
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used in the membrane assays in an attempt to differentiate 
chemotactic from chemokinetic responses. The protocol 
involves setting up of different gradients across a number of 
chambers in two directions so that the chemotaxin concerned is 
both below and above the membranes. Thus a positive gradient 
(higher concentration below) a negative gradient (higher 
concentration above) or zero gradient (equal concentrations) 
can be achieved. In this way a chemokinetic or chemotactic
response can be implied, since a kinetic response can be 
observed even in the absence of a gradient.
2.4.4.4 The under-agarose assay:
This system consists of a series of three wells punched
out in an agarose gel. Cells are placed in the middle well,
and a chemotaxin or control medium is placed in each of the
other two wells. The cells crawl under the agarose towards
the chemotaxins and the distance (A) migrated by the leading
front can be measured. Subtraction of the distance (B)
migrated by the cells towards the control medium gives rise to 
the chemotaxis differential (A-B). In the original description 
of this method, albumin or serum were incorporated into the
agarose and Chenowith (1979) modified this by substituting
gelatin for serum. This assay also offers cell and chemotaxin
economy and works well for PMN. Despite the authors' claim
that this assay works for monocytes many workers have had no 
success with it in monocyte chemotaxis (Wilkinson, 1985). Very 
few studies have used this method successfully in AM
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migration. Some workers have succeeded in studying 
chemotactic responses by filming the under surface (Wilkinson,
1982) but on the whole this method is used mainly in studying 
populations of cells. Attempts at setting up checkerboard 
assays have been met with limited success.
2.4.4.5 The skin window technique:
This in vivo method involves scraping an area of skin on
the forearm with a scalpel or abrasing it with a high speed 
drill until the dermal papillae are evident. The chemotaxin 
under test is applied and the cells migrating to the area are
collected in a coverslip or a collecting chamber and counted.
The main pitfall of this method is that it does not
distinguish between cell accumulation and cell migration. The 
former can be due to vascular injury or change in
permeability.
2.4.5 Problems in Monocyte and Macrophage Chemotaxis
Locomotion of mononuclear cells is less well studied and 
their responses less well understood. This is mainly because 
of the technical problems involved in their study. Among
these is the difficulty of obtaining pure cell populations in
sufficient quantities. Many macrophage enrichment methods 
involve an adhesion procedure following which non-adherent 
cells are washed off. The problem then arises of removing 
adherent cells for locomotion studies without damaging them.
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Again because these cells are adherent most of the studies 
have had to depend on membrane assays which are not adequate 
in elucidating cell responses. Finally it is becoming 
increasingly clear that macrophages are a heterogenous 
population even those from a single site such as the lung. 
Whether a subpopulation is concerned principally with 
locomotion is not yet known.
2.4.6 Methodological details of assays used
2.4.6.1 Under-agarose assay:
Before assessment of AM migration using this assay PMN
n
(2.5 x 10 /ml) and PBMC from healthy donors were used. Cells 
were prepared as previously described. Agarose-gelatin (final 
concentrations 1% - 0.25% respectively) in minimal essential 
medium (MEM) was prepared as detailed in Appendix I. 
Unstimulated migration as well as migration towards zymosan 
activated serum (ZAS), FMLP 10-^M and E .coli supernatant (all 
prepared as detailed in the Appendix) was assessed. 10 ul 
volumes of cells or chemotaxins were placed in the inner 
wells or outer wells respectively and were incubated at 37°C 
in an atmosphere containing humidified 5% CO2 for 4 hours 
(PMN) or 18 hours (PBMC). Cells were fixed by covering with 
5 mis methanol for 30 minutes followed by 10% buffered 
formalin for another 30 minutes. The agarose gel was removed 
and the plates were stained with Leishman's stain before 
examining under an inverted microscope. The linear distances
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migrated by the leading edge of cells towards the chemotaxin 
(stimulated migration - A) and towards the medium 
(unstimulated migration - B) were measured by a micrometer 
(units) attached to the microscope eyepiece. Chemotactic 
differential (CD) was obtained by subtracting B from A.
2.4.6.2 AM chemotaxis using under-agarose method
BAL cells were prepared as previously described and were 
suspended in medium 199 containing antibiotics and 
concentration was adjusted to 5 x 10^/ml and 2.5 x 10^/ml. 
The remaining part of the procedure was as described above 
apart from incubation period which was 18 hours initially and 
later 24 hours.^ No migration was achieved and it was clear 
that only the few contaminant PMN had actually migrated. The 
failure of AM migration was persistent with all above 
chemotaxins despite preparation of fresh agarose plates and 
rechecking the pH media etc. Six experiments were performed 
before the procedure was finally abandoned.
2.4.6.3 Microchemotaxis chamber:
The 48-well microchemotaxis chamber was used instead of 
the standard Boyden chambers because of cell economy. 
Macrophages were enriched by density gradient as described 
earlier and resuspended in medium 199 containing antibiotics 
and concentration was adjusted to 1 x 10  ^ cells/ml (minimum 
viable cells 8 x 10^/ml). This concentration was found
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optimal (See Table 2.6(a). Unstimulated migration (UM) and 
stimulated migration towards ZAS, casein and FMLP was assessed 
(See Tables 2.6(b,c & d) and Figures 2.3 a,b,c). 25 ul
volumes of medium 199 (for U.M.) or a chemotaxin (for SM) were
placed in the lower wells. A 10 u thick 8 u pore size
polycarbonate membrane (25 mm x 80 mm) was carefully laid on 
the lower wells, followed by the gasket and the top plate was 
screwed in position. The upper wells were covered with a 
microscope slide and the chamber was incubated at 37°C in an 
atmosphere containing humidified 5% CC>2 in air, for 10 minutes 
to allow temperature stabilization. The upper wells were 
filled with 50 ul volumes of cells and the chamber was
incubated in the same environment for 4 hours before removing 
the membrane, carefully wiping the top surface cells (avoiding 
the disturbance of the undersurface cells which have migrated 
through the membrane). The membrane was air-dried overnight 
before fixing the cells for 2 minutes in methanol for
Leishman's stain or for 1 minute in citrate-acetone-methanol 
mixture for esterase stain. Leishman's staining was done by 
immersing the membrane in undiluted stain for 3 minutes 
followed by 50% diluted stain for 5 minutes before rinsing the 
excess stain in water. Esterase stain (20 minutes incubation) 
was performed according to previously described method. The 
membrane was mounted (spirit based for Leishman's and aqueous 
based for esterase) on a double width microscope slide (50 mm 
x 76 mm) before examination under the microscope. Cells in 5 
fields (magnification x 400) from each well were counted and a 
mean of 3 wells was used for UM or SM towards each chemotaxin.
118
For PMN chemotaxis cells were suspended in gel Hanks and 
3u pore size membrane was used with an incubation period of 30 
minutes. For monocytes 5 u pore size membranes with 45 
minutes incubation.
Experiments were performed to determine optimum
concentration of cells and chemotaxins. Tables 2.6(a-d) show 
the results of experiments using different concentrations of 
cells and chemotaxins.
Table 2.6(a): Macrophage migration, with variable cell
concentration (mean of 3 wells x 400 n = 4).
Concentration 
of cells x 105 5 7.5 10 25 50
Unstimulated Mean 15.6 21 24.4 27.5 39.6
Migration (SD) (6) (9.8) (13.7) (9.1) (14.0)
Casein Mean 20.3 30.6 32 59 71
10 mgs/ml (SD) (2.1) (7) (11.3) (36.3) (52.4)
ZAS Mean 49.6 54 55.6 85.6 92.3
(SD) (27.2) (27.5) (35) (55.9) (60.5)
Increases in the cell concentration showed that there
was a higher but disproportionate increase in cells migrating
through to the undersurface of the membrane. For ease of
counting and "cell economy" it was decided to use a
£
concentration of 1 x 10 cells/ml for the study. These 
results are also shown in Figure 2.2.
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Table 2.6(b): Migration of AM towards different concentrations 
of casein.
Concentration casein mg/ml
n = 4 1.5 3 6 10 20
Mean (SD)
No. of cells/ 
5 fields
48
(7.0)
55.8
(17.4)
45.8
(16.0)
62
(34.9)
46.8
(10.7)
There was no definite dose response to different 
concentrations of casein. However the concentration of 10 
mgs/ml gave the maximum response and this concentration was 
used for the study.
Table 2.6(c): Migration of AM towards various concentrations 
of ZAS.
ZAS Dilution Factor
n = 3 1 (Neat) 2 4 8 16 32
Mean (SD) 
cells/5 
fields 
(mean of
49.6 56 74.8 74.3 61.6 47.6
3 wells) (1.5) (18.5) (40.3) (20.7) (21.7) (15.0)
AM migration towards ZAS showed a dose-response which 
peaked at a four-fold dilution. However it was decided to 
use undiluted ZAS for the study because of ease of cell 
counting.
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Table 2.6(d): Migration of AM towards various concentrations 
of FMLP.
Molar Concentration of FMLP
n = 3 10 6 10 7
001oX—1
i 
i
ox—ii0x—1
cn1ot—1 O
1 H> I-1 10 12
Mean (SD) 
Cells/5 
fields 
(mean of
27.0 34.6 31.3 33.3 35 41.6 25.6
3 wells) (9.6) (17.2) (9.5) (2.5) (6.2) (14.2) (5.7)
No definite dose-response curve was obtained but there
. . —11 was a major peak at a concentration of 10 M and a minor one
— 7 —7at 10 . A concentration of 10 was used in the study.
The results of AM migration towards varying 
concentrations of chemotaxins are presented in Figure 2.3 (a-c) 
Intrasubject variability of the migration data was assessed 
using cells from 3 control patients. Measurement of 
unstimulated migration and migration towards ZAS was done 
using six wells in each case. Table 2.7 shows the number of 
cells in each well and the means, standard deviation and 
coefficient of variation for each set of six wells.
Some variability is seen between different wells but on 
the whole, measurement of macrophage migration using 
microchemotaxis chamber is fairly well reproducible.
Comparison of esterase and Leishman's staining of cells 
which have migrated through the membranes was done in 5 
control subjects and 4 patients with smoke inhalation injury.
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Fig. 2.3(a-c): Effect of varying concentrations of chemotaxins on AM 
migration.   ■
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These data are conveniently presented here (Tables 2.8(a) and 
(b)) (Plates 2.6a&b).
Table 2.7: Variability between wells in cells which have. 
migrated through the membrane.
ZAS Unstimulated Migration
Exp. No./ 
Well No. 1 2 3 1 2 3
1 46 30 47 35 21 33
2 48 52 42 40 24 37
3 50 40 38 35 23 36
4 54 48 35 27 39 27
5 38 61 49 37 38 30
6 64 38 36 51 40 26
Mean 50 44.8 41.2 37 .5 30.8 31.5
S.D. 8.67 11 5.8 7.9 9 4.6
Coefficient 
of variation 0.17 0.24 0.17 0.21 0.29 0.14
Table 2.8(a): Comparison of Leishman's and esterase staining
of chemotaxis membranes (control subjects, n=5)
Mean (SD) <cells / 5 fields
Unstimulated Casein ZAS FMLP
Leishman's 
stain 31.4 (10.4) 31. 6(16.0) 50 .2 (16.6) 39.8 (17.1)
Esterase
stain 31.0 (12.3) 32. 0(18.5) 52 .6(17.2) 33.8 (17.3)
rg value 0.80 0.90 0.9211 0.80
rs = Spearman rank correlation.
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Plate 2.6(a): Leishman's stain of BAL cells from a patient 
with smoke inhalation and b u m s  injury.
Chemotaxis membrane
i
A 4
f
bL
Plate 2.6(b): Esterase stain of BAL cells from a patient with 
smoke inhalation injury. A few PMN can be seen 
(arrow).
Chemotaxis membrane
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Excellent correlation between the two stains was obtained 
in samples from 5 control subjects.
Table 2.8(b): Comparison of Leishman's and esterase staining
of chemotaxis membranes (smoke inhalation
patients (n = 4)).
Mean (SD) cells / 5 fields
Unstimulated Casein ZAS FMLP
Leishman's 
stain 67.3 (29.3) 91.8 (34.4) 246.0 (148 .7) 66.0 (47
Esterase
stain 63.0 (35.4) 103.8 (45.1) 274.5(136.6) 68.0 (42
rs 0.971 0.907 0.992 0.996
rg = Spearman rank correlation.
A good correlation was obtained between the two stains 
although there was a tendency to higher numbers of positive 
cells in the wells with high migration counts (such as ZAS) 
than the corresponding number of macrophages in the 
Leishman's stain. This could be due to the presence of 
monocytes which are more easily recognized with esterase 
stain than with the Leishman's. Alternatively this could be 
due to an artefact resulting from non-specific staining of 
the esterase negative cells by the intense esterase stain 
originating from the numerous surrounding macrophages.
The effect of neutrophils on migration of macrophages 
was studied on cells from two control patients. Increasing 
proportions (5-60%) of purified neutrophils were mixed with 
purified macrophages. Migration of these cells towards ZAS
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was measured (Table 2.9).
Table 2.9: Effect of neutrophils on migration of AM through 
polycarbonate filters: (Mean cells/5 fields).
Macrophage content (%) of cell mixtures
99 95 90 80 70 60 50 40
Patient 1 50 41 42 37 23 18 14 12
Patient 2 55 49 40 38 39 24 21 10
Increasing proportions of neutrophils in the cell 
mixtures resulted in progressive reduction of macrophages 
which migrated through the membranes. This could be due to 
the fact that neutrophils migrate faster and they physically 
compete with the macrophages through the pores, or it could be 
due to the injurious effect of neutrophils on macrophage 
migration. Whatever the underlying cause may be, it is clear 
that substantial neutrophil contamination has an effect of 
underestimating the true macrophage migration.
2.5 Chemiluminescence
2.5.1 The principle of chemiluminescence (CL):
Light emission by phagocytes was first noted by Allen 
(1972) in a PMN-bacterial phagocytosis system. Later he
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described luminol-dependent CL in peritoneal and alveolar 
macrophages. The precise mechanism by which photon emission 
demonstrable as CL is not clear. Allen proposed that PMN non 
luminol-dependent CL (unamplified CL) was due to relaxation to 
ground state of electronically excitable carbonyl groups 
released during the oxidative respiratory burst. Later Cheson 
et al. (1976) suggested that this might be due to reaction 
between oxidative metabolism of leucocytes and bacterial 
products. Whatever the exact mechanism involved there is a 
strong evidence identifying the importance of the 
myeloperoxidase-halide-hydrogen peroxide system. The evidence 
lies firstly in the observation that CL of normal PMN can be 
inhibited by catalase (H2O2 scavenger), superoxide dismutase 
(superoxide scavenger) and sodium azide (myeloperoxidase 
inhibitor). Secondly, neutrophils deficient of
myeloperoxidase have been found to be deficient in CL activity 
(Allen, 1975). CL has been shown to be quantitatively 
proportional to bacterial and neutrophil populations in 
phagocytic systems and also to the concentration of luminol in 
luminol-dependent CL (Quie, 1982). Non phagocytic membrane 
stimulation by soluble stimulants such as phorbol myristate 
acetate (PMA) and FMLP or adherence of phagocytes to vial 
surfaces, has been shown to produce CL similar to phagocytic 
stimulation. The pattern of PMN-CL produced by soluble 
stimulants was recently defined. Luminol-dependent CL was 
found to have bimodal peaks; an early one during the first 
two minutes and a second one at 10 minutes. Using cell-free 
and cell-containing oxidation systems with or without
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inhibition of CL it was possible to attribute these peaks to 
extracellular (first peak) or intracellular (second peak) CL 
activity (Brieheim, 1984) . The diffusion of luminol to the 
intracellular compartment was thought necessary for the 
production of the second peak. The finding in some later work 
(Dahlgren, 1985) that lucigenin, a substrate with a large 
molecular weight, thought incapable of diffusing into the cell 
is associated with only one (first) peak is in keeping with 
this concept.
2.5.2 CL of Alveolar Macrophages:
In a study of metabolic activity of peritoneal and 
alveolar macrophages, Allen (1976) failed to elicit any 
chemiluminescent response from these phagocytes either in a 
resting state or following phagocytosis. However addition of 
luminol elicited a strong CL which was inhibited by addition 
of superoxide dismutase (superoxide scavenger) and sodium 
benzoate (hydroxyl radical scavenger). Production of CL in
this system was proposed to be due to relaxation to ground 
state of electronically excited aminophthalate anion molecule 
produced during the phagocytic process. Further work by
Williams et al. (1981a) revealed that luminol-dependent CL
activity of bronchoalveolar cells correlated well with their
PMN content and that human alveolar macrophages produced 
little or no luminol-dependent CL. This was attributed to low 
peroxidase activity of the AM. These workers also found that 
alveolar macrophages produce lucigenin-dependent CL of the
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order of magnitude produced by PMN (Williams, 1981b). Because 
this activity was found to be more than 95% suppressed by 
superoxide dismutase, superoxide radical is implicated in its 
production.
2.5.3 CL-Method:
BAL cells, PMN and monocytes were prepared as described
above and the concentrations adjusted to 2.5 x 10^/ml, 1 x
7 f10 /ml and 2.5 x 10 /ml respectively. For preliminary
experiments, the cell concentration was adjusted as required.
An overnight growth of Staph aureus 502A in MH broth was
o
washed, its concentration adjusted to 2.5 x 10 cfu/ml and
— S . . — 4opsonised m  10% serum. Luminol 10 M and lucigenin 10 M
previously found to be optimal for PMN and AM respectively 
were used. A Packard luminometer with a computerised protocol 
was operated at a stable temperature of 37°C, and was
programmed to make 10 second counts at five minute intervals 
for a total of 70 minutes. 0.1 ml phagocytes were added to 4 
luminometer tubes placed in luminometer chambers before adding 
bacteria 0.05 mis (phagocytes + bacteria in 2 tubes), followed 
by the addition of luminol or lucigenin 0.05 mis. In 2 tubes 
with phagocytes only (spontaneous CL) gel Hanks was added 
instead of bacteria. A printout is obtained at the end of the 
experiment, and peak counts were used for analysis.
Experiments were performed to determine optimum cell
concentration and reproducibility of chemiluminescence data.
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2.5.4 Effect of varying concentration of cells in 
chemiluminescence of AM.
The intensity of the chemiluminescent response of a 
phagocytic cell exposed to a particulate stimulus such as 
Staphylococcus aureus depends to some extent on the 
particulate:cell (bacteria:cell) ratio. To determine the 
optimum bacteria:cell ratio, varying concentrations of cells 
were used against a constant bacterial concentration with an
o
optical density of 0.45 (approximately 2.5 x 10 cfu/ml).
Table 2.10: Effect of varying bacteria:AM ratio on the
chemiluminescent response.
n = 4 Mean (SD) counts/sec/10^ cells
CellsxlO'V Bacticell 
0.1 ml
Lucigenin Luminol
10 12.5:1 2.73 (1.86) 0.51 (0.57)
5 25:1 13.70 (10.96) 2.1 (3)
2.5 50:1 28.64 (24.4) 4.34 (5.70)
1 125:1 26.60 (11.55) N.D.
ND = Not done.
For both luminol and lucigenin there was an increase in 
CL response with the higher bacteria:cell ratios. On that 
basis a concentration of 2.5 x 10^ AM/0.1 ml was used for the 
study.
The reproducibility of chemiluminescence was tested using
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mononuclear cells with luminol as a substrate (n = 3) and
using alveolar macrophages with luminol (n = 5) and lucigenin 
(n = 4) as substrates. Table 2.11(a&b) shows the
Table 2.11(a): Variability in luminol-dependent
chemiluminescence of mononuclear cells and AM.
O
Counts/second/10 cells
Mononuclear cells + Luminol AM + Luminol
Exp. 
NO. 1 2 3 1 2 3 4 5
Range
From
to
195
223
129.2
242
26.5
50
3.84
4.03
0.029
0.035
11.92 2.52 1.21 
12.8 2.76 1.36
Repli­
cates 5 10 9 5 3 2 2 3
Mean 203 187.7 39.7 3.95 0.031 12.39 2.6 1.29
S.D. 10.6 39.5 6.99 0.09 0.003 0.66 0.14 0.07
Coeff. 
Var. 0.05 0.21 0 .17 0.02 0.10 0.05 0.05 0.05
Table 2.11(b): Variability of Lucigenin dependent CL of
AM. (All experiments were done in duplicates)
Exp. 
No. 1
o
Counts/second/10 cells 
2 3 4 5
Range 120-150 4.30-4.58 8.68-9.16 30-30 160-17
Mean 135 4 .44 8.92 30 165
S.D. 21.2 0.19 0.33 0 7.07
Coefficient
Variation 0.16 0.04 0.04 0 0.04
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*3
range, mean, standard deviation of counts/second/x 10 cells 
and coefficient of variation in each experiment.
These results show that while there is an enormous 
intersubject variability, there is little intrasubject 
variability and the test is highly reproducible.
Finally the effect of neutrophils on AM lucigenin 
dependent chemiluminescence was studied in 3 samples. 
Purified preparations of AM were mixed with increasing 
proportions of neutrophils before measuring S t aphy lococcus 
aureus stimulated 1ucigenin-dependent chemiluminescence 
(Table 2.12). Neutrophil 1 ucigenin-dependent chemi­
luminescence was of the same order as that of AM (data not 
shown).
Table 2.12: Effect of neutrophils on lucigenin-dependent
chemiluminescence of AM.
Counts/second/10 cells
% :Neutrophils added
Sample No. *M (%) * o ,5 10 20 30 40 50 60
1 84.4 110 90 110 170 120 ND ND ND
2 98 140 150 150 150 210 140 100 170
3 92 100 100 100 100 90 100 ND ND
Mean 116.6 113.3 120 140 143. 3 120 100 170
S.D. 20.8 32.1 26.4 41. 6 58 .5 28.2 - -
ND = Not done.
*M(%) = Percentage of macrophages: before addition of PMN.
These results suggest that mixing of neutrophils with AM 
does not have an adverse effect on lucigenin-dependent 
chemiluminescence of AM.
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2.6 Monoclonal markers
2.6.1 Introduction and historical background:
t
Labelling of antibody with fluorescent dye was first 
achieved by Albert Coons and his colleagues in 1941. Since 
then various labels including fluorescein dyes such as 
fluorescein or rhodamine isothiocyanate; enzymes such as 
peroxidase (Nakane & Pierce, 1966), alkaline phosphatase 
(Mason & Summons, 197 6) have been widely used. The technique 
of indirect linking of a label to the antibody, exploitation 
of strong attraction between avidin and biotin and linking of 
enzymes to electron dense materials such as colloidal gold or 
radioactive materials have greatly increased the sensitivity 
of these methods. Early monoclonal antibody work was hampered 
by limitation in production techniques and lack of 
specificity. The major breakthrough in this field came with 
the publication by Kohler and Milstein (1975) of their method 
of production of monoclonal antibodies of predetermined 
specificity by culture of spleen cells "immortalized" by 
fusion with myeloma cells.
2.6.2 Use of Monoclonal Markers in BAL Cells:
T-cell markers have been widely used and substantial data 
in various disease states are now available. The relevance of 
these data to the clinical situation has been discussed
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earlier and will not be repeated. Monocyte/macrophage lineage 
cell markers have been used less extensively than T-cell
markers and their role in clinical practice is still
uncertain. Campbell et ad (198 6) have applied these to BAL 
cells from patients with interstitial lung diseases and found 
quantitative differences in subpopulations of alveolar
macrophages, as identified by different markers, between 
patients and control groups. A similar approach has been
employed by other workers (Hance et al.) . It was therefore 
regarded reasonable to explore this approach in the 
investigation of acute lung injury.
2.6.3 Monoclonal Markers - Methodology:
Two methods were assessed involving either labelling of 
cells in suspension or after fixation on glass slides.
2.6.3.1 Labelling of Cells in Suspension:
BAL cells were prepared from an original aliquot which 
was cleared of mucus (sieved if necessary), washed in PBS 
twice before adjusting the concentration to 5 x 10^ cells/ml. 
A 5 ul aliquot of primary antibody was added to 200 ul of BAL 
cells (1 x 106) and was left standing on ice for 30 minutes 
(gently mixed every 10 minutes). Cells were washed by 
centrifuging at 200g at 4°C for 5 minutes and resuspending the 
cells in PBS twice before finally discarding the cell free 
supernatant leaving behind the cell pellet suspended in about
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100 ul PBS. 100 ul of appropriate secondary antibody (goat 
antimouse-FITC) was added to the cells and placed on ice for 
30 minutes before washing in PBS twice and resuspending the 
cells in 1 ml of PBS. Cells were examined as wet 
preparations, by flow cytometry (FACS analyser) or cytospins.
2.6.3.1.1 Wet preparation:
15 ul aliquot of cells suspended in PBS placed on a 
microscope slide was covered with a cover slip (24 mm x 24 mm) 
and was examined under a fluorescent microscope. All cells in 
a field were counted using a phase contrast and positive cells 
from the same field were recognised by their lemon green 
fluorescent ring when examined under fluorescence. This
method was technically acceptable apart from nonspecific 
staining of dead cells which had a characteristic appearance. 
However this method had to be abandoned because it was very 
labour intensive since each preparation needed at least 20 
minutes of microscopy.
2.6.3.1.2 Cytospins:
These were fixed in formalin and stained in 0.1% 
methylene green for 45 seconds, and mounted with PBS/glycerol 
and coverslip edges sealed with a moist varnish. The nuclei 
appear red when examined under a filter of the fluorescent
microscope, and positive cells were recognised by the
fluorescent ring. Examination of cytospins was much less
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labour intensive compared to the wet preparations but 
"smudging" and widespread nonspecific background fluorescent 
staining was a major problem that rendered the technique 
unsuitable.
2.6.3.1.3 Use of FACS analyser;
At Glasgow Royal Infirmary, this equipment has been set 
up at the Leukaemia Research Institute for diagnosis and 
follow-up of hematological malignancies. With the help of the 
senior technician in charge, counting of labelled BAL cells 
was assessed. The following problems were encountered and 
this method was abandoned:
i) Alveolar macrophages often showed spontaneous 
autofluorescence of high intensity which precluded 
identification of positive cells from pseudo-positive cells. 
Indeed some of unlabelled specimens showed between 40-45% 
positive cells! This problem as mentioned earlier has been 
experienced by other workers (Hance, 1985) .
ii) "Gating" of small cells such as lymphocytes could not be 
achieved adequately because of their small numbers. 
Superimposition of sizes of small macrophages, monocytes (MO^  
or MC>2 positive cells) and large lymphocytes was another 
problem.
iii) Because the very nature of this machine involves flow of
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cells in "single file" through the very small orifice 
(maximum size 100 u ) BAL fluid preparations often resulted 
in blockage of the channel, necessitating elaborte cleaning 
procedures.
2.6.3.2 Labelling of cells on cytospins:
Both immunoperoxidase (IPX) and immunoalkaline 
phosphatase (IAP) methods were assessed but the former was 
soon abandoned because of non-specific peroxidase activity of 
macrophages from specimens of heavy smokers. A resume of 
these methods is given overleaf.
2.6.3.2.1 IAP staining:
Cytospins were prepared from the original aliquot of 
cells on microscope slides covered with a thin layer of 
polylysine to enhance sticking of the cells, before fixing in 
chloroform:acetone (1:1) mixture for 5 minutes. These were air 
dried for at least one hour, circled with a diamond cutter and 
stored at -20°C in slide carriers wrapped in cling film until 
they were stained. Preliminary experiments were performed on 
cryostat tonsillar.sections to determine appropriate dilutions 
of primary antibody (see Appendix I). Labelled slides were 
placed on a flat (spirit levelled) surface in a humidified 
chamber and cytospins were covered with 75 ul of 1/5 normal 
rabbit serum for 15 minutes. After this excess serum was 
discarded and the cells were uniformly covered by a 50-75 ul
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LABELLING CELLS ON CYTOSPIN PREPARATIONS
MOSfOPEROXIDASE IM4JNQALKALINE PHOSPATASE
75 ul normal sheep serum )
1/5 in tris-buffer ) 15 min.
75 ul Normal Rabbit Serum)
Primary Ab. 
50-75 ul
)
) 2 hrs
Wash tris-saline 2 minutes
1/5 in tris-buffer
Primary Ab 
50-75 ul
Wash tris-saline
Sheep-Antimouse ) 45 mins 
HRP conjugate )
Wash tris-saline 2 minutes
DAB 10 minutes
Tap water 1 minute
Haematoxylin 30-60 sec. 
Tap water 10 sec.
STWS 10 sec.
Tap water 
Water
Microscope check
If excess 
stain
Acid Alcohol
Acid
Industrial Alcohol Alcohol
Xylene X2
Mount
Harleco Synthetic 
resin.
Double
Staining
Technique
Rabbit Anti-mouse 
AP-conjugate
Wash tris-saline
Solution A 
AB-Substrate
Tap water
Haematoxylin 
Tap water 
STWS
Tap water
Microscope check
Mount or repeat 
stain if needed
) 15 min 
)
) 2 hrs 
2 mins
) 1 hr 
)
2 mins 
)
) 15 mins 
2 minute
30-60 sec.
10 sec.
10 sec.
139
aliquot of the primary antibody for 2 hours. Control 
cytospins were covered with PBS instead of primary antibody. 
Cells were gently washed in Tris-saline for 3 minutes, excess 
Tris saline wiped off, and were covered with 50 ul 1/20 
alkaline phosphate conjugated for one hour, before they were 
washed again in Tris saline for 3 minutes. Freshly prepared 
solution A was applied for 15 minutes on the cytospins which 
were then washed in distilled water and counterstained in 
Gill's haematoxylin for 30-60 seconds. To render nuclei blue, 
slides were immersed in Scots tap water substitute for 1 
minute and placed in warm tap water before mounting. Avoiding 
any drying of the cells, the cytospins were mounted in 
glycerol. Cells were examined at 400x and positive cells were 
recognised by the red staining of the plasma membrane. (Plate 
2.7(a)& (b).
2.6.3.2.2 Immunoperoxidase and double staining technique:
IPX is similar to IAP with minor variations as shown 
schematically (page 139). This method was assessed first but 
was soon abandoned because of nonspecific peroxidase activity 
of alveolar macrophages especially from heavy smokers. IAP 
was found suitable and was adopted as the method of choice in 
this work. However in samples obtained from areas of 
consolidation in CAP patients the monocyte marker UCHM-^  
appeared to be taken up by neutrophils and this was not 
observed among controls or other patient groups. To obviate 
this problem a double staining technique was employed.
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Specimens were labelled initially with UCHM^ using IPX up to 
the stage following the application of the chromogen 
diaminobenzidine (DAB) and then a second antibody HLADR was 
applied on the same specimen using IAP technique. Cells which 
were both HLADR and UCHM-^  positive showed a mixed colour of 
brown and red and were regarded as being of true monocyte 
lineage, thus excluding the granulocytes which took up UCHM-^  
alone. (Plate 2.8). All the other marophage markers were also 
tested using the double staining technique but were not found 
to be taken by neutrophils. Technical help with the double 
staining method given by Mr J. Richmond, Immunocytochemistry 
Department, Glasgow Royal Infirmary, is gratefully 
acknowledged.
2.6.3.3 Problems encountered with IAP and IPX techniques:
i) Wiping off or denudation of cells (?during washing) from 
the slides was the most common problem. When this happened a 
fresh specimen was stained. This underlined the need to have 
sufficient cytospins stored.
ii) Unexplained failure of staining: This problem occurred 
more commonly with RFD^ and on a couple of occasions it was 
attributed to a poor batch of the antibody.
iii) Pale staining of nuclei: This was a problem with T4 
marker which for some reason appeared to interfere with 
haematoxylin staining of the nuclei. No other marker did
Plate 2.7(a): IAP staining of AM with RFDR marker (HLA-DR) 
showing that virtually all are positive.
• M
Plate 2.7(b): IAP staining of AM with RFD^ marker.
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this. This problem was minimised by increasing the staining 
period time to 2 minutes.
iv) Non-specific staining of macrophages: marker appeared
to have this special problem and this has been reported by 
other workers (Wood et al, 1983). This problem was minimised 
by diluting the primary antibody in 20% normal human serum 
instead of tris-buffer, but this procedure unfortunately made 
problem number (iii) above worse. Morphology of the cells was 
also helpful.
2.6.3.4 Reproducibility of immunoalkaline phosphatase 
technique
This was tested by staining cytospin preparations from 3 
patients with T4, Tg, RFD-^  and RFDg markers on separate 
occasions. Cells were counted on different days, and Table 
2.13(a) & (b) show the results of each batch of staining.
However, the presence of very low numbers of T-cells in the 
BAL fluid of these patients (cigarette smokers) means that 
the coefficient of variation is exaggerated. Presentation of 
the raw data is more helpful (Table 2.13(a)). Plate 2.9 shows 
two Tg positive cells from a non-smoking control subject.
These experiments show that while the staining technique 
is fairly well reproducible when the raw data is examined, 
the fact that there are such small numbers of cells in each 
specimen, renders the coefficient of variation between 
experiments very high. This effect is not seen with staining
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Plate 2.8(a): Shows i) non-specific staining of neutrophils with UCHM^
ii) one AM stained only with RFDR^ marker (AM)
iii) AM stained both by RFDR and UCHM^ (U)
iv) Intense non-specific IPX activity of an 
eosinophil (E ).
Q
Plate 2.8(b): Double staining with RFDR^/RFDy. Note
i) RFDR^(HLADR) + AM but RFDy - (N)
ii) RFDR1 + /RFD7 + AM (P)
iii) Neutrophils take up little or no stain unlike Plate 8(a) above,
iv) Intense non-specific peroxidase stain of an Eosinophil (E).
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for macrophage markers in BAL where high proportions of cells 
are positive. Table 2.13(b) presents the results of 4 batches 
of staining with RFD-^  and RFDg markers.
Table 2.13(a): Variability in proportions of T-cells 
stained by immunoalkaline phosphatase 
technique.
No. of positive cells/500 cells (%)
Patient 1 Patient 2 Patient 3
Batch No. T4 t8 T4 T8 T4 t8
1 1 (0.2) 1 (0.2) 1 (0.2) 5 (1) 0 (0) 0 (0)
2 2 (0.4) 0 (0) 4 (0.8) 9 (1.8) 0 (0) 0 (0)
3 1 (0.2) 0 (0) 2 (0.4) 7 (1.4) 2 (0.4) 1 (0.2)
4 3 (0.6) 1 (0.2) 2 (0.4) 4 (0.8) 0 (0) 0 (0)
Mean 1.75 (0.35) 0.5 (0.1)2.25(0. 45) 6.25 (1.25)0.5(0.1)0 .25 (
S.D. 0.95(0.19)0 .57(1.12) 1.25 (0.25)2.2 (0.44) 1 (0.2) 0.5(0
Coeff. 
Variat. 0.54 1.5 0.56 0.35 2 2
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Table 2.13(b): Variation of staining of macrophage markers 
in BAL on different occasions.
% positive cells
Patient 1 Patient 2 Patient 3
Batch No.1 D1 d9 D1 d9 D1 d9
1 78.8 68.8 88.0 70.4 85.4 56.8
2 94.4 67.8 97.5 74.8 90.0 56.8
3 85.0 59.0 94.0 59.6 90.0 70.0
4 ND 82.8 ND 67.0 98.4 70.8
Mean 86.1 69.4 93.2 67.9 91.0 63.6
S.D. 7.8 9.48 4.8 6.4 5.4 7.9
Coeff. 
Variat. 0.09 0.14 0.05 0.09 0.06 0.12
ND = Not done.
These results show that immunoalkaline phosphatase 
staining with these macrophage markers is fairly reproducible 
when the same preparation is stained on more than one 
occasion.
2.7 Measurement of albumin and complement levels in
concentrated BAL supernatants:
Measurement of albumin was kindly made by Dr D.S. 
O'Reilly and his team (D. McLean, J. Cooper and R. Martin) 
using double label radioimmunoassay (RIA). Complement levels
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were measured by Professor Whaley's assistant, Dr. Holmes, 
using an ELISA assay for all complement fragments except C5a 
and C3a where a RIA was employed. I am deeply grateful to 
all of them.
Plate 2.9: Tg positive cells from a non-smoking control, 
(immunoalkaline phosphatase)
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CHAPTER 3
COMMUNITY-ACQUIRED PNEUMONIA (CAP)
3.1 Introduction:
Acute lung injury sustained in pneumonia represents 
microbiologically triggered injury and is one of the 
commonest in clinical practice. The reason for choosing this 
group of patients is evident.
3.2 Aims of the Study:
1. to catalogue cell types and proportions of BAL cells and 
compare with control subjects.
2. to identify BAL cell profiles according to aetiological 
agents.
3. to assess complement activation in BAL fluid from these 
patients.
4. to assess AM function in these patients.
3.3 Definition of Study Groups
3.3.1 Control Subjects (CS) :
Because of the lack of normal healthy volunteers it was 
decided to use patients undergoing bronchoscopy for the 
following indications as control subjects.
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i) Patients with haemoptysis, normal chest X-rays and 
negative bronchoscopies and other relevant investigations. 
This group formed the vast majority of control subjects.
ii) Doubtful hilar shadow on chest X-rays with negative 
bronchoscopy and other relevant investigations.
All patients gave informed written consent.
A total of 36 CS were recruited in the study. Tv:o 
patients' data were excluded from final analysis: They had
elevated calcium and abnormal liver function tests and were 
presumed to have underlying malignancy. Further details of 
the 34 control subjects is given in Table 3.1.
3.3.2 Community Acquired Pneumonia:
Patients were recruited from the acute general medical 
admission ward. The following criteria were applied for 
inclusion into the study or the final analysis of the 
results:
i) Clinical and radiological evidence of pneumonia with or 
without microbiological identification of the aetiological 
agent.
ii) No known underlying medical condition predisposing to 
pneumonia including bronchial carcinoma, diabetes, multiple 
myeloma. None of these patients was on steroid or cytotoxic
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therapy.
iii) Age below 70 years.
iv) Tolerability of bronchoscopy: Safety of the procedure 
was assessed on clinical grounds and arterial blood gases, 
often by a consultant chest physician. In the few doubtful 
cases "unbiased" independent advice was sought from another 
consultant.
v) Informed consent.
vi) Normal bronchoscopic findings other than those 
attributable to pneumonia.
vii) Complete resolution of chest X-rays to normal at follow- 
up .
Most of the patients were bronchoscoped within 24 hours 
of admission and a few within 48 hours. All X-rays were 
within 24 hours of bronchoscopy. Clinical management of 
these patients was done by the physician in charge and the 
decision to resume antibiotic therapy was not influenced by 
bronchoscopy request. Most of the patients had received one 
or two doses of antibiotics (usually intravenous ampicillin 
with or without erythromycin) by the time they were 
bronchoscoped.
There were no serious complications attributed to
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bronchoscopy. One patient died of type 3 pneumococcal 
pneumonia. 27 patients were recruited in the study but four 
patients were excluded in the final analysis because of other 
diagnoses (2 cases pulmonary tuberculosis, 1 case pulmonary 
embolism and 1 case portal vein thrombosis, deep venous 
thrombosis and cardiomyopathy).
Of the remaining 23 patients, 13 patients had bilateral 
lavages, 5 had lavages performed on radiologically clear 
areas (RCA) and another 5 on areas of consolidation (AOC) 
only. Further details of these patients is given in Table 
3.1.
Table 3.1: Age and sex distribution and smoking history of
patients groups.
Age Range 
(Mean)
Sex
Distribution 
M F
Smoking
N-smokers
History
Smokers
Control 
Subjects 
(n = 34)
30-63 (48.9) 22 11 8 26
CAP Patients 
(n = 23)
19-65 (47.8) 16 7 2 21
Both in the pneumonia group and control subjects there 
is male preponderance, and similar to many chest disorders, 
the influence of smoking is apparent even in these small 
groups.
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The following data was obtained in this study group.
1. Cell yields and differential counts.
2. Monoclonal markers (macrophage and T-cells).
3. AM migration (microchemotaxis chamber).
4. Chemiluminescence.
5. Effect of BAL supernatants on neutrophils from healthy 
donor.
6. Function of peripheral blood cells from another group of 
patients with community acquired pneumonia.
7. Albumin and complement levels of the BAL supernatants.
3.4 Results.
3.4.1 BAL fluid volumes, original cell yields and
differential counts.
The proportion of fluid volumes recovered between
smoking and non-smoking controls and between CAP and CS were 
similar. However the proportion of fluid recovered from AOC 
when compared to RCA in CAP patients was significantly lower
(P < 0.02) . This could be due to mucosal oedema in these
areas. (Table 3.2(a)).
The cell yield was significantly lower in non-smoking
controls when compared to smoking controls or CAP-RCA (P < 
0.05). Cell yields from RCA in CAP and smoking controls were 
similar. There was more than a four-fold rise in cell yields 
from AOC in CAP patients when compared to control subjects or
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Table 3.2a: BAL-fluid volumes and cell yields.
BAL Fluid Volumes (mis)
CellsxlO 
/ml BAL 
Fluid
Instilled Recovered
Proportion 
of recovered 
fluid
Control
Subjects Range 
Non-smokers Mean
150-300
(205)
25-125
(83.75)
0.13 - 0.52 
(0.40)
0.5 - 3 
(1.3)++
Control
Subjects
Smokers
Range
Mean
120-280
(202.6)
35-160
(94.0)
0.20 - 0.70 
(0.4)
0.6 -12.5 
(3.67)
CAP - RCA Range
Mean
60-240
(153.5)
20-110
(75.5)
0.4 - 0.73 
(0.51)
0.75 - 16.5 
(4.57)
CAP - AOC Range
Mean
50-240
(147.3)
25-135
(54.3)
* 0.25 - 0.60 
(0.37)
**2.0 - 27.5 
(20.2)
++ when compared to smoking controls P = 0.033.
* when compared to RCA significantly lower. P < 0.02.
** when compared to smoking controls (P < 0.02).
** when compared to RCA (P < 0.002).
RCA (Figure 3.1). Table 3.2(b) shows further breakdown of 
data on cell yields in these patients and smoking controls.
These results show that there was a highly significant 
increase in total cells from areas of consolidation compared 
to control subjects and CAP (RCA). This was mainly due to 
increases in neutrophils and to a lesser extent the 
lymphocytes. The increase in neutrophils and lymphocytes in 
RCA is a reflection of those few patients who had developed 
pneumonic changes in radiologically clear areas. This is 
demonstrated further in Table 3.3 which shows proportions of 
cells in control groups and CAP patients.
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Table 3.2(b): Absolute cell yields.
Cells x 105/ml BAL fluid
Patients' Mean Macro­ Neutro­ Lympho­
groups Median Total phages phils cytes
Control
subjects Mean (SD) 3.67(2.97) 3.50 (2.97) 0.07 (0. 05) 0.07 (0.07)
n = 21 Median (SEM) 3.2 (0.65) 2.998 (0.65) 0.008 (0 .01) 0 .045 (0.01)
CAP RCA Mean (SD) 4.57 (3.98) 3.75 (3.01) 0.67 (1.13) 0.18 (0.21)
n = 17 Median (SEM) 4.02(0.96) 3.02 (0.73) 0.17 (0.27) 0 .08 (0.05)
P value NS NS P = 0.041 P = 0.03
CAP AOC Mean (SD) 20.23(24.2) 4.13(4.9) 10.2 (10.26) 0.93(1.18)
n = 15 Median (SEM) 13.75 (6.23) 2.60 (1.26) 9.32 (2.65) 0.44 (0.30)
P value *P < 0.002
• .V , 1
NS **P < 0.002;
i  ' ‘ ’ ’ ‘ 1 ' • /
***P = 0.001
All P values in the table refer to comparison with control
subjects.
* when compared to RCA P < 0.002.
** when compared to RCA P < 0.002
*** when compared to RCA P < 0.05.
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Table 3.3: Original differential cell counts.
Original differential cell counts
Macrophages Neutro- Eosino- Lympho-
phils phils cytes
Control 
Subjects 
(Non-smokers) 
n = 8
Range
Mean
(SD)
Median
71.2-93.6 
85.5 (9)
86.8
0 - 5.4 
1.8 (1.95)
1
0 - 2.8 
0.02 12. 
(0.07)
0
6.4 - 28 
4 (8.5)
8.5
Control Range 78.8-99.6 0.2-8.3 0 - 2.4 0 - 12.2
Subjects Mean 93.8 (4.75) 2.8 (2.23) 0.36(0.57) 2.79(2.91)
(Smokers) (SD)
n = 26 Median 94.95 2.4 0.1 2
CAP-A11 Range 50 - 99 0-48 0 - 1  0.8-16
patients Mean 84.2 (13.8) 11.7 (13.1) 0.21(0.32)3.8(3.5)
(including (SD)
2 non-smokers) Median 88.6 7.8 0.1 2.85
RCA n = 18 P value NS NS (P=0.052) NS NS
CAP-(Smokers) Range 75.5-98.4 0 - 8.6 0 - 0 .9 0.8 - 16
excluding 5 Mean 92.5(6.7) 3.94(3.5) 0.2(0.31) 3.5(4.3)
patients with (SD) 94.5 2.6 0 2.0
>10% Neutro­ Median
phils RCA n = 11 P value NS NS NS NS
CAP All Range 0.8 - 69.5 3 - 99.2 0 - 1 0-60
patients. Mean 27.2(22.8) 59.8(34.7) 0.14(0.25) 12.8(18.8)
AOC n = 18 (SD) Median 24.3* 72.4** 0 3.0
P value P < 0.001 P < 0.001 NS NS
P values in the table relate to comparison with C.S.
* when compared to RCA. significantly lower P < 0.002. 
** significantly higher than RCA P < 0.002.
The above table shows the cell composition of 
unprocessed BAL fluid from control subjects and CAP patients. 
The two control groups show differences in their lymphocyte 
and neutrophil contents. Cells from radiologically clear 
(RCA) show some neutrophil contamination although in the
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majority of patients this contamination is small. The cell 
composition from areas of consolidation (AOC) show a 
predominance of neutrophils with a reduction in the 
proportion of macrophages. Few patients only show an 
increased lymphocyte population. Further examination of 
these data according to aetiological agent of pneumonia is 
helpful (Table 3.4).
Table 3.4: BAL cell composition according to the nature of
the aetiological agent.
(%) Differential counts 
ranges according to
of original 
aetiological
cells. Means 
agent
and
Aetio­
logical
agent
Macro­
phages
Neutro­
phils
Eosino­
phils
Lympho­
cytes
Strepto­
coccus
Pneumo-
moniae
RCA
n=4
84.8
(62.2-94.5)
12.7
(2.3-34.3)
0.2 
(0 - 0.7)
2.3 
(1.4-3.5)
AOC
n=4
9
(1-18)
89
(83.6-95.6)
0.05 
(0 - 0.2)
1.9 
(0.2 - 3)
Legion­
ella
Pneumo­
phila
RCA
n=3
97.6
(96.5-98.4)
1
(0 - 2.6)
0.1 
(0 - 0.3 )
1.4 
(1 - 2.6)
AOC
n=2
47.3 
(37 - 57.6)
12.7 
(3 - 22.4)
0
0
40
(20-60)
RCA
n=2
85.2
(71.5-99)
12.2 
(0 - 24.3)
0.1 
(0 - 0.2)
2.5 
(0.8-4.2)
sp.
AOC
n=2
50
(30.6-69.5)
26.5 
(12.5-39.6)
0.7 
(0.4 - 1)
23.3
(17-29.6)
Undeter­
mined
aetiology
RCA
n=9
79.2 
(50 - 94)
14.8 
(1.2 - 48)
0.23 
(0 - 1)
5.6 
(2 - 16)
AOC
n=ll
26
(2 - 56.3)
63.8 
(9.2 - 95.6)
0.09
(0.03)
9.97 
(0.4 - 58)
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The above table shows cell content according to 
aetiological agent. Patients with Legionnaire's disease show 
least contamination of their macrophage population from RCA. 
In addition these patients appear to have a lymphocyte 
preponderance in areas of consolidation unlike patients with 
pneumococcal pneumonia. The cell composition from the two 
patients with mycoplasma infection show a mixture of 
neutrophils and lymphocytes from AOC and with some degree of 
contamination in RCA. Cells from patients with pneumococcal 
pneumonia contained the largest proportion of neutrophils.
3.4.2 Monoclononoal markers
3.4.2.1 Macrophage markers
(Table 3.5): There was considerable variation between
subjects in all groups in most of the markers. However BAL 
cells from CS and from CAP-RCA showed a remarkable similarity 
in their profile as determined by the panel of macrophage 
markers used. One exception to this was the proportion of 
Langerhans cells NA1/34 (Tg positive cells) which was 1.57% 
(_+ 0.91) in control subjects compared to 0.65 (_+ 0.63) in
CAP-RCA, which was significantly lower (P < 0.02).
BAL cells from AOC in CAP patients showed significant 
differences in some markers when compared to those from CS or 
from RCA with UCHM^ positive cells constituting only 0.97% (_+ 
1.38) in CS, 1.28% (+ 0.84) in RCA and 49.2% (+ 31.7) in AOC 
(P < 0.002). Some of this difference was due to neutrophils
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taking up the UCHM^ marker. However the presence of higher 
proportions of (monocytes) UCHM^ positive cells was confirmed 
by higher proportions of UCHM-^  DR positive cells 29.24% (+_
21.6) (P < 0.002). It is interesting that the few patients 
with increased neutrophil content of BAL cells from RCA did 
not show any increase in the proportion of UCHM-^  positive 
cells. This can be illustrated in two patient's profiles 
(Table 3.6).
Table 3.6:
Patient Differential count of cells from RCA
Macrophage PMN Eosinophil Lymphocyte UCHM-^  
+ve
A.N. 72.8 21 0.2 6 1.2
M.Y. 50 48 0 2 2
There was also a significant increase in RFD-y positive 
cells from AOC compared to those from CS (P = 0.02) . The
proportions of UCHM^ positive cells is presented in Figure 
3.2.
3.4.2.2 T cell markers:
These were prepared as previously described (Table 3.7).
• The absolute proportion of T-cells among the smoking 
controls were low as previously documented (Costabel, 1986). 
The T4/Tq ratio of 1.37 was slightly higher than the
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Fig. 3.2: UCHM^  positive cells in CAP.
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Table 3.7: Proportions of T-cell subsets in CAP and CS 
BAL samples.
Mean % Counts 
(SD)
t3 t4 t8 t4/t8
Control Subjects 
(Smokers) n = 13 2.6 (3.35) 1.35 (1.19) 1.88 (2.60) 1.37 (1.16
CAP RCA 
(Smokers) n = 11
5.51 (6.5) 2.39 (2.59) 3.31 (5.55) 1.49(0.85
CAP - AOC 
(Smokers) n = 9
*19.6 (22.2) 13.2 (15.6)**7.4 (5.1) 2.0 (1.87
* . Compared to CS. P < 0.02.
** When compared to RCA. P < 0.05.
previously reported ratio of 0.9 for smokers. The T-cell
profile was similar between CS and CAP-RCA; and although the
T^/Tg ratio was slightly higher (1.49) there was no
significant difference between them. Proportions of Tg 
positive (Pan T-cells) and Tg positive cells were also higher 
from AOC compared to those from CS. The T^/Tg ratio of cells 
from AOC was not significantly different to those from CS or 
from RCA. Scrutiny of these data according to the nature of
the aetiological agent does not show any pattern of T4/T8
ratio amongst any patient group, although there was a total 
increase of T-cells in patients with Legionnaires' Disease 
(Plate 3.1(a) and (b)) and mycoplasma pneumonia. This is a 
reflection of an increase in the total proportion of
lymphocytes from AOC in these patients. However these
subgroups are too small from which to draw any clear
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conclusions.
3.4.3 Purification of alveolar macrophages from BAL
Ficoll hypaque centrifugation gave excellent macrophage 
enrichment in BAL samples from CS and from RCA in CAP 
patients (Table 3.8).
The final macrophage and neutrophil content of samples 
from RCA as a whole group showed no statistically significant 
differences with CS although the neutrophil content was 
slightly higher in the CAP group. This was due to incomplete 
clearing in samples (5) which contained more than 10% 
neutrophils originally. When these samples are excluded from 
analysis, none of the remaining samples (RCA) contained more 
than 3% neutrophils. Purification of macrophages from areas 
of consolidation was less satisfactory. Specimens from these 
areas generally contained more mucus and debris and this 
rendered density gradient centrifugation less effective in 
removing neutrophils. (Plate 3.2(a)). Migration of AM from 
such specimens is impaired by the neutrophil contamination. 
(Plate 3.2(b)). The mean viability (%) (SD) for CS, CAP 
(RCA) and AOC was 67.0 (15.0), 73.6 (12.8) and 82.3 (11.4)
respectively.
3.4.4 AM Migration
Using microchemotaxis technique as described in chapter 
two, migration of AM from RCA in CAP patients was compared to
164
Table 3.8: Cell composition of BAL fluid after density
gradient centrifugation.
Differential counts of interface layer of cells
Macrophages Neutrophils Eosinophils Lympho­
cytes
Control Range 71.7-97.4 0.2-4.3 0 - 0.2 2-24
Subjects Mean (SD) 89.4(8.3) 
(Non-smokers)
1.3(1.4) 0.02(0.07) 8.9(7.0)
n = 7 Median 92.4 0.8 0 7.2
Control Range 87.0-99.6 0 - 5.0 0 - 1 0 - 8.0
Subjects Mean (SD) 96.7(3.1) 1.61(2.07) 0.15(0.25) 1.6(1.99)
(Smokers)
n = 26 Mfedian 98.0 0 0 0.90
CAP - All Range 65 - 99.6 0-35 0 - 0.6 0 - 5.3
patients. Mean (SD) 92.2(9.4) 6.0(9.4) 0.06(0.16) 1.76(1.69)
RCA n = 18 Median 95.5 2.0 0 1.1
P value* 0.160 0.052 0.147 0.675
CAP-RCA Range 92.6-99.6 0 - 3.0 0 - 0.4 0 - 4.8
(Smokers) Mean 95.9(3.7) 2.5(3.32) 0.03(0.11) 1.5(1.48)
excluding Median (SD) 98.0 1.7 0 1.1
5 patients P value 0.63 0.86 0.107 0.863
with > 10% 
PMN in 
original 
cell 
counts 
RCA n = 11
CAP - AOC Range 2 - 86.2 1 - 96.4 0 - 0.6 0 - 42.4
patients. Mean (SD) 38(25.88) 52.6(35) 0.06(0.18) 9.4(15.2)
n = 18 Median 30.0 70.0 0 2.0
* P values: when compared to smoking controls.
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Plate 3.2(a): BAL cells from AOC in a CAP patient, after Ficoll-
hypaque centrifugation. Typical immature PMN (arrows) 
which are bilobed or unilobed are commonly seen. 
Unlike AM or monocytes these are esterase negative.
Plate 3.2(b): Chemotaxis membrane flooded with PMN allowing
the occasional macrophage migrating through, 
(arrow).
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control subjects. Data on migration of AM from AOC are not 
satisfactory as purification of macrophages from these areas 
was not achieved. Table 3.9 shows data from RCA and CS only.
Measurement of macrophage movement shows a marked 
impairment of unstimulated migration and stimulated migration 
of AM from CAP (RCA) towards casein, ZAS (C5a) and f-met-leu- 
phe.
In analysis 3 comparison of AM migration from BAL fluid 
samples with comparable cell profile to those of CS, shows 
that the impairment of AM migration from CAP in RCA is 
genuine and not merely a function of neutrophil contamination 
in these samples. These results are demonstrated in Figures 
3.3(a) and (b).
3.4.5 Respiratory burst generation in alveolar macrophages
Assessment of generation of respiratory of burst by AM 
from these patients was compared to CS by measurement of
chemiluminescence. Both luminol and lucigenin dependent 
chemiluminescence was measured for 7 0 minutes with readings 
taken every 5 minutes for 10 seconds. Peak counts per second 
(cps) generated by 10^ cells are presented in Tables 3.10(a) 
and (b) .
Lucigenin dependent chemiluminescence (Luc-D-CL) of 
cells from CAP-RCA tended to be lower as compared to CS. 
This trend was not significant. Spontaneous (cells + gel 
Hanks) Luc-D-CL of cells from AOC was low compared to those 
of CS and CAP-RCA. This was statistically significant when
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Table 3.9: Chemotaxis (stimulated and unstimulated migration
of purified alveolar macrophages.
Unstimulated 
migration Casein ZAS(C5a) FMLP
Mean (+ SD) 29.1 (12.2) 37 (15) 61 (2) 33.4 (17.6)
Control
Subjects
n = 19 Median(+SEM) 30 (2.8) 31.0 (3.5) 55.5(6.6) 26.0 (4.3)
Mean (+SD) 12.5 (6.8) 22.4 (12.1) 30.3 (18.2) 13.6(9.5)
CAP
n = 16 Median(+SEM) 12.0 (1.7) 21.5 (3.0) 26.0 (4.5) 13.5 (2.4)
Analysis 1 P value P < 0.002 P < 0.02 P < 0.002 P < 0.002
Mean(+SD) 13.0 (7.1) 24.4(11.6) 31. 9(18.8)
15.0 (9.3)
CAP
n = 14 Median(+SEM) 12.0 (1.9) 27.0 (3.1) 28.0 (5.0) 14.0 (2.6)
Analysis 2 P value P < 0.002 P < 0.05 P < 0.002 P < 0.002
Mean (+SD) 14.0 (7.6) 25.6(10.8) 39.8 (16.1) 16.4 (10.0)
CAP
n = 10 Median(+SEM) 13.0 (2.4) 26.5(3.4) 37.5 (5.1) 24.5 (3.2)
Analysis 3 P value P < 0.01 P < 0.05 P < 0.05 P < 0.01
All P values relate to comparison with control subjects.
AM MIGRATION IN CAP
(ANALYSIS 2)
UNSTIMULATED
p<0.002
CASEIN
p<0.05
■  CONTROL SUBJECTS (n=19) 
E3 CAP (n=14)
p<0.002
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Fig. 3.3 (a&b): AM migration in CAP.
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Table 3.10(a): Lucigenin dependent chemiluminescence of AM
from CS and CAP patients.
Peak/cps/10^
cells
Lucigenin Dependent
Cells + Bact. Cells + Gel Hanks
Control Subjects Mean (SD) 
Median (SEM) 
n = 10
812.4 (852.5) 
400.0 (269.6)
821. 1 (876.9) 
415.0 (277.3)
CAP - RCA Mean (SD) 
Median (SEM) 
n =
P value
453.2 (587) 
180 (195)
9
NS
548 (644) 
235 (228) 
8 
NS
CAP-AOC Mean (SD) 
Median (SEM) 
n =
P value
85.5 (81) 
50 (27) 
9 
NS
56.3 (70.2) 
20 (22.2) 
10
**P < 0.01
** when compared to CAP-RCA and CS.
Table 3.10(b): Luminol-dependent chemiluminescence of AM from 
CS and CAP patients.
Peak counts/ 
sec x 10 cells
Cells + 
Bacteria
Cells + 
gel Hanks
Control Subjects 
n = 17
Mean
Median
(SD)
(SEM)
21.5
3.8
(58.4)
(14.1)
14.4
2.7
(39.5) 
( 9.5)
CAP - RCA 
n = 11
Mean
Median
(SD)
(SEM)
30.3
10.0
(38.4)
(11.5)*
8.9
4.5
(10.5) 
( 3.7)
CAP - AOC 
n = 14
Mean
Median
(SD)
(SEM)
77.5
25.0
(101.3) 
(27.0)**
3.7
4.2
(18.2) 
( 5.2)
e < u.Ud }when compared to CS 
** P < 0.01
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compared to CAP-RCA (P < 0.01). (Figure 3.4(a)).
Luminol dependent chemiluminescence (Lum-D-CL) of cells 
from CAP patients (both RCA and AOC) was significantly higher 
than CS and this is likely to be due to higher neutrophil 
content of cells from those areas. (Figure 3.4(b)).
3.4.6 Effect of BAL supernatants on migration of
neutrophils from healthy donors
The presence of large numbers of neutrophils in areas of 
consolidation in CAP patients was thought likely to be due to 
various chemotactic products including AM neutrophil derived 
chemotactic factor and complement activation products. In 
order to test this, the effect of 10-fold concentrated BAL 
supernatants from CS, and from RCA and AOC in CAP patients 
were used as chemotaxins for healthy donor neutrophils. 
Neutrophils were obtained on two different days from two 
healthy donors and BAL concentrates were tested against each 
donor's cells. Normal saline was used as a negative control 
and ZAS (C5a) was used as a positive control.
Because of a wide variation between the two donors, 
neutrophil migration (donor 1 unstimulated migration (U.M.) = 
151; donor 2 UM = 5), the chemotactic differential of each 
supernatant was used. (Chemotactic differential = Migration 
towards a chemotaxin (supernatant) - migration towards normal 
saline). A mean of two donors' chemotactic differentials 
against BAL supernates for each patient group was obtained, 
(Table 3.11 and Figure 3.5)
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Fig. 3.4(a&b) : AM lucigenin and luminol-dependent chemiluminescence in CAP
172
Table 3.11: Effect of BAL supernatants on healthy donor
neutrophils.
Cells/5 fields 
(x 400)
Control 
Subjects 
(n = 9)
CAP-RCA 
(n = 6)
CAP-AOC 
(n = 7)
Mean (SD) 32.3 (95.2) 56.6 (95.7) 212.1 (125.7)
Median (SEM) 36.0 (31.7) 52.0 (39.0) 160.5 (47.5)
*P value NS P < 0.05
* compared to control subjects.
These results indicate that BAL supernatants from CAP 
were more active chemotactically towards donor neutrophils 
than supernatants from CS. This chemotactic activity was 
significantly greater in BAL supernatants from AOC (P < 
0.05). Furthermore there was no indication to suggest the 
presence of any inhibitory activity of supernatants from the 
RCA which might have accounted for the observed impairment of 
migration of AM obtained from those areas.
In order to compare the chemotactic activity of 
supernatants from RCA and AOC in CAP, matched samples in 
patients with bilateral lavages were analysed. (Table 3.12).
In keeping with a much higher neutrophil content from 
areas of consolidation, the supernatant fluid from these 
areas showed significantly greater chemotactic activity 
towards healthy donor neutrophils.
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Table 3.12: Effect of BAL supernatants from CAP with
bilateral lavage as a chemotactic stimulus for 
health donor neutrophils.
Neutrophil Migration
3 II CT> CAP - RCA CAP - AOC
Mean 5 6.6 (95.7) 185.4 (114.0)
Median 52.0 (39.0) 150.0 ( 46.5)
*P value P = 0.028
* Wilcoxon
3.4.7 Peripheral Blood Cell Function in CAP
Having demonstrated that AM migration and 
chemiluminescence is impaired in this group of CAP patients, 
the question that arises is whether this impairment is part 
of a systemic effect of the pneumonic illness, or whether the 
impairment of AM function could have predisposed these 
patients to pneumonia. In an attempt to answer this 
question, data were obtained on peripheral blood neutrophil 
and monocyte migration from another group of CAP patients and 
compared to healthy donor controls, (table 3.12).
3.4.7.1 Monocytes and neutrophil migration
Monocytes were enriched using monocyte-nycodenz gradient 
(Boyum, 1983) with a purity of 80% esterase positive
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: Patients from whom peripheral PMN and MN
obtained.
Age Range (Mean) Sex
Distribution
Controls 
n = 10
24.56 (38.2)
M F 
6 4
CAP
n = 11
28-73 (54.1) 8 3
cells, (Plate 3.3). Unstimulated migration and migration 
towards ZAS (C5a) and f-Met-Leu-Phe was assessed, Table
3.14(a). Migration of neutrophils was assessed in the same 
way, Table 3.14(b).
Table 3.14(a): Monocytes migration.
Monocyte Migration
Unstimulated ZAS (C5a) FMLP
Mean'(SD) 33.4 (23.3) 130.7 (79.4) 38.3 (22.5)
CS Median (SEM) 29.0 ( 7.7) 122.0 (26.4) 33.0 ( 9.2)
n = 9 n = 9 n = 9
Mean (SD) 34.7 (20.8) 79.5 (36.5) 42.1 (16.4)
CAP Median (SEM) 25.0 ( 7.8) 93.0 (13.8) 48.0 (6.2)
n = 7 n = 7 n = 7
NS NS NS
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Table 3.14(b): Neutrophil migration.
Unstimulated ZAS (C5a) FMLP
Mean (SD) 48.0 (52.9) 214.1 (79.3) 86.8 (32.2)
CS Median (SEM) 31.5 (18.7) 192.0 (28.0) 80.6 (11.4)
n = 8 n := 8 n = 8
Mean (SD) 62.3 (36.5) * 113.0 (116.1) 122.8 (51.8)
CAP Median (SEM) 41.0 (11.0) 51.0 (35.0) 105.0 (16.4)
n = 11 n = 11 n = 10
*P < 0.05.
Unstimulated migration and stimulated migration of 
monocytes towards ZAS and FMLP were similar between CS and 
CAP patients. Unstimulated neutrophil migration and migration 
towards FMLP from CAP patients showed an increased trend but 
this was not significant. In contrast however, migration of 
neutrophils towards ZAS was significantly impaired in CAP 
patients. (Figure 3.6(a) and (b)).
3.4.7.2 Measurement of chemiluminescence in peripheral 
blood monocytes and neutrophils.
Generation of respiratory burst in peripheral blood
ME
DI
AN
 
(S
EM
) 
CE
LL
S 
/ 
5 
FI
EL
D
S 
ME
DI
AN
 
(S
EM
) 
CE
LL
S 
/ 
5 
FI
EL
DS
 
(m
ea
n 
of 
3 
w
el
ls
)
(m
ea
n 
of 
3 
w
el
ls
)
1 78
MONOCYTE MIGRATION IN CAP
150 - i
■  CONTROL SUBJECTS (n=9) 
E3 CAP (n=7)
UNSTIMULATED ZAS FMLP
NS NS NS
NEUTROPHIL MIGRATION IN CAP
■  CONTROL SUBJECTS (n=8) 
B CAP (n=11)
UNSTIMULATED
NS
Fig. 3.6(a&b) : Monocyte and neutrophil migration in CAP.
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cells in CAP patients was assessed by measuring lucigenin and 
luminol dependent chemiluminescence and was compared to 
healthy donor cells. Cells were prepared as previously 
described. Both monocytes and neutrophils showed a trend of 
increased lucigenin and luminol dependent chemiluminescence 
in the CAP group compared to the CS. (Tables 3.15 a-d). This 
heightened activity was highly significant in the neutrophil 
lucigenin-dependent chemiluminescence (P < 0.01) (Table
3.15b) and (Figure 3.7(a)).
Lucigenin Dependent Chemiluminescence 
Table 3.15(a): Monocytes Luc-D.CL.
Peak cps/10^ Cells + Cells +
cells Bacteria gel Hanks
Mean (SD) 112.8 (49.5) 85.0 (55.7)
CS Median (SEM) 100.0 (18.7) 95.0 (22.7)
n = 7 n = 6
Mean (SD) 304.5 (475.8) 445.0 (509.3)
CAP Median (SEM) 130.0 (143.0) 95.0 (207.9)
n = 11 n = 6
No significant differences between the two groups. (Figure 
3.7(b)).
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Table 3.15(b): Neutrophil Luc-D-CL
Peak cps/10^ 
cells
Cells + 
Bacteria
Cells + 
gel Hanks
Mean (SD) 44.2 (51.9) 32.0 (40.5)
CS Median (SEM) 30.0 (19.6) 20.0 (15.3)
n = 7 n = 7
Mean (SD) 180.9 (131.0) 155.4 (163.0)
CAP Median (SEM) 140.0 (39.5) 70.0 (49.2)
n = 11* n = 11*
* P < 0.01
Luminol Dependent Chemiluminescence
Table 3.15(c): Monocyte (Lum.-D-CL).
Peak cps/10^ Cells + Cells +
cells Bacteria gel Hanks
Mean (SD) 205.7 (89.0) 4.6 (2.7)
CS Median (SEM) 220.0 (33.6) 3.5 (1.1)
n = 7 n = 6
Mean (SD) 633.3 (775.4) 40.0 (17.3)
CAP Median (SEM) 360.0 (316.5) 50.0 (10.0)
n = 6 n = 3
P value: No significant differences between the two groups.
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Table 3.15(d): Neutrophil Lum-Dep-CL.
Peak cps/10^ 
cells
Cells + 
Bacteria
Cells + 
gel Hanks
Mean (SD) 265.7 (136.0) 1.8 (0.6)
CS Median (SEM) 220.0 (51.4) 2.0 (0.2)
n = 7 n = 7
Mean (SD) 447.2 (412.0) 17.4 (22.5)
CAP Median (SEM) 440.0 (124.2) 10.0 ( 6.8)
n = 11 n = 11
P value: No significant differences between the two groups.
3.4.8 Measurement of albumin and in BAL supernatant.
Albumin measurement was done using a double-label 
radio immunoassay in the Biochemistry Department 
Glasgow Royal Infirmary. The results are presented in 
Table 3.16a.
These results show that although albumin levels in 
BAL supernatant from RCA in CAP are slightly higher than 
those from CS they are not significantly different. 
Levels of albumin from areas of consolidation are 
significantly higher than those from CS (P < 0.002) and
RCA (P = 0.011). This observation is in keeping with the 
degree of inflammation in AOC.
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Table 3.16(a): Albumin levels in miq/L for BAL fluid
from patients with CAP.
Control Subjects CAP (RCA) CAP (AOC)
n=1 6 n=1 2 n=11
Range 3.8 - 111.8 0 - 500.7 0.528-1345
Mean (SD) 37.12(31.27) 77.93(138.5) 542.31(549.73
Median (SEM) 27.45(8.36) 30.55(39.9) 216.6(165.75)
*P value NA NS P<0.002**
NA = Not applicable.
* = All P values relate to comparison with control subjects.
** = Significantly higher than RCA for matched samples
P = 0.011 (Wilcoxon).
3.4.9 Measurement of complement components and products 
of complement activation.
Measurement of complement components was done using 
an ELISA assay. Baseline values for the assay are given 
in Appendix I. The results are presented here in mg/L and 
and since the lower limits for these components are in 
ng/ml (ug/L), where these were not detectable a level of 
0 was assigned for the purpose of analysis Table 3.16b.
It is clear from these results that the levels of 
complement components in supernatants from AOC are 
significantly higher than CS and from RCA.
In order to assess the contribution of passive 
exudation of these components into the alveoli as a
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result of the inflammatory process, these levels were 
related to albumin levels; Table 3.16c).
Relating the levels of complement components to
albumin levels, shows the degree of difference between 
AOC and CS is less than when no correction is made for 
albumin. The majority of the components remain 
significantly higher than the CS. There are now no 
significant differences between AOC and RCA and, indeed 
in some circumstances some of the complement components 
from inflamed areas are lower than in RCA and even in CS. 
A case in point is C3 levels, which are lower (though not 
significantly so) than in RCA or CS. Whether this
indicates consumption must be viewed together with the 
products of complement activation. These are shown in
Table 3.17. Complement activation and cleavage of the
components is a local phenomenon and there is no
justification in correcting for albumin (Whaley
personal communication).
All but one product of complement activation from 
AOC in CAP patients are higher than in CS. C5a was
higher than either the control subjects or RCA but was
not significantly so when compared to the latter. C5b-9 
showed undetectable levels in the majority of the 
specimens throughout the project and the reason for this 
is not clear. Hence no significant differences were found 
in this fragment between groups. Significantly higher 
levels of Cls-CInh complex (P < 0.01), C3-P (P < 0.05)
and C3a (P < 0.05) are higher in AOC than in RCA from the
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same patients. These results suggest that there is both 
classical and alternative pathway complement activation 
in AOC in CAP patients.
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3.5 Discussion
The AM is the predominant cell in BAL fluid from the 
normal lung but is superseded by exudate cells in disease 
states such as pneumonia or ARDS. This study has 
investigated both "normal" and inflamed areas of the lung by 
assessing BAL cells both phenotypically and functionally. 
This was compared with BAL cells from as near normal a 
control group as could possibly be obtained. The proportion 
of BAL cells obtained from the control group and RCA in CAP 
were similar in the original yields and differential counts 
as those reported in other studies (Huninghake, 1979; 
Reynolds, 1987). Cells obtained from RCA of the lung from 
the CAP patients were very similar to those from CS in many 
patients, and exudate cells were only found in a few 
patients. Density gradient centrifugation on Ficoll-hypaque 
rendered final differential counts between the two groups 
similar with no statistical differences in the cell 
composition as a whole. Exclusion of those patients who had 
more than 10% neutrophils.in their original count, yielded a 
subgroup whose final differential count was almost identical 
to that of the control subjects.
Use of a panel of macrophage markers which have been 
used in previously published work (Campbell, 1986; Poulter, 
1986; Alegre, 1986), has enabled further comparison between 
the macrophage populations of these two groups. In five of 
the six macrophage markers tested there were no differences 
detected between CS BAL cell composition and CAP (RCA)
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patients. The one exception is the NA1/34 (Tg equivalent) 
marker which identifies Langerhans cells (Alegre, 1986; 
Chollet, 1982, 1984; Murphy, 1983, 1987; Kawanami, 1981) . The 
proportion of NA1/34 positive cells from CAP patients was 
significantly lower than the control subjects.
This is a hitherto unreported finding and it is 
difficult to compare the results of this work with the 
literature for several reasons. Firstly, all the work using 
this monoclonal antibody on lung cells by various workers 
(Chollet, 1981, 1984; Murphy, 1981, 1983; Kawanami,
1981) employed an OK Tg which may not be identical to NA1/34. 
Secondly these ..workers have used different techniques from 
that used in this study and particularly that used by Chollet 
et al. (1984). In that study they employed immunoperoxidase
labelling of live cells which preserves cisternal peroxidase 
activity which is apparently helpful in identifying 
Langerhans cells. The third and perhaps the most important 
reason is that in all the studies quoted, the control groups 
have been patients with various disease states, and only 3 
normal controls whose proportion of Tg positive cells was not 
mentioned in these papers. Our experience with this 
monoclonal antibody has been similar to others, in that it 
appeared very highly specific and gave a strong reaction (see 
plate 3.4). Chollet (1984) quoted among the miscellaneous 
group one case of viral pneumonia with 1.2% Tg positive cells 
but it is not clear whether these cells were from normal or 
inflamed areas of the lung and the range for our pneumonia 
(RCA) is 0.2 - 2%. These workers have compared various
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Plate 3.4: NA 1/34 (T^) positive cells are typically strongly 
positive.
patient groups with histiocytosis-x patients who were found 
to have much higher proportions of positive cells in their 
BAL fluid. It is possible that the true "normal controls" 
have "intermediate values" comparable to those in this study 
(0.4 - 2.6%). If that were the case then the lower 
proportion of Tg positive cells may be related in an as yet 
unidentified immunological mechanism perhaps in keeping with 
other functional impairment of AM found in this study. It is 
known for instance that antigen presentation form one of the 
other functions of Langerhans cells (Silberberg-Sinakin, 
1980) . However it is clear that these findings need to be 
confirmed by others before such an interesting speculation is 
considered more seriously.
Cells from areas of consolidation in the CAP group as a 
whole were predominantly neutrophils, although the same trend 
was evident when the results were analysed according to the 
aetiological agent. These results are in agreement with some 
and in conflict with others. Abrams et al. (1984) found a 
predominantly neutrophil-rich BAL profile in those pneumonia 
patients with confirmed aetiological diagnosis but none of 
these patients had Legionnaire's disease or mycoplasma 
pneumonia. Pierce and colleagues (1977), using an
experimental model found neutrophils predominant amongst 
lavage cells following E .coli challenge but a weak neutrophil 
response after staphylococcal challenge. Data from 
experimental Legionnaire's disease in guinea pigs showed an 
early neutrophil response, with lymphocytes peaking at 7 days 
of infection (Davis, 1983). Our patients though
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bronchoscoped early following admission, could be regarded as 
late in terms of evolution of the disease, which could 
explain this apparent lymphocytosis. However, this may be 
useful in clinical practice. This was demonstrated 
retrospectively in one of our patients with Legionnaire's 
disease whose serology and other microbiological tests were 
negative and whose lavage profile from AOC was 57.6% 
macrophages, 22.4% neutrophils and 20% lymphocytes. This 
patient seroconverted (titre of 1/1000 for legionella type I 
after three weeks). None of our patients with pneumococcal 
pneumonia showed lymphocytosis and all had very high 
neutrophil counts (83.6 -95.6%). Lafitte et al. (1983)
serially lavaged patients with pneumonia up to 90 days and 
found neutrophils initially in pneumococcal pneumonia 
followed by lymphocytosis at about 10 days.
The results of macrophage markers were interesting. 
There were increased proportions of UCHM^-positive cells 
(monocytes) from AOC compared to RCA or CS. This was 
slightly exaggerated by non-specific staining of neutrophils 
by this monocyte marker but the use of the double-staining 
technique (i.e. in conjunction with HLADR marker) confirmed 
increased proportions but established more accurate 
proportions of these cells. The finding that none of the 
specimens which contained substantial numbers of neutrophils 
in radiologically clear areas had any increase in the 
proportion of UCHM^^-positive cells, indicates that the influx 
of these cells is later compared to neutrophils. This 
is in keeping with the findings of Hudson et al. (1977) in an
194
experimental model. The other macrophage marker that showed a 
difference between AOC and RCA is the RFD7 which has been 
shown to label mature macrophages (Poulter, 1986). This 
monoclonal antibody did not appear to label neutrophils and 
this was confirmed by double-staining technique. This 
suggests that some of the newly arrived mononuclear cells, 
have sufficiently "matured" and have acquired at least some 
of the characteristics of the resident macrophages. This 
marker has been shown not to cross react with UCHM-^-positive 
cells (Poulter, 1986). An increased proportion of RFD7
positive cells has been shown in patients with cryptogenic 
fibrosing alveolitis (Campbell, 1986), a condition known to 
have increased turnover of the macrophage population 
(Bitterman, 1984). Such an increase of these cells in acute 
lung inflammation as seen in our patients underlies the 
versatility of the mononuclear phagocyte system.
The proportions of T-cells in our smoking 
and non-smoking controls are similar to those reported by
other workers (Reynolds, 1987; Costabel, 1986). The T^/Tg 
ratio for our non-smoking controls is also similar to those 
reported earlier but for the smoking controls the ratio of 
1.37 (Hh 1.16) is slightly higher than (0.9 + 0.4) reported by 
Costabel et al. (1986), but lower than the ratio for non-
smokers which is in keeping with their findings. There was
considerable intersubject variation in these counts and 
because the total numbers of lymphocytes on any one cytospin 
are small, missing one or two cells during the process of
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counting could mean a wide margin of error. To reduce this 
often all the cells in the cytospin were counted rather than 
the standard 500 cells used in the study. The increase in 
the total numbers of T-cells in the community-acquired 
pneumonia patients is reflected by the increase in total 
numbers of lymphocytes in some patients but on the whole the 
ratio of T^/Tg was not significantly different compared to 
CS.
The AM is now widely accepted as the principal cell 
responsible for host defences in the lung. Some insight has 
been obtained as to the state of host defence in the CAP 
patients in "normal" and inflamed lung areas. Migration of 
AM obtained from RCA in CAP patients showed marked 
impairment compared to AM from CS. This depression was 
demonstrated towards the three chemotaxins tested as well as 
in unstimulated migration. There are no similar data 
available with which to compare our results, but impairment 
of AM function including migration and phagocytosis has been 
reported in a group of patients with pneumonia following 
allogeneic bone marrow transplantation (Winston, 1982). 
Lucigenin-dependent chemiluminescence of AM from RCA has 
shown a clear trend towards functional depression compared 
with CS although this did not achieve statistical 
significance, perhaps due to smaller numbers of patients 
involved. Such an impairment of AM function could be the 
result of a "systemic effect" of the pneumonic illness or to 
some predisposing factor to pneumonia.
This question was addressed in two ways. Firstly, the
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supernatant fluids from RCA (and from AOC) were used as 
chemotaxins against healthy donor neutrophils although it 
might have been better to use AM or monocytes for this 
purpose. Given the limitation of such an approach, our data 
showed no suggestion of any inhibitory factor (s) in the 
supernatants from these lung areas. Indeed, these 
supernatants were slightly more chemotactic than those of 
C.S. Our complement data in the BAL supernatants confirm 
that there are significantly higher levels of complement 
components and products of complement activation from AOC 
than from RCA or CS. The second approach was the assessment 
of peripheral blood cell function. Both migration and 
chemiluminescence of monocytes from another group of CAP 
patients showed no differences when compared to healthy 
donor cells. Chemiluminescence of neutrophils from CAP 
patients was significantly enhanced compared to CS. The only 
exception to this overall lack of depression of function of 
peripheral blood cells in CAP patients compared to control 
subjects was the migration of neutrophils towards ZAS 
(C5a) . Neither the unstimulated migration nor the migration 
towards F-met-leu-phe of cells from CS were "superior" to 
those from patients with CAP. Thus the data on peripheral 
blood cells in CAP patients do not suggest a systemic 
impairment of function that could also have accounted for the 
impairment of function of AM from RCA of the lung.
Thus bearing in mind the small numbers of peripheral 
blood cells examined it appears that a localised predisposing 
factor within the lung compartment is more likely to lead to
the development of pneumonia than some systemic change. One 
possible cause of depressed AM function sufficient to 
predispose to development of pneumonia is viral infection. 
Epidemiological data as well as experimental data suggest 
that viral infection can predispose to pneumonia. This is 
thought to be due to an AM phago lysosome fusion defect 
(Jakab, 1980) or immune complex deposition on the AM (Astry, 
1984) . In this study there was no comprehensive viral screen 
for all the patients. But when viral titres were obtained, 
nothing was found except in one patient with pneumococcal 
pneumonia an antibody titre towards para influenza virus 
of 1/64. Previous viral infection for some of our CAP 
patients cannot therefore be ruled out. The other 
possibility which might have accounted for impairment of AM 
function in these patients is chronic alcohol abuse. At 
least five of the sixteen patients who had AM migration 
studies admitted to having a "drink problem", although none 
showed obvious features of malnutrition. Patients with 
chronic alcoholism have an increased incidence of pneumonia 
(Bradsher, 1983 and Sullivan, 1972).
Migration data on BAL cells from AOC could not be 
interpreted adequately because of large numbers of 
neutrophils from these areas. However the use of lucigenin- 
dependent chemiluminescence allows comparison of AM from CS 
and from RCA. AM have been shown to produce lucigenin 
dependent chemiluminescence activity of the same order as 
neutrophils (Williams & Cole, 1981b). Thus lucigenin 
dependent chemiluminescence of BAL cells from AOC is
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depressed compared to those from CS and those from CAP (RCA) 
(P < 0.01). These results seem to contrast with those from 
peripheral blood cells which show enhancement of lucigenin- 
dependent chemiluminescence of neutrophils in CAP compared 
to CS. However this is not entirely surprising since these 
lung cells (mainly neutrophils from AOC) could have
degranulated by the time they were lavaged. Such 
degranulation is not unknown in acute lung injury (Yamada,
1982).
3.6 Conclusions:
1. BAL cells from "normal" areas of lung are comparable to 
those from CS, while those from AOC are predominantly 
but not exclusively neutrophils. An early lavage may 
give a useful cellular profile.
2. Lower than expected proportions of Langerhans cells 
were found in patients with CAP. This finding if 
confirmed could have important immunological 
implications regarding function of these cells in the 
lung.
3. Areas of consolidation contain significantly higher 
levels of complement components and products of 
complement activation.
4. Impairment of AM function in CAP patients may 
predispose to the development of pneumonia.
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CHAPTER 4 
SMOKE INHALATION INJURY
4.1 Introduction:
Lung injury due to smoke inhalation among fire victims 
has been identified as the single most important contributory 
factor to mortality in these patients. Fire victims may 
suffer from smoke inhalation only, smoke inhalation and burns 
or burns only. Patients who sustain both injuries carry by 
far the highest risk of mortality. This study endeavours to 
examine cellular and humoral changes in the lung, in the hope 
of filling some of the gaps in our understanding of the 
complex mechanisms involved. This study was planned and 
initiated by the Department of Anaesthesia at Glasgow Royal 
Infirmary in conjunction with the Department of
Microbiology. I am grateful for being allowed to contribute 
to the study. Recruitment of patients was done for the most 
part by research registrars in the Department of Anaesthesia 
initially by Dr A. Pollok and later by Dr J. Kinsella. 
Without their cooperation this part of the study would have 
been impossible. I am deeply grateful to both of them. 
Patients were recruited directly from the Casualty Department 
in liaison with the Fire Officer who would often notify the 
research registrar of the fire incident even before the 
arrival of the patient (s) in the Casualty Department! Those 
patients who were initially admitted in other hospitals often
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arrived here much later. Therefore, the time of bronchoscopy 
after the fire incident is variable (from 4-36 hours).
4.2 Diagnosis of smoke inhalation and definition of study 
group.
Diagnosis of smoke inhalation is not as easy as it may 
appear, and for this the system of clinical scoring 
introduced by Dr C.J. Clark, mentioned in Chapter 1, was
followed. In brief, each one of the following points was
allocated one score and a score of 2 or more was accepted as
diagnostic of significant smoke inhalation:
1. A history of being entrapped in a fire in a closed space.
2. Production of carbonaceous sputum.
3. Perioral facial burns.
4. Altered level of consciousness at any time after the
incident.
5. Symptoms of respiratory distress.
6. Signs of respiratory distress.
7. Hoarseness of voice.
Using these scores and the presence or absence of
cutaneous burns, patients were categorised as follows: I.
Smoke Inhalation only. II. Smoke Inhalation plus burns. III. 
Burns only. Measurement of carboxyhaemoglobin was made as 
soon as the patient was admitted and using a normogram it was 
possible to extrapolate the level of carboxyhaemoglobin at
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the time of the incident. This gave a more accurate 
assessment of the intensity of smoke inhalation. Patients 
who were referred from other hospitals often lacked these 
data.
All patients included in this study gave informed 
consent. Often the procedure was performed because it was 
clinically indicated. BAL was performed as previously 
described between 4 and 36 hours and 13 patients were lavaged 
twice within 24 hours.
Control subjects were those described in the pneumonia 
study (Chapter 3). Table 4.1 gives further details of the 
patients in this study.
Table 4.1: Age, sex distribution and smoking history of study 
groups.
Age Range 
(mean)
Sex Distribution Smoking
History
M F NS S
Control 
Subjects 
n = 34
30-63
(48.9)
23 11 8 26
Smoke
Inhalation 
Study Group 
n = 41
17-78
(46.2)
30 11 3 38
The above table underlines the importance of smoking in 
both the control group and to a greater extent the fire 
victims. It also shows that in both groups males
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predominate. The following table shows a further breakdown of 
patients, subgroups and some clinical details.
Table 4.2: Clinical parameters of patients.
Smoke 
Inhalation 
alone n=15
Smoke 
Inhalation + 
burns n=20
Burns alone 
n=6
< 10 5
% Burns 11-29 NA 9 1
30-50 2 4
> 50 4 1
10-20 1 5
21-30 4 5
% CoHb 31-40 4 3 NA
41-50 1 4
> 51 4 (MD=1) 1 (MD=2)
3 3 5
4 4 4
Symptom 5 3 4 NA
Score 6 2 2
7 - 2
MD 3 3
No. of cases
who died 1 8
NA = Not applicable. MD = Missing Data.
It is clear from Table 4.2 above that by far the highest 
mortality occurs in patients who sustain both inhalation and 
burn injuries.
The following data were obtained from these patients' 
bronchoalveolar lavages.
1. Cell yields and differential counts.
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2. AM and T-cell subsets as determined by monoclonal markers.
3. AM migration (microchemotaxis chamber).
4. Chemiluminescence of AM.
5. Effect of BAL supernatants on migration of neutrophils 
from healthy donors.
6. Data of repeat lavages from some patients including 
functional assays.
7. Albumin and complement levels in BAL supernatants.
4.3 Results
4.3.1 BAL fluid volumes, original cell yields and
differential counts
There was a slight variation in the volume of fluid 
instilled and recovered although these were generally 
comparable. (Table 4.3).
There was no difference between the proportion of fluid 
recovered between control subjects and different patients' 
subgroups. Cell yields were significantly lower in the non­
smoking controls. There was a clear trend of increase in 
cell yields from patients with smoke inhalation and much more 
so in those with combined inhalation and burns injury. These 
however were not statistically significant. However there 
were significant differences between control subjects and 
patients with smoke inhalation in the yield of neutrophils as 
shown in Table 4.3(b).
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Table 4.3a: BAL fluid volumes and cell yield.
BAL Fluid Volumes (mis) Cell
CellsxlO^ 
/ml BAL 
fluid
Instilled Recovered Propor­
tion of 
recovered 
fluid
Control
Subjects
(non-
smokers)
Range
Mean
150-300
205.0
25-130 0 
83.75
.125-0.52
0.40
0.50-3.6 
1.61 *
Control
Subjects
(smokers)
Range
Mean
120-280
202.6
35-160
94.0
0.20-0.70
0.46
0.6-12.5
3.67
Smoke
inhalation
only
Range
Mean
150-300
220.9
60-190
119.1
0.45-0.80
0.56
0.75-8.0
4.44
Smoke
inhalation 
with burns
Range
Mean
150-300
236.7
40-160
116.7
0.18-0.83
0.50
2.0-38
6.06
* Significantly lower than cell yields of smoking controls. 
P = 0.028.
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Table 4.3(b): Yield of different cell types in 
smoke inhalation.
cells x lO'Vml BAL fluid
Patient Macro- Neutro- Lympho-
Groups Total phage phils cytes
Controls Mean(SD) 3.67(2.97) 3.50(2.97) 0.07(0.05) 0.07(0.07) 
n = 21 Median(SEM)3.2(0.65) 2.998(0.65) 0.008(0.01) 0.045(0.01)
Smoke Mean(SD) 4.44(2.1) 3.55(2.02) 0.80(1.03) 0.06(0.07)
Inhalation Med. (SEM) 3. 93 (0.60) 3.55 (0.58) 0.39 (0.29) 0.07 (0.02) 
alone P value NS NS P<0.001 NS
n = 12
Smoke & Mean(SD) 6.05 (8.56) 3.39(4.67) 2.55(4.34) 0.19(0.29)
Burns Med.(SEM)3.30(2.07) 2.23 (1.13) 0.80 (1.05) 0.10 (0.07)
n = 17 P value NS NS PC0.001 NS
Repeat BAL 
(smoke 
with or 
without 
burns) 
n = 12
Mean 
Median 
P value
8.80 (7.79) 
6.37 (2.25) 
P = 0.01
3.98 (2.98) 
3.05 (0.86) 
NS
4.61 (7.79) 
1.18 (2.25) 
P<0.001
0.08 (0.1) 
0.04 (0.02) 
NS
Thesei results show that there is a significant increase
in neutrophils in patients with smoke inhalation with or 
without burn injury. Because of increase in the total cell 
yields the macrophage yields remain comparable to control
subjects. (Fig. 4.1).
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The cell composition of BAL fluid from these patients, 
however, differs significantly from control subjects.
The cell composition of patients with smoke inhalation 
with or without burns showed a reduced proportion of
macrophages and a reciprocal increase in neutrophil content, 
Table 4.4(a). This was highly significant in both subgroups
but was much more pronounced in patients with combined
inhalation and burn injuries. The increase in neutrophil
content was greater with a longer delay of lavage following 
the inhalation injury and this is more apparent in repeat 
lavage data (Table 4.4(b)). It should be mentioned here that 
all repeat BAL were done on the opposite lung to the one 
previously lavaged, usually the right middle lobe or the 
lingula.
The cell yields from repeat BAL samples were
significantly higher than the initial samples. Most of this 
increase is due to the influx of neutrophils, but it is clear
that there is some increase in the absolute numbers of
macrophages as well. The proportion of macrophages is
however significantly lower in the repeat BAL samples than in 
the initial ones. This is associated with the significant 
reciprocal rise in the proportion of neutrophils (P = 0.007). 
The cell composition of BAL fluid from patients with burns 
only was remarkably similar to that from CS and did not show 
any increase in neutrophil population.
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4.3.2 Monoclonal markers
4.3.2.1 Macrophage markers
In an attempt to define the proportions of macrophage 
and T-cell subgroups monoclonal markers were used. Table 
4.5a shows the result of macrophage markers. The proportions 
of subgroups of macrophages between different patient groups 
and control subjects is very similar except for RFD^+ve cells 
in smoke inhalation only patients which were significantly 
higher than CS (P < 0.02). Surprisingly patients with
combined injury also showed an increase, this did 
not achieve significance. There is a trend towards an 
increase in UCHM^, positive cells in patients with smoke 
inhalation and significantly so in those with combined injury 
(P < 0.02). It is interesting that there is no increase in 
the proportion of RFD7 positive macrophages which was 
observed in the AOC from CAP patients. The proportions of 
macrophages as defined by macrophage markers in the initial 
and repeat samples did not show any marked change, but this 
may be because of too few samples being studied (Table 
4.5(b)) .
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In Table 4.5(b) % Macrophage markers in initial and repeat 
BAL samples.
% (Means) r f d-l rfd7 RFC 9 RFDRX (NA1/34)
t6
UCHM1
Initial
samples
(n=6)
87.8 44.4 70.1 99.0 2.40 0.95
(n=5)
Repeat
samples*
(n=6)
88.1 49.3 71.0 98.8 2.0 2.6
(n=5)
*No significant differences were found between initial and 
repeat BAL samples in any of the macrophage markers.
4.3.2.2 T-cell markers:
These were done as previously described, Table 4.6a.
Table 4.6(a): (%) Mean T-cell subset in BAL of control
subjects and smoke inhalation patients.
% Mean (SD) t3 t4 t8 t4/t8
Ratio
Control Subjects 
n = 13
2.6(3.35) 1.35(1.19) 1.88 (2.60) 1.37 (1.16)
Smoke only 
n = 7
1.80 (2.09)1.15(0.65) 0.65(0.41) 2.0 (1.17)
Smoke + Burns 
n = 12
4.71(4.93) 1.9(1.73) 2.64 (3.4) 1.10(0.8)
Burns only 
n = 2
3.48 2.30 2. 61 1.16
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There were no differences detected in the T-cell subsets 
and t4/t8 ratio between control subjects and patient groups. 
However in those patients where repeat BAL samples were 
examined, there was a clear trend emerging so that out of 
seven samples, six showed a relative reduction in T4 positive 
cell proportions with a resultant reduction in T4/Tg ratio. 
The trend however was not statistically significant (P = 
0.063) .
Table 4.6(b): T-cell subsets in initial and repeat BAL cells 
from patients with smoke inhalation with or 
without burn injury (n=7).
% Means (SD) t3 t4 Tg T4/Tg ratio
Control Subjects 
(n = 13)
2.6(3.35) 1.35 (1.19) 1.88(2.60) 1.37(1.16)**
Initial samples 3.2 (2.1) 1.35 (1.1) 1.42(0.93) 0.98(0.46)
Repeat samples 2.67 (2.0) 0.74 (1.1) 2.0 (1.7) 0.33 (0.39)*
^Compared to the initial lavage, all were not significantly 
different. T4/T8 ratio approached significance (P = 0.063). 
**Compared to 2nd lavage, T4/Tg ratio is significantly higher 
(P < 0.01).
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4.3.3 Differential cell counts following macrophage
enrichment
Ficoll hypaque centrifugation allowed removal of 
substantial numbers of neutrophils so that the macrophage 
content of samples from patients with smoke inhalation alone 
was statistically not different to those from CS, (Table 
4.7a) . However neutrophil content in BAL samples from 
patients with smoke and burns injury although greatly reduced 
remained significantly higher than CS. Samples from patients 
with combined injury also achieved some degree of macrophage 
enrichment but neither the macrophage nor the neutrophil 
contents were comparable to those from CS.
Samples from patients with burns only compared extremely 
well with those from CS. The neutrophil content from this 
subgroup was low enough almost to be significantly different 
to those from patients with combined inhalation and burn 
injuries (P = 0.05). Purification of macrophages from repeat 
BAL samples was comparable to that of initial samples despite 
their increased neutrophil content.(see Table 4.7(b)).
The mean (SD) (%) viabilities of cells after ficoll 
hypaque centrifugation from CS patients with smoke inhalation 
only, smoke and burns only were 67(15); 85.5(6.8), 82.1(10.9) 
and 75.6(10.0) respectively.
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Table 4.7(b): Purification of AM from initial and repeat BAL 
samples of patients with smoke inhalation with
or without smoke inhalation.
% Means (SD) Macro­
phages
Neutro­
phils
Eosino­
phils
Lympho­
cytes
Initial Samples 77.4(33.6) 21.3(33.3) 0.07 (0.27) 1.10 (0.81)
Repeat Samples 75.2 (25.4) 21.5 (26.7) 0.16(0.24) 1.66(0.58)
4.3.4 A.M. Migration:
This was done on 10 samples from patients with pure 
smoke inhalation (including one non-smoker) and on 12 samples 
on those with mixed injuries (including 2 non-smokers). Data 
from 5 patients with pure burns were also obtained. The 
results were analysed in two ways: I. Comparing the whole
group of smoke inhalation with or without burns to controls. 
II. Comparing the subgroups to controls. In both cases data 
from non-smokers are excluded.
Measurement of macrophage migration showed significantly 
higher unstimulated migration of AM from the patients with 
smoke inhalation (Table 4.8a and Figures 4.2a-c). There was 
also increased stimulated migration towards casein, ZAS and 
f-met-leu-phe although the latter did not achieve statistical 
significance. There was considerable mtersub^sct variation
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UNSTIMULATED MIGRATION
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Fig. 4.2: (a) : Unstimulated AM migration in smoke inhalation and bums injury.
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Fig. 4.2(b) : Stimulated AM migration towards casein in smoke inhalation and
bums injury.
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Fig. 4.2(c) : Stimulated AM migration towards ZAS in smoke inhalation and bums
injury.
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as is apparent in the standard variations of these values. 
Further analysis of these data into subgroups gives valuable 
information. (Table 4.8(b) and Figure 4.3).
It is clear that AM from patients with inhalation injury 
alone show a trend of increased migration both stimulated and 
unstimulated but this is not significant. However, AM from 
patients with combined smoke inhalation and burn injury show 
significantly higher stimulated and unstimulated migration. 
Migration of AM from patients with burns alone is not 
different from those of CS. Measurement of migration of AM 
from repeat BAL samples was insufficient and data for 4 
patients only is available (Table 4.8(c)) and no clear 
pattern emerged from these experiments.
4.3.5 Respiratory burst generation in alveolar macrophages:
Generation of respiratory burst in AM from patients with 
smoke inhalation was assessed using both lucigenin and 
luminol dependent chemiluminescence. Counts were measured 
for 10 seconds at five minute intervals for a period of 70 
minutes. Results are presented as mean counts per 10 cells 
in tables 4.9a&b.
Measurement of AM lucigenin dependent chemiluminescence 
showed no difference between control subjects and patients 
with smoke inhalation either alone or with burns. (Fig. 
4.4(a)) .
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Table 4.8(c): Measurement of AM migration from initial and
repeat BAL samples from patients with smoke 
inhalation with or without burn injury (n=4).
Mean (SD) Unstimulated Casein ZAS FMLP
Initial Samples 34.2 (27.3) 49.0 (31.2) 150.0 (148.4) 27.2 (26.9)
Repeat Samples 37.0 (24.0) 49.0(41.5) 75.5 (26.5) 37.7 (7.8)
Table 4.9(a): Lucigenin dependent chemiluminescence of AM
from smoke inhalation patients.
o
Peak counts per 10 cells
Cells + 
Bacteria
Cells + 
gel Hanks
Control Subjects Mean (SD) 812.4 (852.5) 821.1 (876. 9)
n = 10 Median 400.0 (269.6) 415.0 (277.3)
Smoke Inhalation Mean 770.0 (779.8) 835.0(718.2)
n = 10 Median 565.0(246.6) 545.0 (227.1)
P value NS NS
Smoke + Burns Mean 671.7 (812.4) 853.8 (927.1)
n = 15 Median 350.0 (209.7) 525 (247.7)
•P value NS NS
NS = Not significant.
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Table 4.9(b): Luminol dependent chemiluminescence of AM from
patients with smoke inhalation.
Peak counts/10 cells
Cells + 
Bacteria
Cells + 
gel Hanks
Control Subjects Mean (SD) 21.5 (58.4) 14.4 (39.5)
n = 17 Median (SEM) 3.8 (14.1) 2.7 ( 9.5)
Smoke Inhalation 
only 
n = 9
Mean (SD) 
Median (SEM)
72.2 (111.2) 
17.0 (37.0)
4.7 ( 5.8)
4.7 ( 1.7)
P value P < 0.01 NS
Smoke Inhalation 
+ Burns 
n = 13
Mean (SD) 
Median (SEM)
45.3 (42.8) 
43.6 (11.9)
10.3 (6.9) 
10.2 (2 .0)
P value P < 0.05 NS
NS = Not significant.
Measurement of luminol-dependent chemiluminescence of 
BAL cells from patients with smoke inhalation only or with 
burns was significantly higher than control subjects and this 
was in keeping with higher neutrophil content in samples from 
these patients. These results are illustrated further in 
Figure 4.4(b). To follow the capability of BAL cells in 
initiating respiratory burst, chemiluminescence was assessed 
in repeat lavage samples from patients with smoke inhalation 
with or without burns. These were not analysed into 
subgroups because of small numbers (Table 4.10(a) and 
4.10 (b)) .
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Table 4.10(a): Lucigenin dependent chemiluminescence of
repeat BAL samples from patients with smoke 
inhalation with or without burn injury (n = 9)
o
Peak counts/10 cells
Cells + 
Bacteria
Cells + 
Gel Hanks
Initial samples Mean (SD) 753.3 (881.8) 1065.2 (1094)
Median (SEM) 350.0(293.9) 490.0 (364.8)
Repeat samples Mean (SD) 196.6(133.7) 327.8 (246.2)
Median (SEM) 180.0 (44.6) 370.0 (82.0)
*P value 0.038 0.066 (NS)
* Wilcoxon matched pairs signed Ranks Test.
Table 4.10(b): Luminol-dependent chemiluminescence of repeat
BAL samples from patients with smoke
inhalation with or without burn injury (n = 9).
Peak counts/10^ cells
Cells + 
Bacteria
Cells + 
gel Hanks
Initial Samples Mean (SD) 72.7 (109. 2) 4.91 (3.6)
Median (SEM) 30.0 ( 36. 4) 4.50 (1.2)
Repeat Samples Mean (SD) 60.6 ( 45.2) 7.75 (3.2)
Median (SEM) 50.0 ( 15.0) 9.0 (1.0)
Tue NS NS
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Stimulated lucigenin-dependent chemiluminescence showed 
significant reduction in subsequent BAL samples, but the 
reduction of spontaneous chemiluminescence of BAL cells from 
these samples was not significant (Table 4.10(a)). Luminol- 
dependent chemiluminescence did not show any change despite 
increased proportions of neutrophils in these samples.
4.3.6 Effect of BAL supernatants on neutrophil migration
To investigate a possible cause of neutrophil 
accumulation in the lungs, and also a measure of AM 
activation (which can result in the release of AM-derived 
neutrophil chemotactic factor), concentrated BAL supernatants 
were tested for their chemotactic activity to neutrophils 
from healthy donors. These were compared to chemotactic 
activity of supernatants from control subjects. These were 
done on two different days from 2 healthy donors and 
calculation of the chemotactic differential is taken as a 
measure of chemotactic activity. (See Table 4.11).
Table 4.11: Effect of 10-fold concentrated BAL supernatants
from smoke inhalation patients on chemotaxis of 
healthy donor neutrophils.
Cells/5 fields Control Smoke Smoke + Burns only
(x 400) Subjects only burns
n=9 n=7 n=5 n=3
Mean (SD) 32.3(95.2) 68.7(72.8) 158.4(114.8) 24.0(130.4)
Median (SEM) 36.^31.7) 48.5 (27.5) 182.0 (51.3) -19.0 (75.3)
P value NS P < 0.05 NS
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Measurements of chemotactic activity of concentrated BAL 
supernatants towards neutrophils from healthy donors showed 
that there was increased chemotactic activity of BAL 
supernatants from patients with smoke inhalation and this was 
significantly so in patients who had combined injury (P < 
0.05). This is in keeping with the higher neutrophil content 
of lavages from this subgroup compared to control patients.
BAL supernatants from patients with burn injury alone did not’
show any increased chemotactic activity above control 
patients. (Figure 4.5).
4.3.7 Albumin in BAL supernatants.
Data for BAL supernatants was obtained by using a 
double labelled RIA as previously acknowledged. The 
results are presented in Table 4.12.
Table 4.12: Albumin levels in mg/L of BAL fluid from
patients with smoke inhalation injury.
Control Subjects Smoke Alone Smoke + Burns 
n = 1 6 n = 7 n = 1 0
Range 0 - 500.7 19.2 - 200 0 - 555.6
Mean (SD) 77.93(138.5) 94.73(77.1) 161.74(183.9)
Median (SEM) 30.55(39.98) 60.0(29.1) 83.0(58.2)
P value NS NS P<0.05
The results ‘ ~ a significant difference
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in albumin levels between patients with combined 
inhalation and burns injury compared to either the CS or 
those with smoke inhalation only. Patients with combined 
injury also had higher levels of albumin in their BAL 
supernatants than those with smoke inhalation alone. 
However this was not statistically significant.
4.3.8 Estimation of complement components and products 
of complement activation in BAL supernatants.
Complement components were measured by an ELISA 
technique as previously mentioned, Tables 4.13a and b. 
These results show that there are significantly higher 
levels of complement on BAL supernatants from patients 
with combined injury. While there is a trend of increased 
levels in patients with smoke inhalation only, none of 
the products is significantly higher than the control 
subjects.
Comparison between patient subgroups shows that 
there is no significant difference in the levels of most 
of these products between the two except the Cls and the 
C3 which are significantly lower in the smoke inhalation 
only patients compared to the smoke inhalation with burns 
patients.
Relating the levels of complement components to 
albumin concentration in the BAL supernatants resulted in 
the reduction of the significance level of differences 
between smoke oatients and control subjects.
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Levels of all components except C3 remained higher in 
smoke and burns patients than either the CS or those with 
single injury. Levels of Clr and Cls and Factor H were 
significantly higher in those with combined injury than 
CS.
Products of complement activation in smoke 
inhalation injury were also measured. These are 
presented in Table 4.14.
All these products were higher in patients with 
combined smoke inhalation and burns injury than CS or 
those with smoke inhalation alone. The level of Cls-CInh 
complex was significantly so (P < 0.05). The results for 
C3-P were particularly interesting in patients subgroups. 
In 10 lavage samples (8 initial and 2 repeat) from the 
smoke inhalation only group, none showed detectable 
levels of C3-P, while 5 out of 13 samples from those with 
smoke and burns injury showed detectable levels.
235
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4.4 Discussion:
Previous studies (Phillips, 1962; Achauer, 1973) have 
underlined the importance of lung injury in morbidity and 
mortality among fire victims. While there is an enormous 
amount of literature in burns injury, there is a conspicuous 
gap in the literature on smoke inhalation injury especially 
the changes in the lung. BAL offers a direct approach in 
studying some of the physiopathological changes that occur in 
the lung. Using this approach, Gemmell (1987) and others 
(Clark 1988(a&b); Demarest 1979) have presented data showing 
some of the cellular and functional changes that occur.
These changes include an influx of neutrophils into the 
lungs and an increase in total cell yields from BAL fluid in 
these patients. Data presented in this study confirm these 
findings. Patients with smoke inhalation and especially 
those with burns injury as well have a moderate increase in 
total cell yields but not significantly so during the early 
period. Patients who were lavaged a second time (from the 
opposite lung) showed significant increases in their total 
cell yields, compared both to their initial lavages (p < 
0.005) and to the CS (p = 0.002) . The increase
is almost completely due to an influx of neutrophils into the 
lungs. This influx soon changes the cell profile in BAL fluid 
of these patients so that there is a reciprocal rise and fall 
in the proportions of neutrophils and macrophages 
respectively. Eve^ in the first 24 hours the proportion of 
neutrophils becoF '‘^ antly higher in patients with
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smoke inhalation alone (p < 0.002 ) and in those with 
combined injury (p < 0.002 ) than in CS (see Table 4.3(b) 
and (c)) . The proportion of macrophages becomes
significantly lower in smoke inhalation only (p = 0.0007)
and smoke plus burns (p < 0.002), when compared with C.S. 
Patients with burns only do not show any increase in 
neutrophil population.
After the first 24 hours this situation progresses 
further so that the cell profiles in repeat BAL samples from 
the same patients with or without smoke inhalation show an 
even greater rise and fall in the proportions of neutrophils 
and macrophages.respectively (p = 0.007), (Table 4.4b).
The influx of neutrophils in the lungs of these patients 
in our study is similar to that reported by others (Gemmpll 
1987; Demarest 1979; Clark 1988a&b) in smoke inha1 ation 
injury. This accumulation of neutrophils may be due (a) to 
the release of macrophage products such as AM-derived % 
neutrophil chemotactic factor known to be released by 
activated macrophages (Huninghake, 1978, 1980) or (b) to
products of complement activation or (c) LTB^. Such factors 
have been shown to attract neutrophils into the lungs. Our 
data on the chemotactic effect on normal neutrophils of BAL 
supernatants from patients with smoke inhalation suggests the 
presence of similar factors (Table 4.11). Data on 
complement levels strongly support this view (Table 4.13a&b 
and 4.14).
Although the '^oportion of macrophages is lower in the 
BAL samples from '^ts, with an increase in total
cell yields, th “ macrophages remain very
2 3 8
similar to those from control patients (Fig. 4.1).
Macrophage markers show a modest rise in UCHM^-positive 
cells (monocytes) in patients with combined smoke and burn 
injury (p < 0.02) (Table 4.5(a)).
Data on macrophage markers also suggest an increase in 
the proportion of RFDg-positive cells in the smoke inhalation
only patients compared to CS (p < 0.02). Surprisingly in
patients with combined injury the trend was not significant. 
The importance of this finding can only be conjectural 
because the function of the subgroups of macrophages defined 
by these markers is not yet known. RFDg-positive cells are
tingible macrophages with wide distribution in the body
(Janossy, 1986) .
It is interesting that these data did not show any 
significant change in RFD-y-positive cells which are supposed 
to be "mature" macrophages. This observation is different 
from that seen in BAL samples from areas of consolidation in 
the CAP patients in which there was an increase in RFD^
-positive cells (Table 3.5). In addition CAP patients (AOC)
showed a large increase in UCHM-^-positive cells.
It is not clear how soon these UCHM-^  positive cells 
acquire RFD7 markers iri vivo but in culture this takes five
days (Linch, 1984) or 7 days (Poulter, 1986). Another
interesting observation in the macrophage markers data is the 
similarity of proportions of NAl/34 (Tg) positive cells 
between these patient groups and CS (in contrast to CAP 
patients). This may be because these patients are similar in 
many ways to CS "»t been for the fire incident a few
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hours earlier.
T-cell markers revealed no differences in the 
proportions of T-cell subsets between CS and patient groups 
in the initial lavage samples. In the repeat BAL samples, 
however, there was a trend towards a lower proportion of T^- 
positive cells and an increase in the Tg-positive cells, 
which in themselves were not different from the initial
lavage samples, but were sufficiently different to affect the 
T^/Tg ratio which was significantly lower than in the CS (p <
0.01) (Table 4.7).
Chemotaxis data on AM from patients with smoke
inhalation showed increased unstimulated and stimulated 
migration towards the various chemotaxins.’ Patients with 
smoke inhalation alone showed only a trend but it was clear 
that patients with combined injury demonstrated highly
significant differences in migration compared to control 
subjects.
This finding is in sharp contrast to that of
Demarest (1979) who reported significantly lower AM 
chemotaxis from a group of seven patients with smoke
inhalation compared to both smoking and non-smoking controls. 
There are some important differences between Demarest's study 
and ours. First the total number of patients whom they 
studied were few, three of whom had no burns, and another two
had sustained only very mild burns. Second, the BAL profile
from Demarest's patients consisted of a high proportion of 
: neutrophils (35%' which in our experience physically
interferes with t ‘ •'n of macrophages through membrane
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pores. BAL cell profiles in our patients who had chemotaxis 
studies, consisted of a mean of 85.8 (_+ 24.9)% macrophages 
and 11.2 (+_ 12.1)% neutrophils after purification with Ficoll 
-hypaque density gradient centrifugation. Thus these 
differences could account for the contrasting results between 
our studies and those of Demarest (1979) .
The finding of increased migration of macrophages from 
patients with smoke inhalation may be due to the presence of 
a new population of macrophages as suggested by increased 
RFDg-positive cells moving into the alveoli and capable of 
expressing various receptors for chemotactic agents such as 
C5a. Such a picture has been previously described, for 
example following inhalation of asbestos (Warheit, 1984). 
Alternatively this could be due to stimulation of the 
resident macrophages by a phagocytic load (smoke debris), 
plate 4.1(a&b), resulting in their activation and expression 
of receptors for chemotactic factors previously internalized.
Our data on lucigenin-dependent-chemiluminescence (luc- 
dep-cl) showed no difference between the patient groups and 
control subjects. Furthermore comparison of the initial luc- 
dep-cl with that of repeat samples from some patients shows a 
significant reduction in this activity (p = 0.038) in the 
repeated samples (Table 4.10a). Luminol-dep-cl from the 
initial and repeat BAL samples from smoke inhalation patients 
was significantly higher than CS. The latter is most likely 
to be related to the increased neutrophil proportions in 
these samples.
The apparent discrepancy between AM migration data and
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chemiluminescence activity is possibly due to the different
time scale involved in these two functions. Jtn vitro data
suggest that initiation of the respiratory burst is a 
rapidly activated function, so that in most of our 
experiments, the peak counts are obtained within 5-15 
minutes. This contrasts sharply with migration, which is of 
the order of 3-4 hours. The reduction of luc-dep-cl activity 
of AM from the repeat BAL samples, suggests that by the time 
these patients were lavaged this function of AM was "winding 
down". In a systematic study where patients were serially 
lavaged by Gemmell (1987 ) chemiluminescence of BAL cells 
was low at 0 hours (at admission to hospital), higher than 
normal at 4 hours and lower again at 24 hours. Our patients 
were not lavaged according to such a strict schedule, and
there was a wide variation in the duration of time between
smoke inhalation and lavage.
The picture that comes over then in these patients with 
smoke inhalation is that of accumulation of neutrophils and 
activation of AM. This phnomenon is accentuated in patients with 
burns and smoke inhalation and is qualitatively different 
from that of simple "depression" of systemic immune functions 
described in burns only. In addition there are increased 
levels of components of complement and complement activation 
products patients with combined injury.
4.5 CONCLUSIONS:
1. Accumulation of neutrophils in the lung of patients
243
with smoke inhalation.
2. Activation of AM in these patients.
3. Presence of products of complement activation in the
lungs of patients with smoke inhalation.
4. Accentuation of all these findings in patients with
smoke inhalation and burn injury.
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CHAPTER 5 
RADIATION INJURY
5.1 Introduction
Radiation pneumonitis is one of the most important 
complications limiting the dosage of radiotherapy. Radiation 
pneumonitis occurs within the first few months after 
irradiation but the cellular and biochemical events leading 
up to the development of the full clinical picture of the 
disease are poorly understood. The aim of this study was to 
catalogue cellular changes in the lung during the early 
period before the development of clinical disease. It was 
decided to lavage patients before and after radiotherapy. The 
initial lavage was performed during the diagnostic 
bronchoscopy on patients who were identified as being likely 
to receive radiotherapy; before histological diagnosis was 
available. Of the 20 patients so identified, 13 did receive 
radiotherapy but only 7 were available for repeat lavage 
following radiotherapy. Repeat lavages were done four weeks 
after the last dose of treatment in six patients and after 
three weeks in one patient. Three patients had received 
radiotherapy 12 weeks after a course of chemotherapy. In 
these patients their initial lavage was done four days before 
initiation of radiotherapy.
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5.2 Definition of study group:
Six patients received palliative radiotherapy, and one 
patient received radical radiotherapy. The dosage of 
radiation varied from 2,500 cGy to 5, 00 c G y  given over a 
period of 7-10 days. Further details of the patients with 
bronchial carcinoma are given in Table 5.1(a) and 5.1(b). All 
patients were smokers.
Table 5.1(a): Age and sex distribution of patients with 
bronchial carcinoma.
Age range 
(mean)
Sex
M
Distribution
F
Control subjects 
(n = 26)
(Smokers) 30 - 66 (48.0) 17 9
Bronchial 
carcinoma 
patients 
(n = 20) 36 - 75 (60.2) 14 6
The following data was obtained:
1. BAL cell yields and proportions.
2. Proportion of macrophage and T-cell subsets as defined
by the monoclonal antibodies.
3. AM migration.
4. Measurement of chemiluminescence.
5. Albumin and complement levels in BAL supernatants.
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Table 5.1 (b): Details of patients who had radiotherapy.
Cell type Chemo- Radiation Main area
No. Age & Sex & site of therapy & Dosage of radiat-
tumour iation
1 36 M Squamous None Radical Tumour area
Right Upper 5500 c-Gy Right (R)
lobe (RUL) in 21 upper chest
fractions & mediastinum
over 5.5
weeks
59 Adenocar- 
carcinoma 
Right lower 
lobe
None 3000 c Gy 
in 10 
fractions 
over 2 weeks
R. chest 
& mediastinum
68 M Squamous None 3000 cGy Left (L) 
Left upper in 10 chest and
lobe (LUL) fractions mediastinum
over 2 weeks
75 M Undetermined None 2000 cGy Left apex 
LUL in 5 and
fractions mediastinum 
over 1 week
5 62 M Small Cell Vincristine 4000 _cGy R. chest
RUL Adriamycin, in 15 and mediastinum
VP 16 and fractions 
cyclophos- over 3 weeks 
phamide
6 59 . F Small Cell As above 4000 cGy R. chest
RUL in 15 and mediastinum
fractions 
over 3 weeks
7 61 M Small Cell As above 4000 cGy L. chest
Left lower in 15 and mediastinum
lobe fractions
over 3 weeks
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5.3 Results
5.3.1 BAL fluid volumes, original cell yields and counts.
BAL was performed as previously described. Lavages from 
"tumour area" were obtained by wedging the bronchoscope in 
subsegment nearest to the (often occluded) subsegment 
containing the tumour. In a few instances this was done in 
the nearest lobe to that containing the tumour. Lavage from 
the "opposite lung" was accordingly performed in the right 
middle lobe or the lingula. The retrieval of fluid from 
these patients was again on the whole not very different to
control subjects. Table 5.2(a) shows the cell content
and fluid volumes from these patients.
The proportion of fluid volume retrieved from both 
tumour areas of the lung and opposite lung before
radiotherapy was similar to control subjects. Retrieval of 
fluid from tumour areas after radiotherapy was significantly 
lower than the opposite lung. This may be due to mucosal 
oedema. This finding was similar to that in areas of
consolidation in the patients with CAP. The total cell yields 
were slightly higher in patients with bronchial carcinoma but 
these were not statistically different compared to control 
subjects. The cell yields are represented in Table 5.2(b) 
and Figure 5.1.
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Table 5.2(a): BAL-fluid volumes and cell yields.
BAL Fluid Volumes Proportion 
of recover­
ed fluid
Cell Yields 
x 10 /ml of 
BAL fluidInstilled Recovered
Control Subj. 
Smokers n=26
Range
Mean
120-180
202.6
35-160
94.0
0.20 - 0.70 
0.46
0.60 - 12.51 
3.66
Tumour Area 
Before DXT** 
n = 14
Range
Mean
80-180
145
22-105
63.0
0.16 - 0.625 
0.43
0.85 - 10.2 
(4.40)
Opposite lung 
Before DXT 
n = 20
100-270
163.1
30-160
80.5
0.16 - 0.70 
0.48
1.30 - 16.0 
5.09
Tumour area 
After DXT 
n = 7
150-200
171.4
25-90
59.2
0.125 - 0.63 
0.37*
0.50 - 12.0 
5.57
Opposite lung 
After DXT 
n = 7
120-150
145
50-110
77.1
0.33 - 0.73 
0.52
2.35 - 10.0 
5.35
* Significantly lower than the opposite lung after DXT. P = 
0.028.
** DXT = Deep x-ray therapy.
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Table 5.2(b): Absolute cell yields in bronchial carcinoma.
Cells x 105/ml BAL Fluid
Patient groups Total Macro­
phages
Neutro­
phils
Lympho
cytes
-
Control Mean (SD) 3. 67 (2.97) 3.50 (2.97) 0.07 (0.05) 0.07 (0.07)
Subjects 
n = 21
Median(SEM) 3.2 (0.65) 2.99(0.65) 0 . 008 (0.01) 0.045 (0.01)
P Tumour Mean (SD) 4.40(2.81) 3.86(3.12) 0.418 (0.88) 0.07 (0. 1)
R Area Median(SEM) 3.68(0.81) 3.69(0.90) 0.05 (0.2) 0.04 (0.07)
E n = 12 P value NS NS NS NS
D Opp. Mean (SD) 5.09(4.47) 4.59(4.0) 0.33(0.69) 0.15 (0. 18)
X lung Median(SEM) 3.5 (1.08) 3.2(0.97) 0.07 (0.16) 0.07 (0.05)
T n = 17 P value NS NS NS NS
P Tumour Mean (SD) 5.57(4.63) 3.43 (3.76) 1.99(3.63) 0.07 (0. 1)
0 area Median(SEM) 3.7 (1.75) *1 . 84 (1.42) 0 . 08 (1 .37)* 0.01 (0.04)
S n = 7 
T
P value NS NS NS(P=0.067) NS
D Opp. Mean (SD) 5.35 (3.06) 5.21 (3.06) 0.063 (0.04) 0.02 (0.03)
X lung Median(SEM) 4.55(1.16) 4.51(1.15) 0.07(0.01) 0.01 (0.01)
T n = 7 P value NS NS NS NS
P values in the table relate to comparison with control 
subjects.
^Significantly lower macrophage content than the opposite lung. 
P = 0.018 and higher neutrophil content approaching
significant level (P = 0.063). (Wilcoxon).
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Fig. 5.1: Cells yields in bronchial carcinoma.
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This shows that there was an increase in neutrophil 
content of BAL from areas of tumour after radiotherapy 
compared to the opposite lung. This was not statistically 
significant (P = 0.063). However the total macrophage yields 
were significantly lower from these areas compared to those 
from the opposite lung (P = 0.018), although these were not 
significantly different from control subjects. Table 5.3 
shows proportions of cells in the original BAL fluid from 
these patients and control subjects.
Comparison of data before and after radiotherapy is 
limited by the disproportionately fewer patients lavaged 
following radiotherapy. However despite these constraints, 
it is clear that following radiotherapy there is a 
significant increase in proportions of neutrophils and 
reduction of macrophages from the tumour areas compared to 
control subjects. Interestingly, this is mirrored by a 
relative increase in the macrophage population from the 
opposite lung compared to proportions from the same area 
before radiotherapy.
5.3.2 Monoclonal markers
5.3.2.1 Macrophage markers (Table 5.4):
These did not show significant differences between 
control subjects and patients with bronchial carcinoma before 
radiotherapy. Comparison of proportions of macrophages in 
samples before and after radiotherapy was difficult because 
too few samples after radiotherapy were available. There was 
a clear trend emerging in the D7 positive cells which were
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reduced in tumour areas following DXT but this was not 
significant.
Table 5.3: Original differential cell counts in BAL from
bronchial carcinoma patients.
Cell Counts (%)
Macro- Neutro- Eosino­ Lympho­
phages phils phils cytes
Control Subjects Range 78.8-99.6 0.2-8.3 0 - 2.4 0 - 12.2
(Smokers) Mean(SD) 93.8(4.75) 2.88(2.23) 0.36(0.57) 2.79(2.9)
n = 26 Median 94.95 2.4 0.1 2.0
Tumour Area 
(Before DXT) 
n = 14
Range 
Mean (SD) 
Median
9.8-99.6
81.1(30.8)
92.5
0 - 88.6 0 - 2.8 
15.23(30.3)0.59(0.85) 
1.8
0 - 19.0 
3.13(5.19) 
0.8
Opposite Lung 
(Before DXT) 
n = 20
Range 
Mean (SD) 
Median
61.6-98.4
89.8(10.8)
95.85
0.3-23 
5.3(7.2) C 
2.15
0 - 2.8 
1.51(0.70) 
0.25
0 - 28.0 
4.34(6.31) 
2.35
Tumour Area Range 
(After DXT) Mean (SD) 
n = 7 Median
11-93.6 
68.57(37.5) 
+ 82.5*
3 - 88.6 
28.9(38.5) 
+ 6.6**
0 - 5.0 
1.22(1.81) 
0.8
0 - 2.8 
0.98(1.00) 
0.45
Opposite Lung Range 
(After DXT) Mean(SD) 
n = 7 Median
93.2-99.2
97.1(2.35)
98.0***
0.4-3.6 
1.37(1.10) 
0.8
0 - 4.6 
0.82(1.69) 
0
0 - 3.2 
0.68(1.13) 
0.50
* Significantly lower than CS P = 0.004.
** Significantly higher than CS P = 0.021
*** Proportions of macrophages higher in the opposite lung after 
DXT compared to Pre-DXT values from same areas of the lung.
P = 0.041. (Wilcoxon).
+ Significantly higher neutrophil and lower macrophage 
proportions than the opposite lung. P = 0.018.
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Interestingly there was no trend to increase in UCHM^ 
positive cells.
5.3.2.2 T-cell markers:
These were assessed as previously described.
Table 5.5: T-cell subsets in patients with bronchial
carcinoma.
Mean (%) (SD) T3 T4 t8 t4/t8
Control subjects 
n = 13
2.6(3.35) 1.35 (1.19) 1.88 (2 .6) 1.37 (1.16)
Tumour Area 
(Before DXT)
n = 13
5.3(8.13) 2.75 (4.54) 3.09 (3.52) 1.46(1.33)
Opposite Lung 
(Before DXT)
n = 16
4.78(5.26) 2.62 (3.15) 2.97(3.71) 0.99(0.65)
Tumour Area 
(After DXT)
n = 7
2.37(1.64) 1.04 (0.73) 1.19(1.21) 1.52 (1.25)
Opposite Lung 
(After DXT)
n = 7
1.85 (1.44) 0.48 (0.29) 0.73 (0.69) 1.64(1.64)
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There were no differences detected in proportions of T- 
cell subsets or the T^/Tg ratio between control subjects and 
patients with bronchogenic carcinoma before or after 
radiotherapy. There were also no differences in these 
proportions in samples obtained from comparable areas in the 
same patients before and after DXT.
5.3.3 Purification of AM with Ficoll-hypaque gradient:
Excellent purification of macrophages was obtained in 
BAL samples from the tumour areas and from the opposite lung. 
Only two samples from the tumour areas before and after 
radiotherapy could not be adequately cleansed of neutrophils. 
(Table 5.6).
There were no significant differences in proportions of 
different cell types between patient groups and control 
subjects and subgroups of patients.
The mean (SD) (%) viabilities of BAL cells from CS and 
patients with bronchial carcinoma from tumour area and 
opposite lung before and after radiotherapy were 67 (15), 
74.6(12.1), 72.4(12.3), 73.4(15.5) and 68.4(12.3)
respectively.
5.3.4 AM Migration:
Measurement of migration of AM from patients with 
bronchial carcinoma showed significant depression in both 
stimulated and unstimulated migration in patients with
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Table 5.6: Differential cell counts following Ficoll-hypague 
gradient centrifugation.
Macro­
phages
Neutro­
phils
Eosino­
phils
Lympho­
cytes
Control Range 87.6-99.6 0 - 9.0 0 - 1.0 0 - 8.0
Subjects Mean (SD) 96.7 (3.1) 1.51 (2.07) 0.15(0.15) 1.6(1.99)
n = 26 Median 98.0 0.90 0 0.90
Tumour Range 13.7-99.6 0 - 86.3 0 - 1.0 0 - 10.9
area Mean (SD) 88.5(23.3) 9.23(23.7) 0.16(0.32) 2.16 (3.50
before Dxt 
n = 13
Median 97.0 1.20 0 0.80
Opposite Range 88.0-100 0 - 10.0 0 - 0.8 0 - 6.5
lung Mean (SD) 96.9 (3.7) 1.52 (3.11) 0.11 (0.22) 1.48 (2.0)
before Dxt 
n = 19
Median 98.8 0.4 0 0.60
Tumour Range 14.0-98.6 0.4-85.2 0 - 1.2 0 - 0.8
area Mean (SD) 72.1 (40.1) 27.0 (40.19) 0.46(0.51) 0.3(0.35)
after Dxt 
n = 6
Median 97.4 1.9 0.3 0.2
Opposite Range 92.4-100 0 - 6.0 0 - 1.6 0 - 1.6
lung Mean (SD) 98.0(2.65) 1.31 (2.19) 0.31 (0.58) 0.37 (0.57)
after Dxt 
n = 7
Median 98.3 0.1 0 0.2
bronchial carcinoma before DXT compared to control subjects
(Table 5.7). (Figure 5.2). None of the samples contained 
more than 10% neutrophil after Ficoll-hypaque centrifugation.
Migration of macrophages from tumour areas were much 
more depressed compared to control subjects than those from 
the opposite lung and this is reflected in significant 
differences of their stimulated migration to Casein and ZAS
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Table 5.7: Migration of AM from patients with bronchial
carcinoma.
Cells/5 fields (x400) 
(mean of 3 wells)
Unstimul­
ated Casein ZAS (C5a) FMLP
Control Ms an (SD) 
Subjects Median (SEM) 
n = 19
29.1(12.2)
30.0(2.8)
37.1(15.4)
31.0(3.5)
61.5(28.3)
55.5(6.6)
33.4(17.6)
26.6(4.3)
Tumour Area Mean (SD) 
Before DXT Median (SEM) 
n = 9 *P value
13.9(4.8) 
15.0(1.6) 
P < 0.002
18.7(5.6) 
18.0(1.9) 
P < 0.002
:k-k
26.9(9.8)
23.0(3.2)
P < 0.002 
**
15.1(5.6) 
15.0(2.1) 
P < 0.01
Opposite Mean (SD) 
Lung Median (SEM) 
Before DXT 
n = 14 *P value
18.6(9.1)
15.0(2.4)
P < 0.01
25.6(6.9)
24.5(1.8)
P < 0.05
38.3(19.2)
35.0(5.1)
P < 0.01
15.7(11.3)
12.5(3.5)
P < 0.002
Tumour Area Mean (SD) 26.5(11.3) 34.5(17.3) 51.5(26.9) 20.0(2.6)
After DXT Median (SEM) 23.5(5.7) 28.0(8.6) 46.0(13.4) 19.0(1.5)
n = 4 *P value NS NS NS NS
Opposite Mean (SD) 24.6(5.4) 38.4(20.6) 50.4(25.1) 23.2(5.6)
Lung Median (SEM) 23.0(2.0) 30.0(7.8) 44.0(9.5) 22.5(2.3)
After DXT
n = 7 *P value NS NS NS NS***
All P values indicate comparison with control subjects.
Significantly lower than migration of AM from the 
opposite lung. P < 0.05.
Significantly higher than migration of AM from same 
areas before DXT. P < 0.05.
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Fig. 5.2: AM migration in bronchial carcinoma.
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(P < 0.05). Migration of AM from these patients following 
radiotherapy showed consistent increase above their pre­
treatment levels so that they were now comparable to 
control subjects. Unstimulated migration towards FMLP of AM 
from the opposite lung following DXT was significantly higher 
to pre-treatment levels (P < 0.05).
5.3.5 Measurement of the respiratory burst in AM from 
patients with bronchial carcinoma:
Assessment of generation of respiratory burst in AM from 
these patients was made by measurement of lucigenin and 
luminol dependent chemiluminescence (Tables 5.8 & 5.9).
Measurement of lucigenin-dependent chemiluminescence in 
patients and control subjects showed lower levels of 
chemiluminescence (CL) in AM from patients with bronchial 
carcinoma before radiotherapy. This was significantly lower 
in AM from the opposite lung (P < 0.01). Chemiluminescence 
of AM from the opposite lung post-treatment showed an 
increase above their pre-treatment levels (P < 0.05)
(spontaneous CL) so that they were now almost comparable to 
control subjects. Chemiluminescence of AM from tumour areas 
remained low, Figures 5.3 and 5.4.
Measurements of luminol dependent chemiluminescence 
showed no differences between control subjects and patients 
with bronchial carcinoma before or after radiotherapy. There 
was a trend towards "recovery" of chemiluminescence activity 
in AM from the opposite lung but this was not significant.
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Table 5.8: Lucigenin-dependent chemiluminescence.
Peak cps/10^ cells Cells + bacteria Cells + gel Hanks
Control Subjects Mean 
n = 10 Median
(SD)
(SEM)
812.3 (852.5) 
400.0 (269.6)
821.1 (876.9) 
415.0 (777.3)
Tumour Area 
Before DXT 
n = 9
Mean
Median
(SD)
(SEM)
378.9(522.5) 
160.0 (174.1)
153.8(225.3) 
34.0 (75.1)
Opposite Lung 
Before DXT 
n = 11
Mean
Median
(SD)
(SEM)
*159.2(252.9) 
40.0 (76.2)
138.75(205.8) 
30.0 (62.0)
Tumour Area 
After DXT 
n = 4
Mean
Median
(SD)
(SEM)
147.5 (74.1) 
140.0 (37.0)
147.5 (91.4) 
130.0 (45.7)
Opposite Lung 
After DXT 
n = 5
Mean
Median
(SD)
(SEM)
420.0 (364.6) 
260.0(163.1)
522.0(307.2) 
** 570.0(137.3)
* Significantly lower than control subjects. P < 0.01.
** Significantly higher than pre-treatment levels in AM from 
the same area. (P < 0.05). (Figures 5.3 and 5.4.
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Table 5.9: Luminol-dependent chemiluminescence.
Peak cps/10^ cells Cells + Bacteria Cells + gel Hanks
Control Subjects Mean(SD) 21.5 (58.4) 14.4 (39.5)
n = 17 Median(SEM) 3.8 (14.1) 2.7 (9.5)
Tumour Area Mean(SD) 20.06 (23.7) 38.8 (65.0)
Before DXT Median(SEM) 20.0 (7.93) 10.0 (21.6)
n = 9
Opposite Lung Mean(SD) 14.09 (14.0) 16.8 (20.8)
Before DXT Median(SEM) 10.0 (4.4) 10.0 ( 6.9)
n = 9
Tumour Area Mean(SD) 91.2 (165.8) 14.7 (13.3)
After DXT Median(SEM) 9.75 (82.9) 8.8 ( 7.7)
n = 4
Opposite Lung Mean(SD) 100.1 (212.3) 9.1 (11.6)
After DXT Median(SEM) 4.3 ( 94.9) 3.9 ( 5.2)
n = 5
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bronchial carcinoma.
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5.3.6 Measurement of albumin in BAL supernatants.
These were done as previously described. Table 
5.10a shows the results of albumin levels.
Table 5.10(a): Albumin levels in mg/L of BAL fluid from 
patients with bronchial carcinoma.
Control 
Subj ects 
n = 16
Pre-DXT Post-DXT
Tumour 
Area 
n = 14
Opp.Lung 
n = 1 4
Tumour 
Area 
n = 6
Opp.
Lung
n=3
Range 3.8-111.8 1 .5-156.5 2.9-117 9.8-214. 9 0.6-64
Mean
(SD)
37.12 
(31.27)
45.07
(45.38)
35.06
(33.92)
91 .67 
(86.51 )
86.51
(32.04
Median
(SEM)
27.45
(8.36)
30.40
(12.59)
23.95
(9.06)
68.15
(35.32)
24.2
(18.5)
**P value *NA NS NS NS NS
* NA = Not applicable.
**P values: relate comparison with control subjects.
The albumin levels were similar between control 
subjects and patients with bronchial carcinoma before 
radiotherapy. Albumin levels from tumour areas after 
radiotherapy were threefold higher than CS but the 
difference between groups was not statistically 
significant. Only 3 samples from the opposite lung after 
dxt were available for examination.
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5.3.7 Measurement of complement components in BAL 
supernatants.
Data on complement components are presented in 
Tables 5.10b and 5.10c. The majority of the components 
were similar in the bronchial carcinoma group to CS. C3 
and factors B and H levels were significantly higher in 
tumour areas before radiotherapy. Factor B is 
significantly higher in the opposite lung than CS (P =
0.05) .
Following radiotherapy tumour areas contained 
significantly higher levels of the same components (C3, B 
and H) than CS. Again factor B levels in the opposite 
lung is significantly higher than CS. Thus factor B has 
remained consistently significantly higher in the 
bronchial carcinoma patients both in the tumour areas and 
in the opposite lung before and after radiotherapy. 
Factor B takes part in the alternative pathway and plays 
an important role when complexed with C3b initially as a 
low activity convertase before being cleaved by activated 
Factor D. The significance of the observation of higher 
levels of Factor B in patients with bronchial carcinoma 
is not clear.
In bronchial carcinoma the significant differences 
seen in tumour areas after radiotherapy (C3, B & H) are 
now lost when albumin is corrected for. These however 
remain significant both in the tumour areas and in the 
opposite lung before radiotherapy but at low levels of
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significance. It should be noted that C3 levels in the 
opposite lung before radiotherapy has now become 
significantly higher than CS while this was not so before 
correction for 
albumin.
Interpretation of complement data in bronchial 
carcinoma group is particularly difficult because of the 
presence of inflammatory activity as evidenced by 
presence of neutrophils in some patients before 
radiotherapy. The contribution of radiotherapy (if any) 
to the differences, observed in some complement compounds 
is thus difficult to assess. It is unfortunate that data 
on complement activation products is not available in 
this patient group.
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5.4 Discussion:
Data from bronchoalveolar lavage in radiation pneumonitis 
in man are scanty. One of the few studies is that by Cordier 
(1986) who reported cellular and humoral changes in BAL fluid 
from six patients with radiation pneumonitis. Among other 
findings in that study was an increase in the lymphocyte 
proportions in BAL from five out of the six patients studied. 
One patient had an increased neutrophil content. Our data do 
not show such an increase in lymphocytes but suggest an 
increase in the neutrophil counts. This difference between the 
two studies is likely to be due to the time interval between 
radiation and lavage. In the study by Cordier, patients were 
lavaged between 5-12 weeks after radiation except in one 
case when lavage was performed 1 week after the initiation of 
treatment. This patient developed hyper-acute radiation 
pneumonitis and showed an increase in neutrophil content. 
Irradiation of mice has shown that the number of macrophages 
are initially reduced reaching a minimum at around 2 weeks and 
this is followed by return to normal levels 6-10 weeks after 
irradiation (Gross, 1977b). The finding in our study of low 
normal (in comparison to pre-radiation) levels of macrophages 
from the tumour area and high normal levels from the opposite 
lung is in keeping with the experimental data. The lower 
numbers from the tumour area could reflect the higher dosage 
of radiation sustained by the tissue in and around the tumour 
in comparison to the opposite lung hence earlier "recovery" 
in the opposite lung (Fig.5.1). This is again reflected in
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the fairly low levels of mature macrophages from the tumour 
areas as defined by the RFD-y monoclonal marker. The absence 
of any increase in UCHM^-positive cells (monocytes) in this 
study is interesting. Alveolar macrophages are regarded as 
radioresistant cells so that they are not completely 
eliminated by thoracic irradiation and regeneration partly 
depends on local multiplication of macrophages. Bowden (1969) 
showed that following irradiation of the hemithorax of rats 
there was no influx of monocytes into the alveoli of the 
irradiated mice, which would be consistent with our findings.
Our finding of depressed migration of AM from patients 
with bronchial carcinoma especially from areas of tumour is 
similar to that reported by Le Marie (1984) . It is not clear 
whether the depression of AM chemotaxis in patients with 
bronchial carcinoma especially in macrophages obtained from 
the neighbourhood of the tumour is due to the presence of an 
"inhibiting factor" possibly released by the tumour or part of 
the poor general condition of these patients. The "recovery" 
of this function could thus be because of destruction of the 
tumour (albeit temporary) and reduction of the inhibiting 
factor or due to improvement in the general condition of the 
patient. The "recovery" of the capacity of AM from the 
opposite lung to generate the respiratory burst is in keeping 
with the chemotaxis data. AM obtained from patients with 
bronchial carcinoma are capable of cytotoxic activity against 
human lung tumour (Swinburne et ad, 1982). This is achieved by 
non-specific binding (Adams, 1984) or through antigen- 
dependent cytolytic activity. This latter mechanism is
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thought to be mediated through the release of ^2^2 (Nathan,
1980). Whether the improvement in migration of AM and
generation of respiratory burst following radiotherapy 
demonstrated in this study is translated into a more efficient 
anti-tumour capacity of these cells in_ vivo remains unclear.
5.5 Conclusion
In conclusion, data from this study suggest:
1. Increase in the proportions of neutrophil population in
BAL fluid from patients who have undergone radiotherapy 
for bronchial carcinoma, before the development of 
overt clinical evidence of radiation pneumonitis.
2. Improvement of previously existing depressed function
of AM from these patients following radiotherapy. Such
a partial recovery occurs initially in the opposite
lung.
3. Some components of complement are elevated in BAL
supernatants from patients with bronchial carcinoma.
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CHAPTER 6 
GENERAL DISCUSSION
The purpose of this thesis was to examine cellular 
and humoral responses to acute lung injury. The types of 
acute lung injury studies were community acquired 
pneumonia, smoke inhalation injury in fire victims and 
radiation injury following radiotherapy for bronchial 
carcinoma.
This was done through examination of bronchoalveolar 
lavage cell composition, measurement of albumin, 
complement components, products of complement activation 
and functional chemotactic activity of the BAL 
supernatants. In addition AM function was assessed by 
measurement of unstimulated and stimulated migration 
towards three chemotaxins, and generation of the 
respiratory burst.
Data on patients with bronchial carcinoma showed 
preponderance of AM both before and after radiotherapy. 
There was however some increase in neutrophils after 
radiotherapy. There was a marked depression of migration 
of AM from these patients. This depression was greater 
in AM obtained from tumour areas than those from the 
opposite lung. Similar observations were made by Le 
Marie (1984). Generation of the respiratory burst was 
also impaired in AM from patients with bronchial 
carcinoma. There was a trend of improvement in AM
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function following radiotherapy but the number of 
patients was too small to draw conclusions from.
The cell composition from RCA in CAP patients was 
similar to CS, but AM function appeared to be depressed. 
The latter did not appear to be due to a systemic effect 
of pneumonia since peripheral blood monocytes were not 
similarly depressed. This is a hitherto unreported 
observation in non-immunocompromised patients. The cause 
for such a depression of AM function in our patients is 
not clear.
Data on experimental pneumonia have documented 
functional impairment from animals previously subjected 
to viral infection (Jakab 1974; 1980 and 1982, Astry
1984) although this was not confirmed by Nugent (1979).
In clinical practice the evidence for predisposition 
to bacterial pneumonia by preceding viral infection has 
largely come from influenza epidemics (Schwarzmann 1971, 
Martin 1959). In non-epidemic situations, the association 
of viral infection and the development of bacterial 
pneumonia is more common in children (Nichol 1967) than 
in adults (Sullivan 1972; Mufson 1967; Fekety 1971; and 
Bath 1964). Alcoholism is another risk factor identified 
in pneumonia studies (Sullivan 1972; Mufson 1971). Thus 
the cause of apparent impairment of AM function in our 
patients may be multifactorial. The significance of this 
functional impairment in the development of disease in 
the infected areas (AOC) and the precise role AM play in 
limiting such infection is not clear.
The composition of cells from these areas was 
different from either the CS or RCA. There was extensive 
accumulation of neutrophils in AOC in most patients with 
CAP. Studies on migration of AM from AOC were hindered by 
difficulties in purification of AM. Chemiluminescence 
data however suggested that the respiratory burst in BAL 
cells from AOC in CAP was depressed. Assuming that the 
major part of chemiluminescence activity is from 
neutrophils which are the predominent cells this 
impairment of chemiluminescence contrasts with peripheral 
blood neutrophils from the CAP group examined later, 
which showed activation. Lung neutrophils appear to 
behave differently from peripheral blood neutrophils. 
This finding could be explained on the basis of prolonged 
stimulation of lung neutrophils by particulate (bacteria, 
debris) and soluble stimuli (C5a) , to which the 
peripheral blood neutrophils have not been similarly 
subjected. Examination of neutrophils from lungs and 
peripheral blood in a model of lung injury has 
demonstrated marked degranulation occurring in the 
former, (Yamada, 1982). This was thought to be due to 
complement activation.
Supernatants from AOC showed significantly higher 
levels of complement components and products of 
complement activation than CS or RCA. There was also a 
suggestion of C3 consumption in these areas. The 
presence of significant levels of C5a and C3a is in 
keeping with the large numbers of neutrophils in AOC.
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This observation is similar to that seen in patients with 
smoke inhalation injury but to a lesser degree.
Patients with smoke inhalation injury with or 
without burns showed accumulation of neutrophils within 
the first 24 hours, and this became more pronounced 
during the following 24 hours. Patients with burns alone 
did not show such a change. Macrophage function assessed 
by migration suggested some activation in patients with 
smoke inhalation only but in patients with smoke and 
burns such activation of AM was markedly increased. 
Again AM function from patients with burns alone did not 
show such activation.
BAL from patients with smoke inhalation only 
contained higher levels of complement components than CS 
but the differences were not statistically significant. 
However BAL supernatants from patients with both injuries 
showed significantly higher levels of Clr, Cls and Factor 
H. They also showed lower levels of C3 than CS along with 
higher levels of C3-P suggesting consumption of C3 with 
activation of the alternative pathway.
Although the difference in the levels of C3-P 
between patients with smoke inhalation alone (or CS) and 
those with combined injury was not significant, 
examination of raw data is very revealing. In smoke 
inhalation only out of 10 samples examined (from 8 
patients) none showed detectable levels of C3-P. In smoke 
with burns patients, 5 samples (5 patients) out of 13 
samples (9 patients) showed detectable levels. Four out
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of five of these patients with combined injury died. 
Furthermore patients with both smoke inhalation and burns 
showed significant activation of the classical pathway as 
shown by the levels of Cls-CInh complex. Unfortunately 
data on complement from patients with burns alone are not 
available but it is reasonable to assume that BAL 
supernatants from these patients did not contain any 
significant levels of complement activation products 
since they did not show any chemotactic activity on 
functional assay. This is also in keeping with lack of 
neutrophil accumulation in the lungs of these patients 
during the study period.
In summary, patients with burns alone bear no 
resemblance at least during the early period to those 
with smoke inhalation injury in terms of AM function, 
neutrophil accumulation and probably complement profile. 
In contrast patients with smoke inhalation injury only 
and those with smoke inhalation and burns show some 
resemblance in the degree of neutrophil accumulation in 
the lungs and to a lesser extent macrophage activation. 
However it appears that complement activation occurs only 
in patients with smoke and burns.
Does this apparent activation of the alternative and 
classical pathway of complement play a key role in 
promoting further physiopathological changes in patients 
with combined smoke inhalation and burns injury with 
subsequent high mortality? Although patients with CAP 
(AOC) also show even greater complement activation, their
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mortality is comparatively low. There are several 
possible causes for this. Firstly in most patients with 
pneumonia, the inflammation is a localized process and 
does not involve the whole bronchial tree as in smoke
inhalation injury. Indeed patients with pneumonia sustain 
increasing mortality in proportion to the number of lobes 
involved (Austrian 1964). Secondly there is effective 
therapy in pneumonia not yet available in smoke 
inhalation and burns injury. Thirdly it is known that 
both serum and lung antiproteases are increased in 
pneumonia (Lonky 1980) although some workers have found 
decreased functional activity of such antiproteases 
(Abrams 1984).
Data on antiproteases are not available from
patients with smoke inhalation and burns. It is not 
unreasonable however to speculate that loss of serum
factors known to occur through burn wounds in these
patients may include antiproteolytic enzymes. This would 
render the lungs of these patients vulnerable to the 
injurious effects of neutrophils. Such reduced 
antiproteolytic activity has been documented in some 
patients with ARDS, (Lee 1981; Cochrane 1983). 
Furthermore and perhaps more importantly the presence of 
products of complement activation such as C5a which is 
capable of neutrophil activation (Davis 1987) would lead 
to the release of proteolytic enzymes, resulting in 
further complement activation (McPhaden 1985). Thus a 
vicious cycle which results in lung damage is set in
-278-
motion .
In smoke inhalation injury, AM activation is perhaps 
sufficient to recruit neutrophils. The presence of 
additional burns injury allows complement activation due 
to tissue damage with further neutrophil sequestration in 
the .lungs. The consequent increase in permeability 
allows exudation of complement components into the lungs 
which are cleaved and activated by neutrophil proteases. 
In severe burns of sufficient magnitude, intravascular 
complement activation may be the starting point of the 
vicious cycle.
Thus in these studies pneumonia patients are seen to 
have intense but localised inflammation. Whereas 
patients with inhalation injury alone have mild but 
generalised inflammation, and those with combined smoke 
and burns injury have both intense and generalised 
inflammatory changes.
Based on the above discussion it is possible to put 
forward an hypothesis on lung injury in these conditions. 
This is outlined in flow charts (Figures 6.1,2 & 3) which 
also serve to highlight the areas about which we have no 
information and on which future studies may be 
undertaken.
Finally an exciting area of research would be the 
investigation of potential use of antioxidants in 
ameliorating lung damage in patients with smoke 
inhalation and burns injury.
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APPENDIX I (TO CHAPTER 2 - MATERIALS)
PROCESSING OF BAL FLUID
Sterile Universal Containers 150 mis (STERILIN Ltd., Feltham, 
England)
Pasteur pipette (disposable plastic)
Surgical Gauze
Fuchs-Rosenthal counting chamber (Weber Scientific 
International Ltd., Sussex, England)
White-cell dilution fluid (Exogen, Clydebank, Scotland) 
Leishman's Stain (Exogen, Clydebank, Scotland)
Non Specific-Esterase Staining
1. Kit No. 90-AI (Sigma Chemical Company Ltd., Fancy Road, 
Poole, Dorset, U.K. BH1 7NH) contains: 
i) Citrate concentrate Solution Cat. No. 386-1 (Reagent A)
i) Trizmal Buffer concentrate pH 7.6 Cat No. 90-2C (Reagent
B)
iii) Capsules each containing RR salt Cat. No. FBS-25 (Reagent
C)
iv) Capsules containing 20 mgs alpha naphthyl acetate Cat. 
No. 90-6 (Reagent D)
v) Ethylene glycol monomethylether solution Cat. No. 90-1 
(Reagent E)
vi) Mayer's Hematoxylin.
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2. Acetone BP (Evans Medical Ltd., Langhurst, Horsham, England).
3. Methanol 99.85% w/w.
4. Distilled water.
Preparation of a fixative (citrate-acetone-methanol mixture).
1 ml Reagent A + 9 mis distilled water + 15 mis acetone. 
Discard 2.5 mis from this mixture and replace with 2.5 mis 
methanol.
Preparation of Esterase Stain:
5 mis Reagent B + 45 mis distilled H2O prewarmed in a 
shaker at 37°C + contents of 1 capsule of Reagent C.
Immediately contents of Reagent D are dissolved in 2 mis of 
Reagent E and emptied into the mixture. Mix for 20 seconds 
and empty into coplin's jar (protected from light by covering 
with tin foil).
Enrichment of macrophages using Ackerman's method (1978)
1. Previously used tissue culture flasks obtained from 
Virology Department (Corning or Flow Laboratories).
2. xlO concentrated Medium 199 (Gibco).
3. Fetal Calf Serum (FCS) Gibco.
4. Phosphate Buffered Saline (PBS) Oxoid Ltd., (1 tab + 100
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mis distilled water).
5. Distilled water.
6. EDTA (di Potassium) Mol. Wt. 404.29 (May & Baker,
Dagenham, England).
Enrichment of Macrophages using Density Gradient:
1. Lumbar Puncture Needle gauge 20.
2. Lymphocyte-Separation Medium: (also referred to as ficoll-
hypaque) specific gravity 1.077 (Flow Laboratories, U.K.).
3. xlO concentrated Medium 199 with Earle's Salt without
NaHC03.
4. HEPES Buffer (1 Molar) pH 7.3.
5. 7.5% Sodium Bicarbonate Solution.
6. Distilled water.
Concentration of BAL Fluid
1. Dialysis Tubing (Cellulose) width 1.7" cut off mol. wt. 
12000 daltons (Sigma Chem.).
2. Polyethylene glycol (approx. mol. wt. 8000) (Sigma 
Chemical Co.).
3. Millipore filters 0.22 urn (Gelman Sciences).
4. Sterile distilled water.
Isolation of Peripheral Blood Cells
5 mis)
1 ml )
1 ml )
43 ml )
Medium 199 
(M199) prepared 
fresh each day
(Ficoll-Hypaque method - (Boyum 1968)).
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1. Heparin (Mucous) Injection BP (Sodium Heparin) 1000
units/ml (Leo Laboratories Ltd., U.K.).
2. 0.9% Sodium Chloride BP 100 mis) 5% Dextran -
)
3. Dextran 150 (M.wt. 100, 000-200, 000) (Fisons) 5 Gm.) Saline
4. Lymphocyte Separation Medium s.gravity 1.077 (Flow
Laboratories Limited, Irvine, Scotland KA12 8NR).
5. Ammonium chloride (Sigma) 8.75 Gm)
) 0.875% w/v
6. Distilled water. 1 litre)
7. xlO concentrated Hanks Balanced Salt Solution (HBSS) (Flow 
Laboratories).
8. Gelatin (Type IV) (Sigma) (1% w/v in distilled H2O
sterilized in 10 ml vol.).
9. NaOH.
10. Conical tubes 110 x 17 mm. (Nunc, Kastrup, Denmark, DK 4000)
Gel Hanks = (xlO concentrated HBSS + 1% Geltain 10 mis + 
sterile distilled water 80 mis; adjust pH to 7.2 with few
drops of NaOH).
Heparinized blood = 100 units heparin per 10 mis venous blood. 
Isolation of monocytes using nydocenz (Boyum, 1983)
10 mis potassium EDTA tubes (Monoject KE/10)
Dextran T500 (Pharmacia, Uppsala, Sweden) 6 Gm )
) 6% w/v dextran-
Normal Saline (0.9% NaCl) 100 mis) saline
Nycodenz Monocytes (specific gravity 1.068, osmolality 337 (jf 5
mosm) (Nyegaard Diagnostica, Post Box 4220, Torshov, N-0401,
Oslo, Norway).
Gel Hanks.
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Conical tubes (110 x 17 mm) (Nunc).
Preparation of Bacteria for phagocytosis and killing assays
1. Mueller Hinton Broth (Oxoid).
2. ^H-Adenine (Specific activity 20 uCi/mmol, 0.74 TBq/mmol) 
(Radiochemical Centre, Amersham).
3. ^H-Uridine (specific activity 38 Ci/mmol - 1.41
TBq/mmol). 1/10 Stock Solution in distilled water is prepared
and stored at 4°C.
4. 0.9% Sodium Chloride.
5. Cecil Spectrophotometer CE 272 (Cecil Instruments,
Cambridge)
6. Pooled human serum.
7. Gel Hanks.
8. Blood agar plates.
9. Solid CC>2 and methanol.
10. Scintillation vials (Fisons Lab. Supplies, Belton Road 
West, Loughborough LE11 OTR).
11. Scintillation fluid (Hydro Luma) (May & Baker Ltd.,
Liverpool Road, Manchester M30) .
12. Test tubes (70 x 11 mm) (Nunc).
Preparation of chemotaxins
1. Zymosan (Sigma).
2. N-Formyl-L-Methionyl-L-Leucyl-L-Phenylalamine (FMLP) (Sigma).
3. Mueller Hinton Broth (Oxoid Ltd., Basingstoke).
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4. Casein Hammarsten (BDH).
5. Dimethyl Sulphoxide (DMSO) (Sigma).
6. Sodium Dihydrogen Orthophosphate (NaHoPO*.2HoO mol. 
wt. 156.01) (BDH).
7. Minimum Essential Medium (Flow Laboratories).
Zymosan Activated Serum:
125 mgs Zymosan + 5 mis human serum, incubated in a shaker at 
37°C for 60 minutes. Centrifuge at 800xg for 10 minutes. Heat 
in a water bath at 56°C for 30 minutes. Store in aliquots of
0.4 ml at -70°C.
FMLP
43.7 6 mg FMLP + 10 mis DMSO = FMLP 10~^M solution 10^ fold 
dilution m  MEM is done to give 10 ^M solution. Store at 
70°C in aliquots of 0.1 ml.
Casein:
Final concentrations of 1.5 mgs/ml, 3 mgs/ml, 6 mgs/ml, 10 
mgs/ml and 20 mgs/ml were prepared. Appropriate amounts of 
casein was dissolved in 10 mis MEM (pH 11 adjusted with NaOH 
drops) was incubated at 37°C for 60 minutes and the pH 
adjusted back to 7.2 by addition of a few drops of 1 molar 
NaH2PO4.2H20 stored in 0.4 ml aliquots at -70°C.
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Under-agarose chemotaxis Assay:
Agarose (B.D.H. Poole) 
gelatin
x 10 Concentrated Minimum Essential Medium (MEM) (Flow 
Laboratories Ltd).
NaHC03 (Sigma)
NaOH
60 x 15 mm culture plates (Gibco, Paisley Ltd)
Rigid Template with 3 mm holes.
3 mm diameter cork borer.
Preparation of 2% agarose (w/v) and 0.5% gelatin w/v in MEM
Agarose 4 Gm + Gelatin 1 Gm + 200 ml distilled water, warmed 
to boiling, to dissolve gelatin, cooled to 48°C. (Solution A).
Preparation of x 2 MEM (Solution B)
x 10 concentrated MEM 40 mis )
NaHCOg 7.5% 4 mis ) Adjust pH to 7.2 with few drops
Distilled water 156 mis) NaOH. Warm to about 50°C.
Solution A + Solution B warmed at 56°C in a water bath. On a 
flat surface pour 5 mis into each culture plate, refrigerate 
at 4°C.
5 pairs of wells are punched out using the cork borer through 
the solid template on the day of the experiment.
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Microchemotaxis Assay
48-well microchemotaxis chamber with accessories (Neuroprobe 
Inc. 7621 Cabin Road, Cabin John, MD. 20818).
Polyvinylpyrrolidone-free polycarbonate membrane filters (25 
mm x 80 mm) 8u, 5u or 3 u pore size, lOu thick. (Neuroprobe). 
Medium 199 with antibiotics (Penicillin 10 i.u./ml, gentamycin 
10 mcg/ml, amphotericin-B 1 mcg/ml).
Chemiluminescence:
Luminometer tubes (55 x 12 mm) (Sarstedt Ltd., 68 Boston Road, 
Beumont Leys, Leicester LE4 1AW).
Packard Picolite Luminometer - model 6500 (Packard Instruments 
C5. 2200 Warrenville Road, Downers Grove, IL. 60515).
Luminol (5-amino-2,3,dihydro-1, 4 phthalazinedione) mol. wt. 
177 (Sigma).
Lucigenin (dimethylbiacridinium nitrate) Mol. wt. 510.5
(Sigma)
x 10 Concentrated HBSS (Flow Laboratories)
HEPES Buffer 1 Molar (Gibco)
Dimethylsulfoxide (DMSO) (Sigma)
Sodium Bicarbonate 7.5% (Gibco)
Preparation of Luminol:
17.7 mg luminol was dissolved in 10 mis DMSO to obtain 
10~^M and serial dilutions were made in distilled water to 
10“5M.
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Preparation of Lucigenin:
Buffered HBSS was prepared as follows: 
x 10 HBSS 2 mis + HEPES 0.4 mis + NaHC03 0.3 mis + Distilled
H2O 17.3 mis. Dissolve 51.05 mg lucigenin in 10 mis of
_ 9
buffered HBSS to obtain 10 M solution from which further 
dilution in buffered HBSS is made.
Monoclonal Markers
I. Labelling cells in suspension:
The following markers were used:
Primary antibodies used: Mouse antihuman antibodies of various 
Ig subclasses.
T-Cell Markers from Coulter Clone (Coulter Electronics Ltd.,
Northwell Drive, Luton, LU3 3RH, England).
T3 Pan T-cell marker IgG^ subclass
T4 Helper T-cell marker IgG^ "
Tg Suppressor/Cytotoxic
T-cell marker IgG-^  "
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Monocyte markers: (Coulter clone)
Mo-^  IgM subclass 
Mo2 IgM
Macrophage Marker
Anti-Leu-M^ (IgG^) (Beckton-Dickinson Immunocytochemistry 
Systems, P.O. Box 7375, Mountain View, California 94039).
Secondary Antibodies;
Goat-anti mouse - FITC conjugated antibodies (Coulter 
Clone).
Other Materials:
PBS (filtered through 0.22 u pore size filters)
Fluorescent microscope (Leitz Wetzlar - 48 Park Street, 
Luton).
Methylene green (M77 66) (Sigma Chemical Co.)
FACS Analyser (Becton Dickinson)
II. Labelling cells on cytospins
(Immunoperoxidase (IPX)/Immunoalkaline phosphatase (IAP) 
techniques).
The above primary antibodies failed to work with these 
methods and the following were gratefully supplied by Scottish 
Antibody Production, Law Hospital, Carluke ML8 5ES) and were 
found to be satisfactory.
T-cell markers (Tg 1/10, T^ 1/5, Tg 1/20 dilutions)
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Monocyte marker UCHM-^ 1/4 dilution
HLA-DR marker RFDR-^  1/40 dilution
The following macrophage markers were kindly supplied by 
Dr L.W. Poulter, Department of Immunology, Royal Free 
Hospital, London
RFD1 IgG^ )
)
) mouse antihuman 
)
)
1/10 dilution
rfd7 IgG^ 1/10 VI
Rfd9 IgG! 1/5 II
NA1/34 <T6 equivalent) 1/5
II
Secondary antibody: for IPX - Horse Radish Peroxidase (Anti
mouse IgG) (SAPU).
For IAP: Alkaline Phosphatase Conjugated Rabbit antimouse
(RAM) D314 (Dakopatts, Glustrup, Denmark).
Preparation of secondary antibody
(1/20 alkaline phosphatase conjugate)
0.5 ml filtered normal human serum + 0.5 mis tris buffer 
+ 50 ul RAM-AP (D314)
Normal Rabbit Serum (SAPU): Filtered and 1/5 dilution in Tris- 
Buffer.
Mountant: glycerol (Dako)
Microscope slides thoroughly cleaned in methylated spirit. 
Poly-L-Lysine Hydrobromide 0.1% (BDH)
Slide carriers (Sterilin Ltd., Feltham, England).
Cling Film (H.D. Plastics Ltd., Letchworth, Herts.).
Coverslips (Chance Propper Ltd., Smethwick, Warley, England)
3 2 0
Gills Haematoxylin (Solution Gill No.2 - Sigma Diagnostics) 
Scots Tap Water Substitute:
Sodium Bicarbonate (BDH) 7 g dissolved in distilled H2O 
Magnesium Sulphate (BDH) 40g " " "
Two solutions are mixed and made up to 2000 mis in 
distilled H2O. A crystal of thymol is added to prevent mould 
growth.
Other Reagents (IPA)
Tris Buffer: 48.48 g Trizma HC1 (Sigma)
11.12g Trizma Base (Sigma)
8 litres distilled water - adjust pH to 7.6 
Tris Saline: 8.76g NaCl (BDH) + 1 litre distilled
H2O = saline 
10 parts saline + 1 part Tris Buffer. 
Veronal Acetate Buffer (pH 9.2)
5.886g Barbitone Sodium
3.886g Sodium Acetate Trihydrate (BDH)
990 mis distilled H2O 
10 mis N/10 HC1 (BDH)
Store in a dark bottle at 4°C 
Solution A - AP substrate:
2.5 mg Naphthal-AS B-^ Phosphoric Acid (Sigma)
1 drop Dimethyl Formamide (Sigma)
2.5 mg Fast Red TR salt (Sigma)
5 mis Veronal Acetate Buffer pH 9.2
100 ul ImM Levamisole (Sigma)
321
a) Suspend naphthol AS-B-^ , Phosphoric acid in dimethyl 
formamide
b) Dissolve fast red TR salt in veronal acetate buffer.
c) Add b) to a).
d) Add Levamisole.
e) Mix well and filter through 0.22u pore size filter before 
use. Mixture tube used within one hour.
Immunoperoxidase
3,3 Diaminobenzidine tetra hydrochloride (DAB) (D5637 - Sigma) 
Hydrogen Peroxide (H2O2) 30% w/v (10128 - BDH) .
T
0.05% DAB = 50 mg DAB + 100 mis Tris-buffer. Mix and filter
DAB/H2O2 = 33 ul of 30% H2O2 is added to 100 mis of 0.05% DAB.
Stir and use immediately. DAB is handled with gloves as it is 
a suspected carcinogen.
Industrial Alcohol + Methylated Spirit (Charles Tennent & Co., 
Whistleberry Road, Blantyre G72 OTQ).
Xylene: (May & Baker) 200 mis) Harleco Synthetic
Piccolyte Resin (AS 20944 - Kodak) 120 gm) Resin
- 3 2 2 -
Baseline levels of complement components and. products of 
Complement Activation.
Complement Components: in ug/litre
Clq 5
Clr 6
Cls 8
C4 12
C3 2
Cl-Inh 4
B 3
H 0.5
Products of Complement Activation
ClsCINH 1500
C3-P 900 Units/Litre
C5b-9 4000
C5a 10 ug/litre
C3a 40 ug/litre
Albumin 10 mg/litre
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Fig. A. 1: Correlation between colony-forming units / ml of 
Staphylococcus 502A and optical density.
(mean of 4 experiments)
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APPENDIX 2
STATISTICAL ANALYSIS
Basic Definitions:
Means (x): =
Sum of all observations
Total number of observations
1 v —  lx
n
where n = number of observations
Median value of an observation which lies in the 
middle of all the observations if they 
were arranged in increasing or decreasing 
order. For an odd number of observations 
this is the:
n + 1 th
observation. For an even number this is 
the mean of the middle two observations.
Standard deviations (SD) a measure of a spread of 
observations about the mean. It is useful for data with 
normal distribution.-
-3 2 5-
✓ '*2 
I** ~
.2 lx‘
n
n - 1
where £x = sum of all observations
Standard Deviation 
Standard Error of Mean (SEM) : _________________—
n - 1
Standard Deviation 
Coefficient of Variation: __________________
Means
2 Ix2
n . —  
x
n - 1
The Null hypothesis (HQ) = is the assumption that there 
is no difference between the two sets of data being 
compared.
Two tail test: Compares the two sets of data at both the 
lower end and the upper end of the 
distribution.
Probability (p): Denotes the number of times (%) an
incident would occur by chance. It is 
conventional to accept that this was 
significant and not merely due to chance
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if it occurred in 5% or less number of 
times. Thus when p < 0.05 this is
significant and if it is < 0.01 it is 
highly significant.
Statistical tests used in this thesis: All statistical 
analyses were made using a computer based Haessle 
statistical pack (prepared by Haessle university and 
Huddings Stockholm). The following tests were used.
1. Mann Whitney U test:
All comparisons between two sets of data in this thesis 
were made using this non- parametric test. All 
significance levels (p values) were for the two tail 
test. Mann Whitney u test does not assume criteria for 
the normal distribution and does not require that the 
standard deviations between the two groups be similar. It 
analyses ranks of scores between data. The scores of the 
two groups are rank ordered in a common pool and the sum 
of the ranks is obtained. Tied observations (i.e. 
observations with equal values) are assigned the mean of 
rank position that they would have occupied if there had 
been no ties.
n-i (n-i + 1)
U = ^1^2 +   " Rq
2
-3 2 7-
R-^ = sum of ranks assigned to the groups with smaller 
number of observations (n^).
R2 = sum of ranks assigned to the group with larger 
number of observations (n2).
It has been shown that the larger the sample size the 
sampling distribution of u value rapidly approaches 
normal distribution (Siegel 1956) . Therefore when either 
of the groups is larger than 20, the significance level 
of observed u value is determined by computing the Z 
value. The P value associated with the occurrance of (or 
rejection) of HQ is determined by reference to the table 
for values as extreme as observed value of Z.
u - n^n2 
2
Z = _
nin2 (n^  + n2 + 1)
J 12
When ties occur between two or more values in both 
groups, the u value is affected and correction for u 
value needs to be applied. Thus Z will be computed as 
follows:
ni n
u - 1“2
Z =
ni n1XI2 
N <N - 1)
N3 - N
12
- IT
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N = + i\2
T
12
t = number of observations tied for a given rank.
2. Wilcoxon matched pairs signed-rank test:
This test was used to compare matched pairs of 
observations from the same patients. Differences between 
pairs are ranked from smallest to largest and pairs with 
difference of 0 are dropped. Tied differences are 
assigned the average of the ranks had there been no ties. 
The ranks are then signed (+ or -). T is the formal test 
for the Wilcoxon matched pairs signed ranks test.
T = smaller sum of like signed ranks. For samples larger 
than 25, T value has to be transformed to a Z score.
T - N (N + 1)
4
Z
N (N + 1) (2N + 1)
24
N = number of matched pairs minus the number of pairs 
whose differences = 0.
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3. Spearman rank correlation coefficient (rs):
Was used to compare the degree of association between two 
groups:
5>2 + £y2 + £d2
2ilx2Iy2
x and y are the values for the two groups.
N
6 I di2 
or rs = 1 - i=l
N3 - N
d = x - y
N = n^ + n2
